%PDF-1.3
1 0 obj
<< /Type /Catalog
/Outlines 2 0 R
/Pages 3 0 R >>
endobj
2 0 obj
<< /Type /Outlines /Count 0 >>
endobj
3 0 obj
<< /Type /Pages
/Kids [6 0 R
63 0 R
71 0 R
74 0 R
124 0 R
192 0 R
]
/Count 6
/Resources <<
/ProcSet 4 0 R
/Font << 
/F1 8 0 R
/F2 9 0 R
/F3 10 0 R
/F4 11 0 R
/F5 12 0 R
/F6 73 0 R
>>
/XObject << 
/I1 13 0 R
/I2 14 0 R
>>
>>
/MediaBox [0.000 0.000 612.000 792.000]
 >>
endobj
4 0 obj
[/PDF /Text /ImageC ]
endobj
5 0 obj
<<
/Creator (DOMPDF)
/CreationDate (D:20180721211517+00'00')
/ModDate (D:20180721211517+00'00')
/Title (The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the vaccine and why? � PLOS Currents Influenza)
>>
endobj
6 0 obj
<< /Type /Page
/Parent 3 0 R
/Annots [ 15 0 R 17 0 R 19 0 R 21 0 R 23 0 R 25 0 R 27 0 R 29 0 R 31 0 R 33 0 R 35 0 R 37 0 R 39 0 R 41 0 R 43 0 R 45 0 R 47 0 R 49 0 R 51 0 R 53 0 R 55 0 R 57 0 R 59 0 R 61 0 R ]
/Contents 7 0 R
>>
endobj
7 0 obj
<<
/Length 23819 >>
stream

q
375.000 0 0 39.000 222.000 738.000 cm /I2 Do
Q
q
15.000 684.354 577.500 53.646 re W n
0.267 0.267 0.267 rg
BT 15.000 718.042 Td /F2 21.0 Tf  [(The 2009 pandemic H1N1 influenza vaccination in France: who )] TJ ET
BT 15.000 693.094 Td /F2 21.0 Tf  [(accepted to receive the vaccine and why?)] TJ ET
Q
0.271 0.267 0.267 rg
BT 15.000 675.088 Td /F3 9.8 Tf  [(October 19, 2010)] TJ ET
BT 26.250 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
BT 31.671 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 37.092 663.247 Td /F1 9.8 Tf  [(Jocelyn Raude)] TJ ET
0.271 0.267 0.267 rg
BT 101.579 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 107.000 663.247 Td /F1 9.8 Tf  [(Anne-Laure Caille-Brillet)] TJ ET
0.271 0.267 0.267 rg
BT 212.651 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 218.072 663.247 Td /F1 9.8 Tf  [(Michel SETBON)] TJ ET
0.271 0.267 0.267 rg
BT 26.250 651.342 Td /F1 9.8 Tf  [(Raude J, Caille-Brillet A, SETBON M. The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the )] TJ ET
BT 26.250 639.438 Td /F1 9.8 Tf  [(vaccine and why?. PLOS Currents Influenza. 2010 Oct 19 . Edition 1. doi: 10.1371/currents.RRN1188.)] TJ ET
q
15.000 40.125 577.500 596.932 re W n
0.271 0.267 0.267 rg
BT 26.250 610.335 Td /F4 12.0 Tf  [(Abstract)] TJ ET
BT 26.250 590.381 Td /F1 9.8 Tf  [(Introduction: Previous studies investigating determinants of 2009 \(H1N1\) pandemic influenza vaccine acceptance have focused )] TJ ET
BT 26.250 578.476 Td /F1 9.8 Tf  [(on target groups such as healthcare workers. Few studies in the European Union have examined the self-reported reasons as )] TJ ET
BT 26.250 566.571 Td /F1 9.8 Tf  [(well as predictive socio-demographic and health factors for pandemic influenza vaccine acceptance in the general population, )] TJ ET
BT 26.250 554.667 Td /F1 9.8 Tf  [(even though influenza vaccine was recommended for all people.)] TJ ET
BT 26.250 535.262 Td /F1 9.8 Tf  [(Methods: A nationwide telephone survey was conducted in France during the peak of the outbreak that occurred in December )] TJ ET
BT 26.250 523.357 Td /F1 9.8 Tf  [(2009 in adults \(? 16 years\), using a proportional random-digit dialing.)] TJ ET
BT 26.250 503.952 Td /F1 9.8 Tf  [(Results: Interviews were completed by 1003 individuals, of whom 275 \(27.4%\) either had received pandemic influenza vaccine )] TJ ET
BT 26.250 492.048 Td /F1 9.8 Tf  [(during the last weeks or intended to get vaccinated in the next weeks. Acceptance rates of pandemic vaccine were significantly )] TJ ET
BT 26.250 480.143 Td /F1 9.8 Tf  [(higher among men, more educated and wealthier people, as well as persons who had a prior experience of influenza )] TJ ET
BT 26.250 468.238 Td /F1 9.8 Tf  [(vaccination. The patterns of self-reported reasons for vaccine acceptance could be broadly divided into 3 groups related to \(1\) )] TJ ET
BT 26.250 456.333 Td /F1 9.8 Tf  [(the mental representation of the threat � in particular the beliefs associated with the severity and personal vulnerability to the )] TJ ET
BT 26.250 444.429 Td /F1 9.8 Tf  [(illness, \(2\) the perception of efficacy and safety of the vaccine, and \(3\) trust/distrust toward those advocating the vaccine.)] TJ ET
BT 26.250 425.024 Td /F1 9.8 Tf  [(Conclusions: This national study indicates that social and cognitive determinants of pandemic influenza vaccine acceptance )] TJ ET
BT 26.250 413.119 Td /F1 9.8 Tf  [(among French adults were relatively similar to those identified by previous studies of acceptance of seasonal influenza vaccine.)] TJ ET
BT 26.250 376.517 Td /F4 12.0 Tf  [(Funding Statement)] TJ ET
BT 26.250 356.562 Td /F1 9.8 Tf  [(This research was funded by a grant from the Service d�Information du Gouvernement \(French Government Office for )] TJ ET
BT 26.250 344.658 Td /F1 9.8 Tf  [(Information\) which was in charge of the public communication related to the 2009 H1N1 pandemic influenza in France.)] TJ ET
BT 26.250 315.555 Td /F4 12.0 Tf  [(Introduction)] TJ ET
BT 26.250 295.601 Td /F1 9.8 Tf  [(In the aftermath of the emergence of the 2009 pandemic H1N1 influenza virus, large scale immunization has gradually became, )] TJ ET
BT 26.250 283.696 Td /F1 9.8 Tf  [(in the majority of the developed countries, the primary public health measure to prevent morbidity and mortality associated with )] TJ ET
BT 26.250 271.791 Td /F1 9.8 Tf  [(the disease. When the first vaccines were delivered in October 2009, a high level of vaccination coverage was reached by the )] TJ ET
BT 26.250 259.887 Td /F1 9.8 Tf  [(French government. As a precaution, enough vaccine was ordered from the pharmaceutical companies in order that 4 out of 5 )] TJ ET
BT 26.250 247.982 Td /F1 9.8 Tf  [(persons could receive two doses. Because vaccine production would take several months to complete, a prioritization plan was )] TJ ET
BT 26.250 236.077 Td /F1 9.8 Tf  [(announced � in which the most vulnerable people at risk \(persons suffering from chronic illness, people working in health or )] TJ ET
BT 26.250 224.172 Td /F1 9.8 Tf  [(child care-giving services, and parents of infants younger than 6 months\) were invited, by letter notification, to get vaccinated )] TJ ET
BT 26.250 212.268 Td /F1 9.8 Tf  [(first for free. In France, as in many other countries, the decision was made to provide immunizations exclusively at )] TJ ET
BT 520.438 212.268 Td /F5 9.8 Tf  [(ad hoc)] TJ ET
BT 26.250 200.363 Td /F1 9.8 Tf  [(vaccination centers for cost-effectiveness reasons. The potential benefits of pandemic H1N1 influenza vaccination for at risk )] TJ ET
BT 26.250 188.458 Td /F1 9.8 Tf  [(groups were threefold: personal protection, protection of relatives, and reduction of absenteeism. In December, the vaccine was )] TJ ET
BT 26.250 176.553 Td /F1 9.8 Tf  [(extended to the rest of the population. At this time, there was good evidence that the vaccine was highly effective in preventing )] TJ ET
BT 26.250 164.649 Td /F1 9.8 Tf  [(serologically confirmed influenza, and that it had limited potential side effects )] TJ ET
0.267 0.267 0.267 rg
BT 359.524 164.649 Td /F1 9.8 Tf  [([1])] TJ ET
BT 370.366 164.649 Td /F1 9.8 Tf  [([2])] TJ ET
0.271 0.267 0.267 rg
BT 381.208 164.649 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 145.244 Td /F1 9.8 Tf  [(Despite considerable efforts to persuade the greatest number of people to receive the 2009 pandemic H1N1 influenza vaccine, )] TJ ET
BT 26.250 133.339 Td /F1 9.8 Tf  [(the rate of immunization among French people was rather low: only 10% of the population had been vaccinated at the end of )] TJ ET
BT 26.250 121.434 Td /F1 9.8 Tf  [(the campaign in January 2010 )] TJ ET
0.267 0.267 0.267 rg
BT 159.571 121.434 Td /F1 9.8 Tf  [([3])] TJ ET
0.271 0.267 0.267 rg
BT 170.413 121.434 Td /F1 9.8 Tf  [(. As in many countries, the relative failure of the immunization campaign against the pandemic )] TJ ET
BT 26.250 109.530 Td /F1 9.8 Tf  [(influenza in France reminds us that the failure or success of any prevention is ultimately determined by the public acceptance of )] TJ ET
BT 26.250 97.625 Td /F1 9.8 Tf  [(the mitigating measures deployed by the public health authorities. The aim of the present study is to better understand the )] TJ ET
BT 26.250 85.720 Td /F1 9.8 Tf  [(reasons for accepting or refusing vaccination. The relative breakdown of the French vaccination program raises 3 critical )] TJ ET
BT 26.250 73.815 Td /F1 9.8 Tf  [(questions: given an equal exposure to information due to intensive media coverage, were individuals of all health and social )] TJ ET
BT 26.250 61.911 Td /F1 9.8 Tf  [(conditions equally likely to accept vaccination? If not, what kinds of individuals were most and least likely to accept vaccination? )] TJ ET
BT 26.250 50.006 Td /F1 9.8 Tf  [(And )] TJ ET
BT 46.306 50.006 Td /F5 9.8 Tf  [(last but not least)] TJ ET
BT 117.305 50.006 Td /F1 9.8 Tf  [( why some kinds of individuals were more likely to accept vaccination?)] TJ ET
Q
q
15.000 684.354 577.500 53.646 re W n
0.267 0.267 0.267 rg
BT 15.000 718.042 Td /F2 21.0 Tf  [(The 2009 pandemic H1N1 influenza vaccination in France: who )] TJ ET
BT 15.000 693.094 Td /F2 21.0 Tf  [(accepted to receive the vaccine and why?)] TJ ET
Q
0.271 0.267 0.267 rg
BT 15.000 675.088 Td /F3 9.8 Tf  [(October 19, 2010)] TJ ET
BT 26.250 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
BT 31.671 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 37.092 663.247 Td /F1 9.8 Tf  [(Jocelyn Raude)] TJ ET
0.271 0.267 0.267 rg
BT 101.579 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 107.000 663.247 Td /F1 9.8 Tf  [(Anne-Laure Caille-Brillet)] TJ ET
0.271 0.267 0.267 rg
BT 212.651 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 218.072 663.247 Td /F1 9.8 Tf  [(Michel SETBON)] TJ ET
0.271 0.267 0.267 rg
BT 26.250 651.342 Td /F1 9.8 Tf  [(Raude J, Caille-Brillet A, SETBON M. The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the )] TJ ET
BT 26.250 639.438 Td /F1 9.8 Tf  [(vaccine and why?. PLOS Currents Influenza. 2010 Oct 19 . Edition 1. doi: 10.1371/currents.RRN1188.)] TJ ET
q
15.000 40.125 577.500 596.932 re W n
0.271 0.267 0.267 rg
BT 26.250 610.335 Td /F4 12.0 Tf  [(Abstract)] TJ ET
BT 26.250 590.381 Td /F1 9.8 Tf  [(Introduction: Previous studies investigating determinants of 2009 \(H1N1\) pandemic influenza vaccine acceptance have focused )] TJ ET
BT 26.250 578.476 Td /F1 9.8 Tf  [(on target groups such as healthcare workers. Few studies in the European Union have examined the self-reported reasons as )] TJ ET
BT 26.250 566.571 Td /F1 9.8 Tf  [(well as predictive socio-demographic and health factors for pandemic influenza vaccine acceptance in the general population, )] TJ ET
BT 26.250 554.667 Td /F1 9.8 Tf  [(even though influenza vaccine was recommended for all people.)] TJ ET
BT 26.250 535.262 Td /F1 9.8 Tf  [(Methods: A nationwide telephone survey was conducted in France during the peak of the outbreak that occurred in December )] TJ ET
BT 26.250 523.357 Td /F1 9.8 Tf  [(2009 in adults \(? 16 years\), using a proportional random-digit dialing.)] TJ ET
BT 26.250 503.952 Td /F1 9.8 Tf  [(Results: Interviews were completed by 1003 individuals, of whom 275 \(27.4%\) either had received pandemic influenza vaccine )] TJ ET
BT 26.250 492.048 Td /F1 9.8 Tf  [(during the last weeks or intended to get vaccinated in the next weeks. Acceptance rates of pandemic vaccine were significantly )] TJ ET
BT 26.250 480.143 Td /F1 9.8 Tf  [(higher among men, more educated and wealthier people, as well as persons who had a prior experience of influenza )] TJ ET
BT 26.250 468.238 Td /F1 9.8 Tf  [(vaccination. The patterns of self-reported reasons for vaccine acceptance could be broadly divided into 3 groups related to \(1\) )] TJ ET
BT 26.250 456.333 Td /F1 9.8 Tf  [(the mental representation of the threat � in particular the beliefs associated with the severity and personal vulnerability to the )] TJ ET
BT 26.250 444.429 Td /F1 9.8 Tf  [(illness, \(2\) the perception of efficacy and safety of the vaccine, and \(3\) trust/distrust toward those advocating the vaccine.)] TJ ET
BT 26.250 425.024 Td /F1 9.8 Tf  [(Conclusions: This national study indicates that social and cognitive determinants of pandemic influenza vaccine acceptance )] TJ ET
BT 26.250 413.119 Td /F1 9.8 Tf  [(among French adults were relatively similar to those identified by previous studies of acceptance of seasonal influenza vaccine.)] TJ ET
BT 26.250 376.517 Td /F4 12.0 Tf  [(Funding Statement)] TJ ET
BT 26.250 356.562 Td /F1 9.8 Tf  [(This research was funded by a grant from the Service d�Information du Gouvernement \(French Government Office for )] TJ ET
BT 26.250 344.658 Td /F1 9.8 Tf  [(Information\) which was in charge of the public communication related to the 2009 H1N1 pandemic influenza in France.)] TJ ET
BT 26.250 315.555 Td /F4 12.0 Tf  [(Introduction)] TJ ET
BT 26.250 295.601 Td /F1 9.8 Tf  [(In the aftermath of the emergence of the 2009 pandemic H1N1 influenza virus, large scale immunization has gradually became, )] TJ ET
BT 26.250 283.696 Td /F1 9.8 Tf  [(in the majority of the developed countries, the primary public health measure to prevent morbidity and mortality associated with )] TJ ET
BT 26.250 271.791 Td /F1 9.8 Tf  [(the disease. When the first vaccines were delivered in October 2009, a high level of vaccination coverage was reached by the )] TJ ET
BT 26.250 259.887 Td /F1 9.8 Tf  [(French government. As a precaution, enough vaccine was ordered from the pharmaceutical companies in order that 4 out of 5 )] TJ ET
BT 26.250 247.982 Td /F1 9.8 Tf  [(persons could receive two doses. Because vaccine production would take several months to complete, a prioritization plan was )] TJ ET
BT 26.250 236.077 Td /F1 9.8 Tf  [(announced � in which the most vulnerable people at risk \(persons suffering from chronic illness, people working in health or )] TJ ET
BT 26.250 224.172 Td /F1 9.8 Tf  [(child care-giving services, and parents of infants younger than 6 months\) were invited, by letter notification, to get vaccinated )] TJ ET
BT 26.250 212.268 Td /F1 9.8 Tf  [(first for free. In France, as in many other countries, the decision was made to provide immunizations exclusively at )] TJ ET
BT 520.438 212.268 Td /F5 9.8 Tf  [(ad hoc)] TJ ET
BT 26.250 200.363 Td /F1 9.8 Tf  [(vaccination centers for cost-effectiveness reasons. The potential benefits of pandemic H1N1 influenza vaccination for at risk )] TJ ET
BT 26.250 188.458 Td /F1 9.8 Tf  [(groups were threefold: personal protection, protection of relatives, and reduction of absenteeism. In December, the vaccine was )] TJ ET
BT 26.250 176.553 Td /F1 9.8 Tf  [(extended to the rest of the population. At this time, there was good evidence that the vaccine was highly effective in preventing )] TJ ET
BT 26.250 164.649 Td /F1 9.8 Tf  [(serologically confirmed influenza, and that it had limited potential side effects )] TJ ET
0.267 0.267 0.267 rg
BT 359.524 164.649 Td /F1 9.8 Tf  [([1])] TJ ET
BT 370.366 164.649 Td /F1 9.8 Tf  [([2])] TJ ET
0.271 0.267 0.267 rg
BT 381.208 164.649 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 145.244 Td /F1 9.8 Tf  [(Despite considerable efforts to persuade the greatest number of people to receive the 2009 pandemic H1N1 influenza vaccine, )] TJ ET
BT 26.250 133.339 Td /F1 9.8 Tf  [(the rate of immunization among French people was rather low: only 10% of the population had been vaccinated at the end of )] TJ ET
BT 26.250 121.434 Td /F1 9.8 Tf  [(the campaign in January 2010 )] TJ ET
0.267 0.267 0.267 rg
BT 159.571 121.434 Td /F1 9.8 Tf  [([3])] TJ ET
0.271 0.267 0.267 rg
BT 170.413 121.434 Td /F1 9.8 Tf  [(. As in many countries, the relative failure of the immunization campaign against the pandemic )] TJ ET
BT 26.250 109.530 Td /F1 9.8 Tf  [(influenza in France reminds us that the failure or success of any prevention is ultimately determined by the public acceptance of )] TJ ET
BT 26.250 97.625 Td /F1 9.8 Tf  [(the mitigating measures deployed by the public health authorities. The aim of the present study is to better understand the )] TJ ET
BT 26.250 85.720 Td /F1 9.8 Tf  [(reasons for accepting or refusing vaccination. The relative breakdown of the French vaccination program raises 3 critical )] TJ ET
BT 26.250 73.815 Td /F1 9.8 Tf  [(questions: given an equal exposure to information due to intensive media coverage, were individuals of all health and social )] TJ ET
BT 26.250 61.911 Td /F1 9.8 Tf  [(conditions equally likely to accept vaccination? If not, what kinds of individuals were most and least likely to accept vaccination? )] TJ ET
BT 26.250 50.006 Td /F1 9.8 Tf  [(And )] TJ ET
BT 46.306 50.006 Td /F5 9.8 Tf  [(last but not least)] TJ ET
BT 117.305 50.006 Td /F1 9.8 Tf  [( why some kinds of individuals were more likely to accept vaccination?)] TJ ET
Q
q
15.000 684.354 577.500 53.646 re W n
0.267 0.267 0.267 rg
BT 15.000 718.042 Td /F2 21.0 Tf  [(The 2009 pandemic H1N1 influenza vaccination in France: who )] TJ ET
BT 15.000 693.094 Td /F2 21.0 Tf  [(accepted to receive the vaccine and why?)] TJ ET
Q
0.271 0.267 0.267 rg
BT 15.000 675.088 Td /F3 9.8 Tf  [(October 19, 2010)] TJ ET
BT 26.250 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
BT 31.671 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 37.092 663.247 Td /F1 9.8 Tf  [(Jocelyn Raude)] TJ ET
0.271 0.267 0.267 rg
BT 101.579 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 107.000 663.247 Td /F1 9.8 Tf  [(Anne-Laure Caille-Brillet)] TJ ET
0.271 0.267 0.267 rg
BT 212.651 663.247 Td /F1 9.8 Tf  [(, )] TJ ET
0.267 0.267 0.267 rg
BT 218.072 663.247 Td /F1 9.8 Tf  [(Michel SETBON)] TJ ET
0.271 0.267 0.267 rg
BT 26.250 651.342 Td /F1 9.8 Tf  [(Raude J, Caille-Brillet A, SETBON M. The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the )] TJ ET
BT 26.250 639.438 Td /F1 9.8 Tf  [(vaccine and why?. PLOS Currents Influenza. 2010 Oct 19 . Edition 1. doi: 10.1371/currents.RRN1188.)] TJ ET
q
15.000 40.125 577.500 596.932 re W n
0.271 0.267 0.267 rg
BT 26.250 610.335 Td /F4 12.0 Tf  [(Abstract)] TJ ET
BT 26.250 590.381 Td /F1 9.8 Tf  [(Introduction: Previous studies investigating determinants of 2009 \(H1N1\) pandemic influenza vaccine acceptance have focused )] TJ ET
BT 26.250 578.476 Td /F1 9.8 Tf  [(on target groups such as healthcare workers. Few studies in the European Union have examined the self-reported reasons as )] TJ ET
BT 26.250 566.571 Td /F1 9.8 Tf  [(well as predictive socio-demographic and health factors for pandemic influenza vaccine acceptance in the general population, )] TJ ET
BT 26.250 554.667 Td /F1 9.8 Tf  [(even though influenza vaccine was recommended for all people.)] TJ ET
BT 26.250 535.262 Td /F1 9.8 Tf  [(Methods: A nationwide telephone survey was conducted in France during the peak of the outbreak that occurred in December )] TJ ET
BT 26.250 523.357 Td /F1 9.8 Tf  [(2009 in adults \(? 16 years\), using a proportional random-digit dialing.)] TJ ET
BT 26.250 503.952 Td /F1 9.8 Tf  [(Results: Interviews were completed by 1003 individuals, of whom 275 \(27.4%\) either had received pandemic influenza vaccine )] TJ ET
BT 26.250 492.048 Td /F1 9.8 Tf  [(during the last weeks or intended to get vaccinated in the next weeks. Acceptance rates of pandemic vaccine were significantly )] TJ ET
BT 26.250 480.143 Td /F1 9.8 Tf  [(higher among men, more educated and wealthier people, as well as persons who had a prior experience of influenza )] TJ ET
BT 26.250 468.238 Td /F1 9.8 Tf  [(vaccination. The patterns of self-reported reasons for vaccine acceptance could be broadly divided into 3 groups related to \(1\) )] TJ ET
BT 26.250 456.333 Td /F1 9.8 Tf  [(the mental representation of the threat � in particular the beliefs associated with the severity and personal vulnerability to the )] TJ ET
BT 26.250 444.429 Td /F1 9.8 Tf  [(illness, \(2\) the perception of efficacy and safety of the vaccine, and \(3\) trust/distrust toward those advocating the vaccine.)] TJ ET
BT 26.250 425.024 Td /F1 9.8 Tf  [(Conclusions: This national study indicates that social and cognitive determinants of pandemic influenza vaccine acceptance )] TJ ET
BT 26.250 413.119 Td /F1 9.8 Tf  [(among French adults were relatively similar to those identified by previous studies of acceptance of seasonal influenza vaccine.)] TJ ET
BT 26.250 376.517 Td /F4 12.0 Tf  [(Funding Statement)] TJ ET
BT 26.250 356.562 Td /F1 9.8 Tf  [(This research was funded by a grant from the Service d�Information du Gouvernement \(French Government Office for )] TJ ET
BT 26.250 344.658 Td /F1 9.8 Tf  [(Information\) which was in charge of the public communication related to the 2009 H1N1 pandemic influenza in France.)] TJ ET
BT 26.250 315.555 Td /F4 12.0 Tf  [(Introduction)] TJ ET
BT 26.250 295.601 Td /F1 9.8 Tf  [(In the aftermath of the emergence of the 2009 pandemic H1N1 influenza virus, large scale immunization has gradually became, )] TJ ET
BT 26.250 283.696 Td /F1 9.8 Tf  [(in the majority of the developed countries, the primary public health measure to prevent morbidity and mortality associated with )] TJ ET
BT 26.250 271.791 Td /F1 9.8 Tf  [(the disease. When the first vaccines were delivered in October 2009, a high level of vaccination coverage was reached by the )] TJ ET
BT 26.250 259.887 Td /F1 9.8 Tf  [(French government. As a precaution, enough vaccine was ordered from the pharmaceutical companies in order that 4 out of 5 )] TJ ET
BT 26.250 247.982 Td /F1 9.8 Tf  [(persons could receive two doses. Because vaccine production would take several months to complete, a prioritization plan was )] TJ ET
BT 26.250 236.077 Td /F1 9.8 Tf  [(announced � in which the most vulnerable people at risk \(persons suffering from chronic illness, people working in health or )] TJ ET
BT 26.250 224.172 Td /F1 9.8 Tf  [(child care-giving services, and parents of infants younger than 6 months\) were invited, by letter notification, to get vaccinated )] TJ ET
BT 26.250 212.268 Td /F1 9.8 Tf  [(first for free. In France, as in many other countries, the decision was made to provide immunizations exclusively at )] TJ ET
BT 520.438 212.268 Td /F5 9.8 Tf  [(ad hoc)] TJ ET
BT 26.250 200.363 Td /F1 9.8 Tf  [(vaccination centers for cost-effectiveness reasons. The potential benefits of pandemic H1N1 influenza vaccination for at risk )] TJ ET
BT 26.250 188.458 Td /F1 9.8 Tf  [(groups were threefold: personal protection, protection of relatives, and reduction of absenteeism. In December, the vaccine was )] TJ ET
BT 26.250 176.553 Td /F1 9.8 Tf  [(extended to the rest of the population. At this time, there was good evidence that the vaccine was highly effective in preventing )] TJ ET
BT 26.250 164.649 Td /F1 9.8 Tf  [(serologically confirmed influenza, and that it had limited potential side effects )] TJ ET
0.267 0.267 0.267 rg
BT 359.524 164.649 Td /F1 9.8 Tf  [([1])] TJ ET
BT 370.366 164.649 Td /F1 9.8 Tf  [([2])] TJ ET
0.271 0.267 0.267 rg
BT 381.208 164.649 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 145.244 Td /F1 9.8 Tf  [(Despite considerable efforts to persuade the greatest number of people to receive the 2009 pandemic H1N1 influenza vaccine, )] TJ ET
BT 26.250 133.339 Td /F1 9.8 Tf  [(the rate of immunization among French people was rather low: only 10% of the population had been vaccinated at the end of )] TJ ET
BT 26.250 121.434 Td /F1 9.8 Tf  [(the campaign in January 2010 )] TJ ET
0.267 0.267 0.267 rg
BT 159.571 121.434 Td /F1 9.8 Tf  [([3])] TJ ET
0.271 0.267 0.267 rg
BT 170.413 121.434 Td /F1 9.8 Tf  [(. As in many countries, the relative failure of the immunization campaign against the pandemic )] TJ ET
BT 26.250 109.530 Td /F1 9.8 Tf  [(influenza in France reminds us that the failure or success of any prevention is ultimately determined by the public acceptance of )] TJ ET
BT 26.250 97.625 Td /F1 9.8 Tf  [(the mitigating measures deployed by the public health authorities. The aim of the present study is to better understand the )] TJ ET
BT 26.250 85.720 Td /F1 9.8 Tf  [(reasons for accepting or refusing vaccination. The relative breakdown of the French vaccination program raises 3 critical )] TJ ET
BT 26.250 73.815 Td /F1 9.8 Tf  [(questions: given an equal exposure to information due to intensive media coverage, were individuals of all health and social )] TJ ET
BT 26.250 61.911 Td /F1 9.8 Tf  [(conditions equally likely to accept vaccination? If not, what kinds of individuals were most and least likely to accept vaccination? )] TJ ET
BT 26.250 50.006 Td /F1 9.8 Tf  [(And )] TJ ET
BT 46.306 50.006 Td /F5 9.8 Tf  [(last but not least)] TJ ET
BT 117.305 50.006 Td /F1 9.8 Tf  [( why some kinds of individuals were more likely to accept vaccination?)] TJ ET
Q
q
0.000 0.000 0.000 rg
BT 291.710 19.825 Td /F1 11.0 Tf  [(1)] TJ ET
BT 25.000 19.825 Td /F1 11.0 Tf  [(PLOS Currents Influenza)] TJ ET

Q
endstream
endobj
8 0 obj
<< /Type /Font
/Subtype /Type1
/Name /F1
/BaseFont /Helvetica
/Encoding /WinAnsiEncoding
>>
endobj
9 0 obj
<< /Type /Font
/Subtype /Type1
/Name /F2
/BaseFont /Times-Bold
/Encoding /WinAnsiEncoding
>>
endobj
10 0 obj
<< /Type /Font
/Subtype /Type1
/Name /F3
/BaseFont /Times-Italic
/Encoding /WinAnsiEncoding
>>
endobj
11 0 obj
<< /Type /Font
/Subtype /Type1
/Name /F4
/BaseFont /Helvetica-Bold
/Encoding /WinAnsiEncoding
>>
endobj
12 0 obj
<< /Type /Font
/Subtype /Type1
/Name /F5
/BaseFont /Helvetica-Oblique
/Encoding /WinAnsiEncoding
>>
endobj
13 0 obj
<<
/Type /XObject
/Subtype /Image
/Width 500
/Height 52
/Filter /FlateDecode
/DecodeParms << /Predictor 15 /Colors 1 /Columns 500 /BitsPerComponent 8>>
/ColorSpace /DeviceGray
/BitsPerComponent 8
/Length 144>>
stream
x���1
0���'ݲ؎�"e����{��dz��A��dz��A��dz��A��dz��A��dz��A��dz��A��dz��A��dz��A��dz��A��dz��A��dz��A��dz��A��tlM0\
endstream
endobj
14 0 obj
<<
/Type /XObject
/Subtype /Image
/Width 500
/Height 52
/SMask 13 0 R
/Filter /FlateDecode
/DecodeParms << /Predictor 15 /Colors 3 /Columns 500 /BitsPerComponent 8>>
/ColorSpace /DeviceRGB
/BitsPerComponent 8
/Length 3574>>
stream
x���}��ƕ���K*8���+0T����
֮��
 �S
��
L*0�߇�d�"	��s�l2���FB��i�Fw��Y0�0����0�0��ŝa����0�
aqg����R܋�x||l���u2�03��U�L۶��B����x�I��0�<nf�{��?|߿U��0�<\�{Q]��q<Q��n�6�cz�u�~�o�v�\�V+�W�A۶���x�0̥�{�u]�着� �w����E���(�l�f^U��0���f���
a�7������]���g��(
Rv!D۶eYή�a����d:Rڶ�
��<)��r�������+����W�u���}����ڶ��a]�u]7�^0���<�j��
��5M�/�ǣ�/�L��t:��TU�v<���y�~b}ߏ�(�skk�<WV�|y�GQdm��2�2k�M��2�а(�����A������iT���yq�]@�,Sۆ��(��vA�v`�e��P�¼˨D�U�w�j��Ȧi��:�yØ���|n���*���t��X;�z��I<��NL����_U�h�(�.���0q�r�Zi��z�]��[�⮍j���Z		�z���h$K��z��)�.��}�nq�[C��j��=��̸ĝ8��dBV<���4����8�N��V.���	�8)�(�5���C��EU�Z�nq?��s���)�2հ5O4$�tLUU�����S��G�,
!f�*����v0�TG>:UU����0�x�;֝�����(���$�z%ș���H��ڶ
ÐV�z��
]�I��S����>â(.*� �TQUu�L5���$��<o�ZUUu��;wq���}�&�P�%&�$ɥk���S�AdY�nw�q3"�eY&I"��6��B����|�N�TJ	�|���$If���:�h�Vv��^TÕs�8{E7�D}yy�뺮�(h�\=S�u]�e�a�td��<>>���������B��v���p�H�0��U:��xk�k�G��J�T{�O��ɗRNy��GOΙyn�)�q7��`(~_Ji���2��v����g�k��]�qV��ꔷ���3�N'ȴ�y4Ikm�6!q:��FJ)�-�0n��܋���v�!�^����}_����Z�� �l6��1���v�a��_�~B���x�w8�m��v;��EJY����8}zz�Q3]�P�ȹ
�,2���_����j�fY�4M����Q[�����'.uO
����O͋���kշ��9b���
6�
.#�ߦ��UU�zh���f�0��9+�n��Kɿ4
��f7��B���u7Ĩ�M�f���rF������0`��s8�4�2����9j���1}���ZW�D�W;A��4ҫ�'T�Q�{��7��C�b��[����$��� �-�"�Ψ�MQg�zN/�2��R�7�T��co*W:��N݋6TUu8`�R�S��i
O>�r��;��z^m��(��0�w�`:m�=�]գ�CE���&�t �|Z�YQ%�{�X[n�R+zb��EF�Χ��5�pzq��`��ުం����I�h��{�9�������G�4�wM��x'	��nm�vEZ����sg7?Z��Q}�&�Ҏ�KGuP
u.j8�Ug�N��K��ꓙ���Q��C��)�s���#�$1��
䧈x��[��Z(|���X��z��c�;t<~5�0Hh_���T3����Ur�>a��$�]��B8���Fz�[?��K����>��Y�/��r������Q=�E��4�����?E��aL�q�������z��p�X��!���(��n�N��ut]�}e(�����/�S�\�fz,��<��Z�OEa]�0sCS��_�����}��I��� �Y��}��n۶�r��(�fg�7�����#�)h6��ա���}�$��üvq��]�Aא�$�c�0ddBDQ��)��u�ey���p��U-��z~��9�Hk<���$I©��y'�����T��k��`y�Y
�	d����}�e������{䨙�ǐ��u>���&�w񚓶(���'G�I�\�r�m[�������G��4Sk������7$�����B� p���E�kYY�C�/��9���&Ʋ��[�V��9����M��Q�':X�|�C���֨ʉ��j�t�"ޡ+r�ttBռG�d�i���MFu��TE�i(łv]f��k�"�8��Ldp'� �^�ה�M�up2`M?������dE��!|���K���J-�\.M��z�کC=��&��¾H�f�R<??_�p�
�u�:��4��֬灝x�&l�I�o�v�X�>7$e��v��,�La0+$�O���F�uEQ��"����i�,ːN�?~�E�������*�t��4��q���Κ�F��:�t�`�,{�R�kR]ޜ(�Ԕѣ$IbN��}��5ل�S1(�Ȱ�$I������$����(eW���p8�L��ٱ3߯ky��۶�&���.Ck�+����'��k��L'`Y��G��<��=j�ͦ�:�l/��@�ߧ��x��$'�U�ewY�V_�|���H獃��ׯ_���ϲ,�j##k4��=�n���̲�,KSq��^��������m[�P����'�̚�ݮ(�8���.����ﱟ5�����f��3�����M�h'ͲI��.������u7��~�~���Ӫ3��'i�91<EH�
�6g�(rF��#�˝���f�<kq7h�����֡�2SZ⸮K'T�#R`>ӜP����	���j�0kY���4j��Bv0��4���Y���-CV'9��H�藗�̑ʬEFX��R�8�~C�������BBg,J�}����<���?��#���&(X�} ����v��m��-��������-1����F��<�6d���
������䣨��*m���������ރ,���;�]u �X.�������a���_��s�����OH5au��U���y�Ӫ3�q�<o��hb�W{�Ê_�׏��d�!�v���0���dYv�(�AՊA01l`�q�I�U�6�A�9$6�
�d�Q�
E��I�H)�/1EQ�[D	!�8���h�|"�{p�Z�]��"�Q�[�MbFq7�F?�Ӊ��uw�dJ=R���S�5>w�IX"@� צYZ�
��iL�A�����+��-�^����!�;5���
ނ_�gB�
�<t	�0���|wX~2bў����k۶�{��0W�\.g{�,O�3�
֊�Ѣz4pu���mqu����&�3�8E=X�}�R~��m����r�t,۩�Z]B�}T�S��Y���i	�zʲD�
s��#���� 	w
]m���+­��{���bq��FQdu�2w�a+���� ѣ�=t��,�7�0��3�[�d��`���D��"���-�e���L��w�Q�����G�[����0����]�h�9I��0�/��{���t��Fw�c�a~!�-�0��B.��a�a~X��a> ,��0w�a��;�0��ŝa��?���9
endstream
endobj
15 0 obj
<< /Type /Annot
/Subtype /Link
/A 16 0 R
/Border [0 0 0]
/H /I
/Rect [ 15.0000 716.1516 589.6020 736.9416 ]
>>
endobj
16 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/article/the-2009-pandemic-h1n1-influenza-25dlajr91hxw3-1/)
>>
endobj
17 0 obj
<< /Type /Annot
/Subtype /Link
/A 18 0 R
/Border [0 0 0]
/H /I
/Rect [ 15.0000 691.2036 381.2610 711.9936 ]
>>
endobj
18 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/article/the-2009-pandemic-h1n1-influenza-25dlajr91hxw3-1/)
>>
endobj
19 0 obj
<< /Type /Annot
/Subtype /Link
/A 20 0 R
/Border [0 0 0]
/H /I
/Rect [ 37.0920 662.3453 101.5785 672.2659 ]
>>
endobj
20 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/jocelynraude/)
>>
endobj
21 0 obj
<< /Type /Annot
/Subtype /Link
/A 22 0 R
/Border [0 0 0]
/H /I
/Rect [ 106.9995 662.3453 212.6505 672.2659 ]
>>
endobj
22 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/annelaurecaillebrillet/)
>>
endobj
23 0 obj
<< /Type /Annot
/Subtype /Link
/A 24 0 R
/Border [0 0 0]
/H /I
/Rect [ 218.0715 662.3453 289.0417 672.2659 ]
>>
endobj
24 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/michelsetbon/)
>>
endobj
25 0 obj
<< /Type /Annot
/Subtype /Link
/A 26 0 R
/Border [0 0 0]
/H /I
/Rect [ 359.5245 163.7468 370.3665 173.6675 ]
>>
endobj
26 0 obj
<< /Type /Action
>>
endobj
27 0 obj
<< /Type /Annot
/Subtype /Link
/A 28 0 R
/Border [0 0 0]
/H /I
/Rect [ 370.3665 163.7468 381.2085 173.6675 ]
>>
endobj
28 0 obj
<< /Type /Action
>>
endobj
29 0 obj
<< /Type /Annot
/Subtype /Link
/A 30 0 R
/Border [0 0 0]
/H /I
/Rect [ 159.5715 120.5326 170.4135 130.4532 ]
>>
endobj
30 0 obj
<< /Type /Action
>>
endobj
31 0 obj
<< /Type /Annot
/Subtype /Link
/A 32 0 R
/Border [0 0 0]
/H /I
/Rect [ 15.0000 716.1516 589.6020 736.9416 ]
>>
endobj
32 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/article/the-2009-pandemic-h1n1-influenza-25dlajr91hxw3-1/)
>>
endobj
33 0 obj
<< /Type /Annot
/Subtype /Link
/A 34 0 R
/Border [0 0 0]
/H /I
/Rect [ 15.0000 691.2036 381.2610 711.9936 ]
>>
endobj
34 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/article/the-2009-pandemic-h1n1-influenza-25dlajr91hxw3-1/)
>>
endobj
35 0 obj
<< /Type /Annot
/Subtype /Link
/A 36 0 R
/Border [0 0 0]
/H /I
/Rect [ 37.0920 662.3453 101.5785 672.2659 ]
>>
endobj
36 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/jocelynraude/)
>>
endobj
37 0 obj
<< /Type /Annot
/Subtype /Link
/A 38 0 R
/Border [0 0 0]
/H /I
/Rect [ 106.9995 662.3453 212.6505 672.2659 ]
>>
endobj
38 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/annelaurecaillebrillet/)
>>
endobj
39 0 obj
<< /Type /Annot
/Subtype /Link
/A 40 0 R
/Border [0 0 0]
/H /I
/Rect [ 218.0715 662.3453 289.0417 672.2659 ]
>>
endobj
40 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/michelsetbon/)
>>
endobj
41 0 obj
<< /Type /Annot
/Subtype /Link
/A 42 0 R
/Border [0 0 0]
/H /I
/Rect [ 359.5245 163.7468 370.3665 173.6675 ]
>>
endobj
42 0 obj
<< /Type /Action
>>
endobj
43 0 obj
<< /Type /Annot
/Subtype /Link
/A 44 0 R
/Border [0 0 0]
/H /I
/Rect [ 370.3665 163.7468 381.2085 173.6675 ]
>>
endobj
44 0 obj
<< /Type /Action
>>
endobj
45 0 obj
<< /Type /Annot
/Subtype /Link
/A 46 0 R
/Border [0 0 0]
/H /I
/Rect [ 159.5715 120.5326 170.4135 130.4532 ]
>>
endobj
46 0 obj
<< /Type /Action
>>
endobj
47 0 obj
<< /Type /Annot
/Subtype /Link
/A 48 0 R
/Border [0 0 0]
/H /I
/Rect [ 15.0000 716.1516 589.6020 736.9416 ]
>>
endobj
48 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/article/the-2009-pandemic-h1n1-influenza-25dlajr91hxw3-1/)
>>
endobj
49 0 obj
<< /Type /Annot
/Subtype /Link
/A 50 0 R
/Border [0 0 0]
/H /I
/Rect [ 15.0000 691.2036 381.2610 711.9936 ]
>>
endobj
50 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/article/the-2009-pandemic-h1n1-influenza-25dlajr91hxw3-1/)
>>
endobj
51 0 obj
<< /Type /Annot
/Subtype /Link
/A 52 0 R
/Border [0 0 0]
/H /I
/Rect [ 37.0920 662.3453 101.5785 672.2659 ]
>>
endobj
52 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/jocelynraude/)
>>
endobj
53 0 obj
<< /Type /Annot
/Subtype /Link
/A 54 0 R
/Border [0 0 0]
/H /I
/Rect [ 106.9995 662.3453 212.6505 672.2659 ]
>>
endobj
54 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/annelaurecaillebrillet/)
>>
endobj
55 0 obj
<< /Type /Annot
/Subtype /Link
/A 56 0 R
/Border [0 0 0]
/H /I
/Rect [ 218.0715 662.3453 289.0417 672.2659 ]
>>
endobj
56 0 obj
<< /Type /Action
/S /URI
/URI (http://currents.plos.org/influenza/author/michelsetbon/)
>>
endobj
57 0 obj
<< /Type /Annot
/Subtype /Link
/A 58 0 R
/Border [0 0 0]
/H /I
/Rect [ 359.5245 163.7468 370.3665 173.6675 ]
>>
endobj
58 0 obj
<< /Type /Action
>>
endobj
59 0 obj
<< /Type /Annot
/Subtype /Link
/A 60 0 R
/Border [0 0 0]
/H /I
/Rect [ 370.3665 163.7468 381.2085 173.6675 ]
>>
endobj
60 0 obj
<< /Type /Action
>>
endobj
61 0 obj
<< /Type /Annot
/Subtype /Link
/A 62 0 R
/Border [0 0 0]
/H /I
/Rect [ 159.5715 120.5326 170.4135 130.4532 ]
>>
endobj
62 0 obj
<< /Type /Action
>>
endobj
63 0 obj
<< /Type /Page
/Parent 3 0 R
/Annots [ 65 0 R 67 0 R 69 0 R ]
/Contents 64 0 R
>>
endobj
64 0 obj
<<
/Length 31495 >>
stream

0.271 0.267 0.267 rg
q
15.000 69.156 577.500 707.844 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(Toward this goal, a nationwide survey was performed during the peak of the outbreak, which occurred one month after the )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(beginning of the immunization campaign, to identify \(1\) socioeconomic and health conditions that were statistically associated )] TJ ET
BT 26.250 743.667 Td /F1 9.8 Tf  [(with vaccination against the 2009 pandemic H1N1 influenza virus and \(2\) to identify primary reasons that people spontaneously )] TJ ET
BT 26.250 731.762 Td /F1 9.8 Tf  [(reported for vaccination acceptance or non-acceptance in France. Understanding the perceived barriers and benefits that affect )] TJ ET
BT 26.250 719.857 Td /F1 9.8 Tf  [(the willingness to get vaccinated may be crucial to the development of more successful programs of immunization in the case )] TJ ET
BT 26.250 707.952 Td /F1 9.8 Tf  [(that a novel wave of pandemic H1N1 2009 influenza should occur in the next few months.)] TJ ET
BT 26.250 671.350 Td /F4 12.0 Tf  [(Data and methods)] TJ ET
BT 26.250 651.396 Td /F1 9.8 Tf  [(The empirical data were collected in France by means of computer-assisted telephone interviews \(CATI\) of French adults aged )] TJ ET
BT 26.250 639.491 Td /F1 9.8 Tf  [(16 and over from 28 November to 18 December 2009. A proportional random digit dialing was used to select the survey )] TJ ET
BT 26.250 627.586 Td /F1 9.8 Tf  [(participants across the country. To ensure the national representativeness of the sample, a stratified selection procedure based )] TJ ET
BT 26.250 615.681 Td /F1 9.8 Tf  [(on the administrative area population \(regions and communes\) was used. Furthermore, the gender, age and occupational status )] TJ ET
BT 26.250 603.777 Td /F1 9.8 Tf  [(of respondents were controlled by the use of quotas so that the sample approximated the last France Census data. A maximum )] TJ ET
BT 26.250 591.872 Td /F1 9.8 Tf  [(of 5 telephone calls were performed to contact each potential respondent � mainly during evenings and weekends. )] TJ ET
BT 26.250 579.967 Td /F1 9.8 Tf  [(Respondents were informed that the survey related to H1N1 influenza pandemic in order to obtain their verbal consent.)] TJ ET
BT 26.250 560.562 Td /F1 9.8 Tf  [(Open-ended questions were asked allowing respondents to identify their reasons for accepting or refusing to be vaccinated )] TJ ET
BT 26.250 548.658 Td /F1 9.8 Tf  [(against the 2009 pandemic H1N1 influenza. These types of questions typically provide relevant insights into common barriers to )] TJ ET
BT 26.250 536.753 Td /F1 9.8 Tf  [(vaccination from the perspective of those being studied )] TJ ET
0.267 0.267 0.267 rg
BT 266.870 536.753 Td /F1 9.8 Tf  [([4])] TJ ET
0.271 0.267 0.267 rg
BT 277.712 536.753 Td /F1 9.8 Tf  [(. The survey also included several close-ended questions addressing )] TJ ET
BT 26.250 524.848 Td /F1 9.8 Tf  [(the social and health conditions of participants: socioeconomic and demographic characteristics, experience of previous )] TJ ET
BT 26.250 512.943 Td /F1 9.8 Tf  [(influenza vaccination, and risk factors identified by the public health authorities for the pandemic influenza \(pregnancy, chronic )] TJ ET
BT 26.250 501.039 Td /F1 9.8 Tf  [(illness, health or childcare work\). Multivariable logistic regressions were performed to identify the predictive variables )] TJ ET
BT 26.250 489.134 Td /F1 9.8 Tf  [(independently associated with the outcome variable �pandemic influenza vaccination acceptance� \(self-reported intention or )] TJ ET
BT 26.250 477.229 Td /F1 9.8 Tf  [(action of vaccination\) by controlling for potential confounders. PASW for Windows Release 18.0 was used to analyze the data )] TJ ET
BT 26.250 465.324 Td /F1 9.8 Tf  [(which were not weighted to the French population because of the use of a proportional sampling method.)] TJ ET
BT 26.250 428.722 Td /F4 12.0 Tf  [(Results)] TJ ET
BT 26.250 408.768 Td /F1 9.8 Tf  [(The computer assisted telephone process resulted in 10,984 telephone contacts from which 1003 interviews were completed. )] TJ ET
BT 26.250 396.863 Td /F1 9.8 Tf  [(Of the persons successfully contacted by the interviewers, 5,413 \(50.2%\) refused to participate, 4,041 \(36.8%\) were not eligible )] TJ ET
BT 26.250 384.958 Td /F1 9.8 Tf  [(\(due to quotas\), and the remainder asked to be called back later or had comprehension problems \(196 and 331, respectively\). )] TJ ET
BT 26.250 373.053 Td /F1 9.8 Tf  [(Overall, 45.9% accepted to participate in the survey. It should be noted that 41.1% of the participants reported at least one )] TJ ET
BT 26.250 361.149 Td /F1 9.8 Tf  [(attribute that placed them in the priority group for pandemic influenza H1N1 immunization. Finally, of the 1003 participants, )] TJ ET
BT 26.250 349.244 Td /F1 9.8 Tf  [(7.5% [95% CI, 5.9% to 9.1%] reported to have been vaccinated and 19.9% [95% CI, 17.5% to 22.3%] the intent to get )] TJ ET
BT 26.250 337.339 Td /F1 9.8 Tf  [(vaccinated against the 2009 pandemic H1N1 influenza virus, so that the total rate of vaccination acceptance could be estimated )] TJ ET
BT 26.250 325.434 Td /F1 9.8 Tf  [(at more than one quarter of the population \(27.4% [95% CI, 24.7% to 30.1%]\).)] TJ ET
BT 26.250 306.030 Td /F4 9.8 Tf  [(Table 1. Acceptance of vaccination against the 2009 pandemic H1N1 influenza virus among participants, according to )] TJ ET
BT 26.250 294.125 Td /F4 9.8 Tf  [(socio-demographic and health-related characteristics.)] TJ ET
1.000 1.000 1.000 rg
31.650 69.156 549.600 215.088 re f
0.000 0.000 0.000 rg
32.025 282.744 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 266.113 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 32.400 272.889 Td /F4 9.8 Tf  [(Characteristic)] TJ ET
0.000 0.000 0.000 rg
302.230 282.744 82.948 1.500 re f
0.271 0.267 0.267 rg
BT 302.230 272.889 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
385.178 282.744 147.918 1.500 re f
0.271 0.267 0.267 rg
BT 385.178 272.889 Td /F4 9.8 Tf  [(% \(95% CI\))] TJ ET
0.000 0.000 0.000 rg
533.095 282.744 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 266.113 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 533.095 272.889 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
32.025 266.113 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 251.732 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 257.008 Td /F4 9.8 Tf  [(Sex)] TJ ET
0.000 0.000 0.000 rg
302.230 266.113 82.948 1.500 re f
385.178 266.113 147.918 1.500 re f
533.095 266.113 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 251.732 0.750 15.881 re f
32.025 236.600 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 241.877 Td /F1 9.8 Tf  [(Male)] TJ ET
BT 302.230 241.877 Td /F1 9.8 Tf  [(154)] TJ ET
BT 385.178 241.877 Td /F1 9.8 Tf  [(33.4 \(29.1 to 37.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 236.600 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 241.877 Td /F1 9.8 Tf  [(461)] TJ ET
0.267 0.267 0.267 rg
32.025 221.469 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 226.745 Td /F1 9.8 Tf  [(Female)] TJ ET
BT 302.230 226.745 Td /F1 9.8 Tf  [(121)] TJ ET
BT 385.178 226.745 Td /F1 9.8 Tf  [(22.3 \(18.9 to 25.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 221.469 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 226.745 Td /F1 9.8 Tf  [(543)] TJ ET
0.267 0.267 0.267 rg
32.025 206.338 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 211.614 Td /F4 9.8 Tf  [(Age group)] TJ ET
0.267 0.267 0.267 rg
580.125 206.338 0.750 15.131 re f
32.025 191.207 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 196.483 Td /F1 9.8 Tf  [(16-24)] TJ ET
BT 302.230 196.483 Td /F1 9.8 Tf  [(14)] TJ ET
BT 385.178 196.483 Td /F1 9.8 Tf  [(17.9 \(9.4 to 26.4\))] TJ ET
0.267 0.267 0.267 rg
580.125 191.207 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 196.483 Td /F1 9.8 Tf  [(78)] TJ ET
0.267 0.267 0.267 rg
32.025 176.075 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 181.352 Td /F1 9.8 Tf  [(25-34)] TJ ET
BT 302.230 181.352 Td /F1 9.8 Tf  [(29)] TJ ET
BT 385.178 181.352 Td /F1 9.8 Tf  [(23.2 \(15.8 to 30.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 176.075 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 181.352 Td /F1 9.8 Tf  [(125)] TJ ET
0.267 0.267 0.267 rg
32.025 160.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 166.220 Td /F1 9.8 Tf  [(35-44)] TJ ET
BT 302.230 166.220 Td /F1 9.8 Tf  [(45)] TJ ET
BT 385.178 166.220 Td /F1 9.8 Tf  [(20.5 \(15.2 to 25.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 160.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 166.220 Td /F1 9.8 Tf  [(220)] TJ ET
0.267 0.267 0.267 rg
32.025 145.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 151.089 Td /F1 9.8 Tf  [(45-54)] TJ ET
BT 302.230 151.089 Td /F1 9.8 Tf  [(65)] TJ ET
BT 385.178 151.089 Td /F1 9.8 Tf  [(25.5 \(20.2 to 30.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 145.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 151.089 Td /F1 9.8 Tf  [(255)] TJ ET
0.267 0.267 0.267 rg
32.025 130.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 135.958 Td /F1 9.8 Tf  [(55-64)] TJ ET
BT 302.230 135.958 Td /F1 9.8 Tf  [(53)] TJ ET
BT 385.178 135.958 Td /F1 9.8 Tf  [(31.2 \(24.3 to 38.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 130.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 135.958 Td /F1 9.8 Tf  [(170)] TJ ET
0.267 0.267 0.267 rg
32.025 115.550 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 120.827 Td /F1 9.8 Tf  [(? 65)] TJ ET
BT 302.230 120.827 Td /F1 9.8 Tf  [(69)] TJ ET
BT 385.178 120.827 Td /F1 9.8 Tf  [(44.2 \(36.4 to 52.0\))] TJ ET
0.267 0.267 0.267 rg
580.125 115.550 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 120.827 Td /F1 9.8 Tf  [(156)] TJ ET
0.267 0.267 0.267 rg
32.025 100.419 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 105.695 Td /F4 9.8 Tf  [(Occupation)] TJ ET
0.267 0.267 0.267 rg
580.125 100.419 0.750 15.131 re f
32.025 85.288 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 90.564 Td /F1 9.8 Tf  [(Students)] TJ ET
BT 302.230 90.564 Td /F1 9.8 Tf  [(10)] TJ ET
BT 385.178 90.564 Td /F1 9.8 Tf  [(16.7 \(7.3 to 26.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 85.288 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 90.564 Td /F1 9.8 Tf  [(60)] TJ ET
0.267 0.267 0.267 rg
32.025 70.156 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 75.433 Td /F1 9.8 Tf  [(Unemployed)] TJ ET
BT 302.230 75.433 Td /F1 9.8 Tf  [(20)] TJ ET
BT 385.178 75.433 Td /F1 9.8 Tf  [(20.4 \(12.4 to 28.4\))] TJ ET
0.267 0.267 0.267 rg
580.125 70.156 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 75.433 Td /F1 9.8 Tf  [(98)] TJ ET
Q
q
15.000 69.156 577.500 707.844 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(Toward this goal, a nationwide survey was performed during the peak of the outbreak, which occurred one month after the )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(beginning of the immunization campaign, to identify \(1\) socioeconomic and health conditions that were statistically associated )] TJ ET
BT 26.250 743.667 Td /F1 9.8 Tf  [(with vaccination against the 2009 pandemic H1N1 influenza virus and \(2\) to identify primary reasons that people spontaneously )] TJ ET
BT 26.250 731.762 Td /F1 9.8 Tf  [(reported for vaccination acceptance or non-acceptance in France. Understanding the perceived barriers and benefits that affect )] TJ ET
BT 26.250 719.857 Td /F1 9.8 Tf  [(the willingness to get vaccinated may be crucial to the development of more successful programs of immunization in the case )] TJ ET
BT 26.250 707.952 Td /F1 9.8 Tf  [(that a novel wave of pandemic H1N1 2009 influenza should occur in the next few months.)] TJ ET
BT 26.250 671.350 Td /F4 12.0 Tf  [(Data and methods)] TJ ET
BT 26.250 651.396 Td /F1 9.8 Tf  [(The empirical data were collected in France by means of computer-assisted telephone interviews \(CATI\) of French adults aged )] TJ ET
BT 26.250 639.491 Td /F1 9.8 Tf  [(16 and over from 28 November to 18 December 2009. A proportional random digit dialing was used to select the survey )] TJ ET
BT 26.250 627.586 Td /F1 9.8 Tf  [(participants across the country. To ensure the national representativeness of the sample, a stratified selection procedure based )] TJ ET
BT 26.250 615.681 Td /F1 9.8 Tf  [(on the administrative area population \(regions and communes\) was used. Furthermore, the gender, age and occupational status )] TJ ET
BT 26.250 603.777 Td /F1 9.8 Tf  [(of respondents were controlled by the use of quotas so that the sample approximated the last France Census data. A maximum )] TJ ET
BT 26.250 591.872 Td /F1 9.8 Tf  [(of 5 telephone calls were performed to contact each potential respondent � mainly during evenings and weekends. )] TJ ET
BT 26.250 579.967 Td /F1 9.8 Tf  [(Respondents were informed that the survey related to H1N1 influenza pandemic in order to obtain their verbal consent.)] TJ ET
BT 26.250 560.562 Td /F1 9.8 Tf  [(Open-ended questions were asked allowing respondents to identify their reasons for accepting or refusing to be vaccinated )] TJ ET
BT 26.250 548.658 Td /F1 9.8 Tf  [(against the 2009 pandemic H1N1 influenza. These types of questions typically provide relevant insights into common barriers to )] TJ ET
BT 26.250 536.753 Td /F1 9.8 Tf  [(vaccination from the perspective of those being studied )] TJ ET
0.267 0.267 0.267 rg
BT 266.870 536.753 Td /F1 9.8 Tf  [([4])] TJ ET
0.271 0.267 0.267 rg
BT 277.712 536.753 Td /F1 9.8 Tf  [(. The survey also included several close-ended questions addressing )] TJ ET
BT 26.250 524.848 Td /F1 9.8 Tf  [(the social and health conditions of participants: socioeconomic and demographic characteristics, experience of previous )] TJ ET
BT 26.250 512.943 Td /F1 9.8 Tf  [(influenza vaccination, and risk factors identified by the public health authorities for the pandemic influenza \(pregnancy, chronic )] TJ ET
BT 26.250 501.039 Td /F1 9.8 Tf  [(illness, health or childcare work\). Multivariable logistic regressions were performed to identify the predictive variables )] TJ ET
BT 26.250 489.134 Td /F1 9.8 Tf  [(independently associated with the outcome variable �pandemic influenza vaccination acceptance� \(self-reported intention or )] TJ ET
BT 26.250 477.229 Td /F1 9.8 Tf  [(action of vaccination\) by controlling for potential confounders. PASW for Windows Release 18.0 was used to analyze the data )] TJ ET
BT 26.250 465.324 Td /F1 9.8 Tf  [(which were not weighted to the French population because of the use of a proportional sampling method.)] TJ ET
BT 26.250 428.722 Td /F4 12.0 Tf  [(Results)] TJ ET
BT 26.250 408.768 Td /F1 9.8 Tf  [(The computer assisted telephone process resulted in 10,984 telephone contacts from which 1003 interviews were completed. )] TJ ET
BT 26.250 396.863 Td /F1 9.8 Tf  [(Of the persons successfully contacted by the interviewers, 5,413 \(50.2%\) refused to participate, 4,041 \(36.8%\) were not eligible )] TJ ET
BT 26.250 384.958 Td /F1 9.8 Tf  [(\(due to quotas\), and the remainder asked to be called back later or had comprehension problems \(196 and 331, respectively\). )] TJ ET
BT 26.250 373.053 Td /F1 9.8 Tf  [(Overall, 45.9% accepted to participate in the survey. It should be noted that 41.1% of the participants reported at least one )] TJ ET
BT 26.250 361.149 Td /F1 9.8 Tf  [(attribute that placed them in the priority group for pandemic influenza H1N1 immunization. Finally, of the 1003 participants, )] TJ ET
BT 26.250 349.244 Td /F1 9.8 Tf  [(7.5% [95% CI, 5.9% to 9.1%] reported to have been vaccinated and 19.9% [95% CI, 17.5% to 22.3%] the intent to get )] TJ ET
BT 26.250 337.339 Td /F1 9.8 Tf  [(vaccinated against the 2009 pandemic H1N1 influenza virus, so that the total rate of vaccination acceptance could be estimated )] TJ ET
BT 26.250 325.434 Td /F1 9.8 Tf  [(at more than one quarter of the population \(27.4% [95% CI, 24.7% to 30.1%]\).)] TJ ET
BT 26.250 306.030 Td /F4 9.8 Tf  [(Table 1. Acceptance of vaccination against the 2009 pandemic H1N1 influenza virus among participants, according to )] TJ ET
BT 26.250 294.125 Td /F4 9.8 Tf  [(socio-demographic and health-related characteristics.)] TJ ET
1.000 1.000 1.000 rg
31.650 69.156 549.600 215.088 re f
0.000 0.000 0.000 rg
32.025 282.744 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 266.113 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 32.400 272.889 Td /F4 9.8 Tf  [(Characteristic)] TJ ET
0.000 0.000 0.000 rg
302.230 282.744 82.948 1.500 re f
0.271 0.267 0.267 rg
BT 302.230 272.889 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
385.178 282.744 147.918 1.500 re f
0.271 0.267 0.267 rg
BT 385.178 272.889 Td /F4 9.8 Tf  [(% \(95% CI\))] TJ ET
0.000 0.000 0.000 rg
533.095 282.744 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 266.113 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 533.095 272.889 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
32.025 266.113 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 251.732 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 257.008 Td /F4 9.8 Tf  [(Sex)] TJ ET
0.000 0.000 0.000 rg
302.230 266.113 82.948 1.500 re f
385.178 266.113 147.918 1.500 re f
533.095 266.113 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 251.732 0.750 15.881 re f
32.025 236.600 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 241.877 Td /F1 9.8 Tf  [(Male)] TJ ET
BT 302.230 241.877 Td /F1 9.8 Tf  [(154)] TJ ET
BT 385.178 241.877 Td /F1 9.8 Tf  [(33.4 \(29.1 to 37.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 236.600 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 241.877 Td /F1 9.8 Tf  [(461)] TJ ET
0.267 0.267 0.267 rg
32.025 221.469 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 226.745 Td /F1 9.8 Tf  [(Female)] TJ ET
BT 302.230 226.745 Td /F1 9.8 Tf  [(121)] TJ ET
BT 385.178 226.745 Td /F1 9.8 Tf  [(22.3 \(18.9 to 25.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 221.469 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 226.745 Td /F1 9.8 Tf  [(543)] TJ ET
0.267 0.267 0.267 rg
32.025 206.338 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 211.614 Td /F4 9.8 Tf  [(Age group)] TJ ET
0.267 0.267 0.267 rg
580.125 206.338 0.750 15.131 re f
32.025 191.207 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 196.483 Td /F1 9.8 Tf  [(16-24)] TJ ET
BT 302.230 196.483 Td /F1 9.8 Tf  [(14)] TJ ET
BT 385.178 196.483 Td /F1 9.8 Tf  [(17.9 \(9.4 to 26.4\))] TJ ET
0.267 0.267 0.267 rg
580.125 191.207 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 196.483 Td /F1 9.8 Tf  [(78)] TJ ET
0.267 0.267 0.267 rg
32.025 176.075 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 181.352 Td /F1 9.8 Tf  [(25-34)] TJ ET
BT 302.230 181.352 Td /F1 9.8 Tf  [(29)] TJ ET
BT 385.178 181.352 Td /F1 9.8 Tf  [(23.2 \(15.8 to 30.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 176.075 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 181.352 Td /F1 9.8 Tf  [(125)] TJ ET
0.267 0.267 0.267 rg
32.025 160.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 166.220 Td /F1 9.8 Tf  [(35-44)] TJ ET
BT 302.230 166.220 Td /F1 9.8 Tf  [(45)] TJ ET
BT 385.178 166.220 Td /F1 9.8 Tf  [(20.5 \(15.2 to 25.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 160.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 166.220 Td /F1 9.8 Tf  [(220)] TJ ET
0.267 0.267 0.267 rg
32.025 145.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 151.089 Td /F1 9.8 Tf  [(45-54)] TJ ET
BT 302.230 151.089 Td /F1 9.8 Tf  [(65)] TJ ET
BT 385.178 151.089 Td /F1 9.8 Tf  [(25.5 \(20.2 to 30.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 145.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 151.089 Td /F1 9.8 Tf  [(255)] TJ ET
0.267 0.267 0.267 rg
32.025 130.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 135.958 Td /F1 9.8 Tf  [(55-64)] TJ ET
BT 302.230 135.958 Td /F1 9.8 Tf  [(53)] TJ ET
BT 385.178 135.958 Td /F1 9.8 Tf  [(31.2 \(24.3 to 38.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 130.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 135.958 Td /F1 9.8 Tf  [(170)] TJ ET
0.267 0.267 0.267 rg
32.025 115.550 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 120.827 Td /F1 9.8 Tf  [(? 65)] TJ ET
BT 302.230 120.827 Td /F1 9.8 Tf  [(69)] TJ ET
BT 385.178 120.827 Td /F1 9.8 Tf  [(44.2 \(36.4 to 52.0\))] TJ ET
0.267 0.267 0.267 rg
580.125 115.550 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 120.827 Td /F1 9.8 Tf  [(156)] TJ ET
0.267 0.267 0.267 rg
32.025 100.419 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 105.695 Td /F4 9.8 Tf  [(Occupation)] TJ ET
0.267 0.267 0.267 rg
580.125 100.419 0.750 15.131 re f
32.025 85.288 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 90.564 Td /F1 9.8 Tf  [(Students)] TJ ET
BT 302.230 90.564 Td /F1 9.8 Tf  [(10)] TJ ET
BT 385.178 90.564 Td /F1 9.8 Tf  [(16.7 \(7.3 to 26.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 85.288 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 90.564 Td /F1 9.8 Tf  [(60)] TJ ET
0.267 0.267 0.267 rg
32.025 70.156 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 75.433 Td /F1 9.8 Tf  [(Unemployed)] TJ ET
BT 302.230 75.433 Td /F1 9.8 Tf  [(20)] TJ ET
BT 385.178 75.433 Td /F1 9.8 Tf  [(20.4 \(12.4 to 28.4\))] TJ ET
0.267 0.267 0.267 rg
580.125 70.156 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 75.433 Td /F1 9.8 Tf  [(98)] TJ ET
Q
q
15.000 69.156 577.500 707.844 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(Toward this goal, a nationwide survey was performed during the peak of the outbreak, which occurred one month after the )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(beginning of the immunization campaign, to identify \(1\) socioeconomic and health conditions that were statistically associated )] TJ ET
BT 26.250 743.667 Td /F1 9.8 Tf  [(with vaccination against the 2009 pandemic H1N1 influenza virus and \(2\) to identify primary reasons that people spontaneously )] TJ ET
BT 26.250 731.762 Td /F1 9.8 Tf  [(reported for vaccination acceptance or non-acceptance in France. Understanding the perceived barriers and benefits that affect )] TJ ET
BT 26.250 719.857 Td /F1 9.8 Tf  [(the willingness to get vaccinated may be crucial to the development of more successful programs of immunization in the case )] TJ ET
BT 26.250 707.952 Td /F1 9.8 Tf  [(that a novel wave of pandemic H1N1 2009 influenza should occur in the next few months.)] TJ ET
BT 26.250 671.350 Td /F4 12.0 Tf  [(Data and methods)] TJ ET
BT 26.250 651.396 Td /F1 9.8 Tf  [(The empirical data were collected in France by means of computer-assisted telephone interviews \(CATI\) of French adults aged )] TJ ET
BT 26.250 639.491 Td /F1 9.8 Tf  [(16 and over from 28 November to 18 December 2009. A proportional random digit dialing was used to select the survey )] TJ ET
BT 26.250 627.586 Td /F1 9.8 Tf  [(participants across the country. To ensure the national representativeness of the sample, a stratified selection procedure based )] TJ ET
BT 26.250 615.681 Td /F1 9.8 Tf  [(on the administrative area population \(regions and communes\) was used. Furthermore, the gender, age and occupational status )] TJ ET
BT 26.250 603.777 Td /F1 9.8 Tf  [(of respondents were controlled by the use of quotas so that the sample approximated the last France Census data. A maximum )] TJ ET
BT 26.250 591.872 Td /F1 9.8 Tf  [(of 5 telephone calls were performed to contact each potential respondent � mainly during evenings and weekends. )] TJ ET
BT 26.250 579.967 Td /F1 9.8 Tf  [(Respondents were informed that the survey related to H1N1 influenza pandemic in order to obtain their verbal consent.)] TJ ET
BT 26.250 560.562 Td /F1 9.8 Tf  [(Open-ended questions were asked allowing respondents to identify their reasons for accepting or refusing to be vaccinated )] TJ ET
BT 26.250 548.658 Td /F1 9.8 Tf  [(against the 2009 pandemic H1N1 influenza. These types of questions typically provide relevant insights into common barriers to )] TJ ET
BT 26.250 536.753 Td /F1 9.8 Tf  [(vaccination from the perspective of those being studied )] TJ ET
0.267 0.267 0.267 rg
BT 266.870 536.753 Td /F1 9.8 Tf  [([4])] TJ ET
0.271 0.267 0.267 rg
BT 277.712 536.753 Td /F1 9.8 Tf  [(. The survey also included several close-ended questions addressing )] TJ ET
BT 26.250 524.848 Td /F1 9.8 Tf  [(the social and health conditions of participants: socioeconomic and demographic characteristics, experience of previous )] TJ ET
BT 26.250 512.943 Td /F1 9.8 Tf  [(influenza vaccination, and risk factors identified by the public health authorities for the pandemic influenza \(pregnancy, chronic )] TJ ET
BT 26.250 501.039 Td /F1 9.8 Tf  [(illness, health or childcare work\). Multivariable logistic regressions were performed to identify the predictive variables )] TJ ET
BT 26.250 489.134 Td /F1 9.8 Tf  [(independently associated with the outcome variable �pandemic influenza vaccination acceptance� \(self-reported intention or )] TJ ET
BT 26.250 477.229 Td /F1 9.8 Tf  [(action of vaccination\) by controlling for potential confounders. PASW for Windows Release 18.0 was used to analyze the data )] TJ ET
BT 26.250 465.324 Td /F1 9.8 Tf  [(which were not weighted to the French population because of the use of a proportional sampling method.)] TJ ET
BT 26.250 428.722 Td /F4 12.0 Tf  [(Results)] TJ ET
BT 26.250 408.768 Td /F1 9.8 Tf  [(The computer assisted telephone process resulted in 10,984 telephone contacts from which 1003 interviews were completed. )] TJ ET
BT 26.250 396.863 Td /F1 9.8 Tf  [(Of the persons successfully contacted by the interviewers, 5,413 \(50.2%\) refused to participate, 4,041 \(36.8%\) were not eligible )] TJ ET
BT 26.250 384.958 Td /F1 9.8 Tf  [(\(due to quotas\), and the remainder asked to be called back later or had comprehension problems \(196 and 331, respectively\). )] TJ ET
BT 26.250 373.053 Td /F1 9.8 Tf  [(Overall, 45.9% accepted to participate in the survey. It should be noted that 41.1% of the participants reported at least one )] TJ ET
BT 26.250 361.149 Td /F1 9.8 Tf  [(attribute that placed them in the priority group for pandemic influenza H1N1 immunization. Finally, of the 1003 participants, )] TJ ET
BT 26.250 349.244 Td /F1 9.8 Tf  [(7.5% [95% CI, 5.9% to 9.1%] reported to have been vaccinated and 19.9% [95% CI, 17.5% to 22.3%] the intent to get )] TJ ET
BT 26.250 337.339 Td /F1 9.8 Tf  [(vaccinated against the 2009 pandemic H1N1 influenza virus, so that the total rate of vaccination acceptance could be estimated )] TJ ET
BT 26.250 325.434 Td /F1 9.8 Tf  [(at more than one quarter of the population \(27.4% [95% CI, 24.7% to 30.1%]\).)] TJ ET
BT 26.250 306.030 Td /F4 9.8 Tf  [(Table 1. Acceptance of vaccination against the 2009 pandemic H1N1 influenza virus among participants, according to )] TJ ET
BT 26.250 294.125 Td /F4 9.8 Tf  [(socio-demographic and health-related characteristics.)] TJ ET
1.000 1.000 1.000 rg
31.650 69.156 549.600 215.088 re f
0.000 0.000 0.000 rg
32.025 282.744 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 266.113 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 32.400 272.889 Td /F4 9.8 Tf  [(Characteristic)] TJ ET
0.000 0.000 0.000 rg
302.230 282.744 82.948 1.500 re f
0.271 0.267 0.267 rg
BT 302.230 272.889 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
385.178 282.744 147.918 1.500 re f
0.271 0.267 0.267 rg
BT 385.178 272.889 Td /F4 9.8 Tf  [(% \(95% CI\))] TJ ET
0.000 0.000 0.000 rg
533.095 282.744 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 266.113 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 533.095 272.889 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
32.025 266.113 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 251.732 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 257.008 Td /F4 9.8 Tf  [(Sex)] TJ ET
0.000 0.000 0.000 rg
302.230 266.113 82.948 1.500 re f
385.178 266.113 147.918 1.500 re f
533.095 266.113 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 251.732 0.750 15.881 re f
32.025 236.600 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 241.877 Td /F1 9.8 Tf  [(Male)] TJ ET
BT 302.230 241.877 Td /F1 9.8 Tf  [(154)] TJ ET
BT 385.178 241.877 Td /F1 9.8 Tf  [(33.4 \(29.1 to 37.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 236.600 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 241.877 Td /F1 9.8 Tf  [(461)] TJ ET
0.267 0.267 0.267 rg
32.025 221.469 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 226.745 Td /F1 9.8 Tf  [(Female)] TJ ET
BT 302.230 226.745 Td /F1 9.8 Tf  [(121)] TJ ET
BT 385.178 226.745 Td /F1 9.8 Tf  [(22.3 \(18.9 to 25.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 221.469 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 226.745 Td /F1 9.8 Tf  [(543)] TJ ET
0.267 0.267 0.267 rg
32.025 206.338 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 211.614 Td /F4 9.8 Tf  [(Age group)] TJ ET
0.267 0.267 0.267 rg
580.125 206.338 0.750 15.131 re f
32.025 191.207 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 196.483 Td /F1 9.8 Tf  [(16-24)] TJ ET
BT 302.230 196.483 Td /F1 9.8 Tf  [(14)] TJ ET
BT 385.178 196.483 Td /F1 9.8 Tf  [(17.9 \(9.4 to 26.4\))] TJ ET
0.267 0.267 0.267 rg
580.125 191.207 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 196.483 Td /F1 9.8 Tf  [(78)] TJ ET
0.267 0.267 0.267 rg
32.025 176.075 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 181.352 Td /F1 9.8 Tf  [(25-34)] TJ ET
BT 302.230 181.352 Td /F1 9.8 Tf  [(29)] TJ ET
BT 385.178 181.352 Td /F1 9.8 Tf  [(23.2 \(15.8 to 30.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 176.075 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 181.352 Td /F1 9.8 Tf  [(125)] TJ ET
0.267 0.267 0.267 rg
32.025 160.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 166.220 Td /F1 9.8 Tf  [(35-44)] TJ ET
BT 302.230 166.220 Td /F1 9.8 Tf  [(45)] TJ ET
BT 385.178 166.220 Td /F1 9.8 Tf  [(20.5 \(15.2 to 25.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 160.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 166.220 Td /F1 9.8 Tf  [(220)] TJ ET
0.267 0.267 0.267 rg
32.025 145.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 151.089 Td /F1 9.8 Tf  [(45-54)] TJ ET
BT 302.230 151.089 Td /F1 9.8 Tf  [(65)] TJ ET
BT 385.178 151.089 Td /F1 9.8 Tf  [(25.5 \(20.2 to 30.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 145.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 151.089 Td /F1 9.8 Tf  [(255)] TJ ET
0.267 0.267 0.267 rg
32.025 130.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 135.958 Td /F1 9.8 Tf  [(55-64)] TJ ET
BT 302.230 135.958 Td /F1 9.8 Tf  [(53)] TJ ET
BT 385.178 135.958 Td /F1 9.8 Tf  [(31.2 \(24.3 to 38.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 130.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 135.958 Td /F1 9.8 Tf  [(170)] TJ ET
0.267 0.267 0.267 rg
32.025 115.550 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 120.827 Td /F1 9.8 Tf  [(? 65)] TJ ET
BT 302.230 120.827 Td /F1 9.8 Tf  [(69)] TJ ET
BT 385.178 120.827 Td /F1 9.8 Tf  [(44.2 \(36.4 to 52.0\))] TJ ET
0.267 0.267 0.267 rg
580.125 115.550 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 120.827 Td /F1 9.8 Tf  [(156)] TJ ET
0.267 0.267 0.267 rg
32.025 100.419 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 105.695 Td /F4 9.8 Tf  [(Occupation)] TJ ET
0.267 0.267 0.267 rg
580.125 100.419 0.750 15.131 re f
32.025 85.288 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 90.564 Td /F1 9.8 Tf  [(Students)] TJ ET
BT 302.230 90.564 Td /F1 9.8 Tf  [(10)] TJ ET
BT 385.178 90.564 Td /F1 9.8 Tf  [(16.7 \(7.3 to 26.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 85.288 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 90.564 Td /F1 9.8 Tf  [(60)] TJ ET
0.267 0.267 0.267 rg
32.025 70.156 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 75.433 Td /F1 9.8 Tf  [(Unemployed)] TJ ET
BT 302.230 75.433 Td /F1 9.8 Tf  [(20)] TJ ET
BT 385.178 75.433 Td /F1 9.8 Tf  [(20.4 \(12.4 to 28.4\))] TJ ET
0.267 0.267 0.267 rg
580.125 70.156 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 75.433 Td /F1 9.8 Tf  [(98)] TJ ET
Q
q
0.000 0.000 0.000 rg
BT 291.710 19.825 Td /F1 11.0 Tf  [(2)] TJ ET
BT 25.000 19.825 Td /F1 11.0 Tf  [(PLOS Currents Influenza)] TJ ET

Q
endstream
endobj
65 0 obj
<< /Type /Annot
/Subtype /Link
/A 66 0 R
/Border [0 0 0]
/H /I
/Rect [ 266.8702 535.8511 277.7122 545.7717 ]
>>
endobj
66 0 obj
<< /Type /Action
>>
endobj
67 0 obj
<< /Type /Annot
/Subtype /Link
/A 68 0 R
/Border [0 0 0]
/H /I
/Rect [ 266.8702 535.8511 277.7122 545.7717 ]
>>
endobj
68 0 obj
<< /Type /Action
>>
endobj
69 0 obj
<< /Type /Annot
/Subtype /Link
/A 70 0 R
/Border [0 0 0]
/H /I
/Rect [ 266.8702 535.8511 277.7122 545.7717 ]
>>
endobj
70 0 obj
<< /Type /Action
>>
endobj
71 0 obj
<< /Type /Page
/Parent 3 0 R
/Contents 72 0 R
>>
endobj
72 0 obj
<<
/Length 41434 >>
stream

0.271 0.267 0.267 rg
q
15.000 0.860 577.500 776.140 re W n
1.000 1.000 1.000 rg
31.650 411.981 549.600 365.019 re f
0.267 0.267 0.267 rg
32.025 746.869 0.750 30.131 re f
0.271 0.267 0.267 rg
BT 32.400 767.145 Td /F1 9.8 Tf  [(Working)] TJ ET
BT 302.230 767.145 Td /F1 9.8 Tf  [(152)] TJ ET
BT 385.178 767.145 Td /F1 9.8 Tf  [(24.4 \(21.1 to 27.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 746.869 0.750 30.131 re f
0.271 0.267 0.267 rg
BT 533.095 767.145 Td /F1 9.8 Tf  [(623)] TJ ET
0.267 0.267 0.267 rg
32.025 731.737 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 737.014 Td /F1 9.8 Tf  [(Retired)] TJ ET
BT 302.230 737.014 Td /F1 9.8 Tf  [(93)] TJ ET
BT 385.178 737.014 Td /F1 9.8 Tf  [(42.1 \(35.6 to 48.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 731.737 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 737.014 Td /F1 9.8 Tf  [(221)] TJ ET
0.267 0.267 0.267 rg
32.025 716.606 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 721.883 Td /F4 9.8 Tf  [(Education)] TJ ET
0.267 0.267 0.267 rg
580.125 716.606 0.750 15.131 re f
32.025 701.475 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 706.751 Td /F1 9.8 Tf  [(Low)] TJ ET
BT 302.230 706.751 Td /F1 9.8 Tf  [(92)] TJ ET
BT 385.178 706.751 Td /F1 9.8 Tf  [(25.4 \(21.0 to 29.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 701.475 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 706.751 Td /F1 9.8 Tf  [(362)] TJ ET
0.267 0.267 0.267 rg
32.025 686.344 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 691.620 Td /F1 9.8 Tf  [(Intermediate)] TJ ET
BT 302.230 691.620 Td /F1 9.8 Tf  [(46)] TJ ET
BT 385.178 691.620 Td /F1 9.8 Tf  [(23.1 \(17.3 to 28.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 686.344 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 691.620 Td /F1 9.8 Tf  [(199)] TJ ET
0.267 0.267 0.267 rg
32.025 671.212 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 676.489 Td /F1 9.8 Tf  [(High)] TJ ET
BT 302.230 676.489 Td /F1 9.8 Tf  [(137)] TJ ET
BT 385.178 676.489 Td /F1 9.8 Tf  [(31.0 \(26.7 to 35.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 671.212 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 676.489 Td /F1 9.8 Tf  [(442)] TJ ET
0.267 0.267 0.267 rg
32.025 656.081 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 661.358 Td /F4 9.8 Tf  [(Monthly Income)] TJ ET
0.267 0.267 0.267 rg
580.125 656.081 0.750 15.131 re f
32.025 640.950 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 646.226 Td /F1 9.8 Tf  [(< �3,000)] TJ ET
BT 302.230 646.226 Td /F1 9.8 Tf  [(134)] TJ ET
BT 385.178 646.226 Td /F1 9.8 Tf  [(23.7 \(20.2 to 27.2\))] TJ ET
0.267 0.267 0.267 rg
580.125 640.950 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 646.226 Td /F1 9.8 Tf  [(565)] TJ ET
0.267 0.267 0.267 rg
32.025 625.819 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 631.095 Td /F1 9.8 Tf  [(�3,000 � �4,500)] TJ ET
BT 302.230 631.095 Td /F1 9.8 Tf  [(59)] TJ ET
BT 385.178 631.095 Td /F1 9.8 Tf  [(28.6 \(22.5 to 34.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 625.819 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 631.095 Td /F1 9.8 Tf  [(206)] TJ ET
0.267 0.267 0.267 rg
32.025 610.688 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 615.964 Td /F1 9.8 Tf  [(> �4,500)] TJ ET
BT 302.230 615.964 Td /F1 9.8 Tf  [(82)] TJ ET
BT 385.178 615.964 Td /F1 9.8 Tf  [(32.2 \(26.5 to 37.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 610.688 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 615.964 Td /F1 9.8 Tf  [(255)] TJ ET
0.267 0.267 0.267 rg
32.025 595.556 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 600.833 Td /F4 9.8 Tf  [(Risk factors)] TJ ET
0.267 0.267 0.267 rg
580.125 595.556 0.750 15.131 re f
32.025 580.425 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 585.701 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 585.701 Td /F1 9.8 Tf  [(62)] TJ ET
BT 385.178 585.701 Td /F1 9.8 Tf  [(36.8 \(29.5 to 44.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 580.425 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 585.701 Td /F1 9.8 Tf  [(168)] TJ ET
0.267 0.267 0.267 rg
32.025 565.294 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 570.570 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 570.570 Td /F1 9.8 Tf  [(213)] TJ ET
BT 385.178 570.570 Td /F1 9.8 Tf  [(25.7 \(22.8 to 28.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 565.294 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 570.570 Td /F1 9.8 Tf  [(829)] TJ ET
0.267 0.267 0.267 rg
32.025 550.163 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 555.439 Td /F4 9.8 Tf  [(Parental status)] TJ ET
0.267 0.267 0.267 rg
580.125 550.163 0.750 15.131 re f
32.025 535.031 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 540.308 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 540.308 Td /F1 9.8 Tf  [(13)] TJ ET
BT 385.178 540.308 Td /F1 9.8 Tf  [(33.3 \(18.5 to 48.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 535.031 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 540.308 Td /F1 9.8 Tf  [(39)] TJ ET
0.267 0.267 0.267 rg
32.025 519.900 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 525.176 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 525.176 Td /F1 9.8 Tf  [(262)] TJ ET
BT 385.178 525.176 Td /F1 9.8 Tf  [(27.2 \(24.5 to 29.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 519.900 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 525.176 Td /F1 9.8 Tf  [(963)] TJ ET
0.267 0.267 0.267 rg
32.025 504.769 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 510.045 Td /F4 9.8 Tf  [(Working in health or child care)] TJ ET
0.267 0.267 0.267 rg
580.125 504.769 0.750 15.131 re f
32.025 489.637 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 494.914 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 494.914 Td /F1 9.8 Tf  [(81)] TJ ET
BT 385.178 494.914 Td /F1 9.8 Tf  [(30.8 \(25.3 to 36.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 489.637 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 494.914 Td /F1 9.8 Tf  [(263)] TJ ET
0.267 0.267 0.267 rg
32.025 474.506 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 479.782 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 479.782 Td /F1 9.8 Tf  [(194)] TJ ET
BT 385.178 479.782 Td /F1 9.8 Tf  [(26.2 \(23.1 to 29.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 474.506 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 479.782 Td /F1 9.8 Tf  [(740)] TJ ET
0.267 0.267 0.267 rg
32.025 459.375 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 464.651 Td /F4 9.8 Tf  [(Previous influenza vaccine receipt)] TJ ET
0.267 0.267 0.267 rg
580.125 459.375 0.750 15.131 re f
32.025 444.244 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 449.520 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 449.520 Td /F1 9.8 Tf  [(156)] TJ ET
BT 385.178 449.520 Td /F1 9.8 Tf  [(41.7 \(36.8 to 46.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 444.244 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 449.520 Td /F1 9.8 Tf  [(374)] TJ ET
0.267 0.267 0.267 rg
32.025 428.112 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 434.389 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 434.389 Td /F1 9.8 Tf  [(119)] TJ ET
BT 385.178 434.389 Td /F1 9.8 Tf  [(18.9 \(15.9 to 21.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 428.112 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 533.095 434.389 Td /F1 9.8 Tf  [(630)] TJ ET
0.000 0.000 0.000 rg
32.025 428.112 270.205 1.000 re f
32.025 411.981 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 411.981 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 418.757 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
302.230 428.112 82.948 1.000 re f
302.230 411.981 82.948 1.500 re f
0.271 0.267 0.267 rg
BT 302.230 418.757 Td /F4 9.8 Tf  [(275)] TJ ET
0.000 0.000 0.000 rg
385.178 428.112 147.918 1.000 re f
385.178 411.981 147.918 1.500 re f
0.271 0.267 0.267 rg
BT 385.178 418.757 Td /F4 9.8 Tf  [(27.4 \()] TJ ET
BT 410.109 418.757 Td /F4 9.8 Tf  [(24.7 to 30.1\))] TJ ET
0.000 0.000 0.000 rg
533.095 428.112 47.780 1.000 re f
533.095 411.981 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 411.981 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 533.095 418.757 Td /F1 9.8 Tf  [(1004)] TJ ET
BT 26.250 364.957 Td /F6 9.8 Tf  [(Predictive factors of vaccine acceptance)] TJ ET
BT 26.250 345.553 Td /F1 9.8 Tf  [(As indicated in table 1, rates of vaccination acceptance did not differ substantially according to the familial \(whether respondent )] TJ ET
BT 26.250 333.648 Td /F1 9.8 Tf  [(had children younger than 6 years of age\) and professional status \(whether respondents worked in health or childcare services\), )] TJ ET
BT 26.250 321.743 Td /F1 9.8 Tf  [(or the level of education of the participants. By contrast, the health status, income, gender, age, and previous influenza vaccine )] TJ ET
BT 26.250 309.838 Td /F1 9.8 Tf  [(receipt of the respondents were significantly associated with the reported vaccination acceptance \()] TJ ET
BT 450.570 309.838 Td /F5 9.8 Tf  [(p)] TJ ET
BT 455.991 309.838 Td /F1 9.8 Tf  [(> 0.05\). However, after )] TJ ET
BT 26.250 297.934 Td /F1 9.8 Tf  [(adjusting for other socioeconomic or health variables, we only found that vaccination acceptance was higher among men than )] TJ ET
BT 26.250 286.029 Td /F1 9.8 Tf  [(women \(adjusted OR = 1.61, )] TJ ET
BT 153.332 286.029 Td /F5 9.8 Tf  [(p)] TJ ET
BT 158.752 286.029 Td /F1 9.8 Tf  [( = 0.003\), higher among more educated people than less educated people \(adjusted OR = 1.20, )] TJ ET
BT 574.454 286.029 Td /F5 9.8 Tf  [(p)] TJ ET
BT 26.250 274.124 Td /F1 9.8 Tf  [(= 0.047\), and higher among wealthier people than poorer people \(adjusted OR = 1.24, )] TJ ET
BT 400.211 274.124 Td /F5 9.8 Tf  [(p)] TJ ET
BT 405.632 274.124 Td /F1 9.8 Tf  [( = 0.024\). The participants who had an )] TJ ET
BT 26.250 262.219 Td /F1 9.8 Tf  [(experience with influenza vaccination in previous years \(adjusted OR = 2.36, )] TJ ET
BT 359.252 262.219 Td /F5 9.8 Tf  [(p)] TJ ET
BT 364.673 262.219 Td /F1 9.8 Tf  [(< 0.001\), as well as those who were working in )] TJ ET
BT 26.250 250.315 Td /F1 9.8 Tf  [(health or child care \(adjusted OR = 1.54, )] TJ ET
BT 204.275 250.315 Td /F5 9.8 Tf  [(p)] TJ ET
BT 209.696 250.315 Td /F1 9.8 Tf  [( = 0.013\), were also significantly more likely to accept vaccination against the 2009 )] TJ ET
BT 26.250 238.410 Td /F1 9.8 Tf  [(pandemic H1N1 influenza.)] TJ ET
BT 26.250 219.005 Td /F4 9.8 Tf  [(Table 2. Categories of reasons reported by participants for accepting vaccination against the 2009 pandemic H1N1 )] TJ ET
BT 26.250 207.100 Td /F4 9.8 Tf  [(influenza.)] TJ ET
1.000 1.000 1.000 rg
31.650 79.419 549.600 125.300 re f
0.000 0.000 0.000 rg
32.025 203.219 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 186.588 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 32.400 193.364 Td /F4 9.8 Tf  [(Categories of self-reported reasons)] TJ ET
0.000 0.000 0.000 rg
442.840 203.219 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 193.364 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
516.936 203.219 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 186.588 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 516.936 193.364 Td /F4 9.8 Tf  [(%)] TJ ET
0.000 0.000 0.000 rg
32.025 186.588 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 172.207 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 177.483 Td /F1 9.8 Tf  [(Self-protection � including perception of personal risk factors)] TJ ET
0.000 0.000 0.000 rg
442.840 186.588 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 177.483 Td /F1 9.8 Tf  [(126)] TJ ET
0.000 0.000 0.000 rg
516.936 186.588 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 172.207 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 516.936 177.483 Td /F1 9.8 Tf  [(45.8)] TJ ET
0.267 0.267 0.267 rg
32.025 157.076 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 162.352 Td /F1 9.8 Tf  [(Protection of significant others \(parents, children, friends, etc.\))] TJ ET
BT 442.840 162.352 Td /F1 9.8 Tf  [(77)] TJ ET
0.267 0.267 0.267 rg
580.125 157.076 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 162.352 Td /F1 9.8 Tf  [(28.0)] TJ ET
0.267 0.267 0.267 rg
32.025 141.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 147.221 Td /F1 9.8 Tf  [(Protection of patients or colleagues � including work ethic)] TJ ET
BT 442.840 147.221 Td /F1 9.8 Tf  [(35)] TJ ET
0.267 0.267 0.267 rg
580.125 141.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 147.221 Td /F1 9.8 Tf  [(12.7)] TJ ET
0.267 0.267 0.267 rg
32.025 126.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 132.089 Td /F1 9.8 Tf  [(Trust in the vaccine; compliance with recommendation)] TJ ET
BT 442.840 132.089 Td /F1 9.8 Tf  [(25)] TJ ET
0.267 0.267 0.267 rg
580.125 126.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 132.089 Td /F1 9.8 Tf  [(9.1)] TJ ET
0.267 0.267 0.267 rg
32.025 111.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 116.958 Td /F1 9.8 Tf  [(Fear of change in the nature of the disease)] TJ ET
BT 442.840 116.958 Td /F1 9.8 Tf  [(6)] TJ ET
0.267 0.267 0.267 rg
580.125 111.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 116.958 Td /F1 9.8 Tf  [(2.2)] TJ ET
0.267 0.267 0.267 rg
32.025 95.551 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 101.827 Td /F1 9.8 Tf  [(Other reasons)] TJ ET
BT 442.840 101.827 Td /F1 9.8 Tf  [(6)] TJ ET
0.267 0.267 0.267 rg
580.125 95.551 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 516.936 101.827 Td /F1 9.8 Tf  [(2.2)] TJ ET
0.000 0.000 0.000 rg
32.025 95.551 410.815 1.000 re f
32.025 79.419 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 79.419 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 86.196 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
442.840 95.551 74.096 1.000 re f
442.840 79.419 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 86.196 Td /F4 9.8 Tf  [(275)] TJ ET
0.000 0.000 0.000 rg
516.936 95.551 63.939 1.000 re f
516.936 79.419 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 79.419 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 516.936 86.196 Td /F4 9.8 Tf  [(100.0)] TJ ET
BT 26.250 32.396 Td /F4 9.8 Tf  [(Table 3. Categories of reasons reported by participants for refusing vaccination against the 2009 pandemic H1N1 )] TJ ET
BT 26.250 20.491 Td /F4 9.8 Tf  [(influenza.)] TJ ET
1.000 1.000 1.000 rg
31.650 0.860 549.600 17.250 re f
Q
q
15.000 0.860 577.500 776.140 re W n
1.000 1.000 1.000 rg
31.650 411.981 549.600 365.019 re f
0.267 0.267 0.267 rg
32.025 746.869 0.750 30.131 re f
0.271 0.267 0.267 rg
BT 32.400 767.145 Td /F1 9.8 Tf  [(Working)] TJ ET
BT 302.230 767.145 Td /F1 9.8 Tf  [(152)] TJ ET
BT 385.178 767.145 Td /F1 9.8 Tf  [(24.4 \(21.1 to 27.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 746.869 0.750 30.131 re f
0.271 0.267 0.267 rg
BT 533.095 767.145 Td /F1 9.8 Tf  [(623)] TJ ET
0.267 0.267 0.267 rg
32.025 731.737 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 737.014 Td /F1 9.8 Tf  [(Retired)] TJ ET
BT 302.230 737.014 Td /F1 9.8 Tf  [(93)] TJ ET
BT 385.178 737.014 Td /F1 9.8 Tf  [(42.1 \(35.6 to 48.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 731.737 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 737.014 Td /F1 9.8 Tf  [(221)] TJ ET
0.267 0.267 0.267 rg
32.025 716.606 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 721.883 Td /F4 9.8 Tf  [(Education)] TJ ET
0.267 0.267 0.267 rg
580.125 716.606 0.750 15.131 re f
32.025 701.475 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 706.751 Td /F1 9.8 Tf  [(Low)] TJ ET
BT 302.230 706.751 Td /F1 9.8 Tf  [(92)] TJ ET
BT 385.178 706.751 Td /F1 9.8 Tf  [(25.4 \(21.0 to 29.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 701.475 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 706.751 Td /F1 9.8 Tf  [(362)] TJ ET
0.267 0.267 0.267 rg
32.025 686.344 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 691.620 Td /F1 9.8 Tf  [(Intermediate)] TJ ET
BT 302.230 691.620 Td /F1 9.8 Tf  [(46)] TJ ET
BT 385.178 691.620 Td /F1 9.8 Tf  [(23.1 \(17.3 to 28.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 686.344 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 691.620 Td /F1 9.8 Tf  [(199)] TJ ET
0.267 0.267 0.267 rg
32.025 671.212 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 676.489 Td /F1 9.8 Tf  [(High)] TJ ET
BT 302.230 676.489 Td /F1 9.8 Tf  [(137)] TJ ET
BT 385.178 676.489 Td /F1 9.8 Tf  [(31.0 \(26.7 to 35.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 671.212 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 676.489 Td /F1 9.8 Tf  [(442)] TJ ET
0.267 0.267 0.267 rg
32.025 656.081 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 661.358 Td /F4 9.8 Tf  [(Monthly Income)] TJ ET
0.267 0.267 0.267 rg
580.125 656.081 0.750 15.131 re f
32.025 640.950 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 646.226 Td /F1 9.8 Tf  [(< �3,000)] TJ ET
BT 302.230 646.226 Td /F1 9.8 Tf  [(134)] TJ ET
BT 385.178 646.226 Td /F1 9.8 Tf  [(23.7 \(20.2 to 27.2\))] TJ ET
0.267 0.267 0.267 rg
580.125 640.950 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 646.226 Td /F1 9.8 Tf  [(565)] TJ ET
0.267 0.267 0.267 rg
32.025 625.819 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 631.095 Td /F1 9.8 Tf  [(�3,000 � �4,500)] TJ ET
BT 302.230 631.095 Td /F1 9.8 Tf  [(59)] TJ ET
BT 385.178 631.095 Td /F1 9.8 Tf  [(28.6 \(22.5 to 34.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 625.819 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 631.095 Td /F1 9.8 Tf  [(206)] TJ ET
0.267 0.267 0.267 rg
32.025 610.688 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 615.964 Td /F1 9.8 Tf  [(> �4,500)] TJ ET
BT 302.230 615.964 Td /F1 9.8 Tf  [(82)] TJ ET
BT 385.178 615.964 Td /F1 9.8 Tf  [(32.2 \(26.5 to 37.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 610.688 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 615.964 Td /F1 9.8 Tf  [(255)] TJ ET
0.267 0.267 0.267 rg
32.025 595.556 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 600.833 Td /F4 9.8 Tf  [(Risk factors)] TJ ET
0.267 0.267 0.267 rg
580.125 595.556 0.750 15.131 re f
32.025 580.425 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 585.701 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 585.701 Td /F1 9.8 Tf  [(62)] TJ ET
BT 385.178 585.701 Td /F1 9.8 Tf  [(36.8 \(29.5 to 44.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 580.425 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 585.701 Td /F1 9.8 Tf  [(168)] TJ ET
0.267 0.267 0.267 rg
32.025 565.294 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 570.570 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 570.570 Td /F1 9.8 Tf  [(213)] TJ ET
BT 385.178 570.570 Td /F1 9.8 Tf  [(25.7 \(22.8 to 28.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 565.294 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 570.570 Td /F1 9.8 Tf  [(829)] TJ ET
0.267 0.267 0.267 rg
32.025 550.163 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 555.439 Td /F4 9.8 Tf  [(Parental status)] TJ ET
0.267 0.267 0.267 rg
580.125 550.163 0.750 15.131 re f
32.025 535.031 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 540.308 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 540.308 Td /F1 9.8 Tf  [(13)] TJ ET
BT 385.178 540.308 Td /F1 9.8 Tf  [(33.3 \(18.5 to 48.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 535.031 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 540.308 Td /F1 9.8 Tf  [(39)] TJ ET
0.267 0.267 0.267 rg
32.025 519.900 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 525.176 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 525.176 Td /F1 9.8 Tf  [(262)] TJ ET
BT 385.178 525.176 Td /F1 9.8 Tf  [(27.2 \(24.5 to 29.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 519.900 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 525.176 Td /F1 9.8 Tf  [(963)] TJ ET
0.267 0.267 0.267 rg
32.025 504.769 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 510.045 Td /F4 9.8 Tf  [(Working in health or child care)] TJ ET
0.267 0.267 0.267 rg
580.125 504.769 0.750 15.131 re f
32.025 489.637 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 494.914 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 494.914 Td /F1 9.8 Tf  [(81)] TJ ET
BT 385.178 494.914 Td /F1 9.8 Tf  [(30.8 \(25.3 to 36.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 489.637 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 494.914 Td /F1 9.8 Tf  [(263)] TJ ET
0.267 0.267 0.267 rg
32.025 474.506 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 479.782 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 479.782 Td /F1 9.8 Tf  [(194)] TJ ET
BT 385.178 479.782 Td /F1 9.8 Tf  [(26.2 \(23.1 to 29.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 474.506 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 479.782 Td /F1 9.8 Tf  [(740)] TJ ET
0.267 0.267 0.267 rg
32.025 459.375 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 464.651 Td /F4 9.8 Tf  [(Previous influenza vaccine receipt)] TJ ET
0.267 0.267 0.267 rg
580.125 459.375 0.750 15.131 re f
32.025 444.244 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 449.520 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 449.520 Td /F1 9.8 Tf  [(156)] TJ ET
BT 385.178 449.520 Td /F1 9.8 Tf  [(41.7 \(36.8 to 46.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 444.244 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 449.520 Td /F1 9.8 Tf  [(374)] TJ ET
0.267 0.267 0.267 rg
32.025 428.112 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 434.389 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 434.389 Td /F1 9.8 Tf  [(119)] TJ ET
BT 385.178 434.389 Td /F1 9.8 Tf  [(18.9 \(15.9 to 21.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 428.112 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 533.095 434.389 Td /F1 9.8 Tf  [(630)] TJ ET
0.000 0.000 0.000 rg
32.025 428.112 270.205 1.000 re f
32.025 411.981 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 411.981 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 418.757 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
302.230 428.112 82.948 1.000 re f
302.230 411.981 82.948 1.500 re f
0.271 0.267 0.267 rg
BT 302.230 418.757 Td /F4 9.8 Tf  [(275)] TJ ET
0.000 0.000 0.000 rg
385.178 428.112 147.918 1.000 re f
385.178 411.981 147.918 1.500 re f
0.271 0.267 0.267 rg
BT 385.178 418.757 Td /F4 9.8 Tf  [(27.4 \()] TJ ET
BT 410.109 418.757 Td /F4 9.8 Tf  [(24.7 to 30.1\))] TJ ET
0.000 0.000 0.000 rg
533.095 428.112 47.780 1.000 re f
533.095 411.981 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 411.981 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 533.095 418.757 Td /F1 9.8 Tf  [(1004)] TJ ET
BT 26.250 364.957 Td /F6 9.8 Tf  [(Predictive factors of vaccine acceptance)] TJ ET
BT 26.250 345.553 Td /F1 9.8 Tf  [(As indicated in table 1, rates of vaccination acceptance did not differ substantially according to the familial \(whether respondent )] TJ ET
BT 26.250 333.648 Td /F1 9.8 Tf  [(had children younger than 6 years of age\) and professional status \(whether respondents worked in health or childcare services\), )] TJ ET
BT 26.250 321.743 Td /F1 9.8 Tf  [(or the level of education of the participants. By contrast, the health status, income, gender, age, and previous influenza vaccine )] TJ ET
BT 26.250 309.838 Td /F1 9.8 Tf  [(receipt of the respondents were significantly associated with the reported vaccination acceptance \()] TJ ET
BT 450.570 309.838 Td /F5 9.8 Tf  [(p)] TJ ET
BT 455.991 309.838 Td /F1 9.8 Tf  [(> 0.05\). However, after )] TJ ET
BT 26.250 297.934 Td /F1 9.8 Tf  [(adjusting for other socioeconomic or health variables, we only found that vaccination acceptance was higher among men than )] TJ ET
BT 26.250 286.029 Td /F1 9.8 Tf  [(women \(adjusted OR = 1.61, )] TJ ET
BT 153.332 286.029 Td /F5 9.8 Tf  [(p)] TJ ET
BT 158.752 286.029 Td /F1 9.8 Tf  [( = 0.003\), higher among more educated people than less educated people \(adjusted OR = 1.20, )] TJ ET
BT 574.454 286.029 Td /F5 9.8 Tf  [(p)] TJ ET
BT 26.250 274.124 Td /F1 9.8 Tf  [(= 0.047\), and higher among wealthier people than poorer people \(adjusted OR = 1.24, )] TJ ET
BT 400.211 274.124 Td /F5 9.8 Tf  [(p)] TJ ET
BT 405.632 274.124 Td /F1 9.8 Tf  [( = 0.024\). The participants who had an )] TJ ET
BT 26.250 262.219 Td /F1 9.8 Tf  [(experience with influenza vaccination in previous years \(adjusted OR = 2.36, )] TJ ET
BT 359.252 262.219 Td /F5 9.8 Tf  [(p)] TJ ET
BT 364.673 262.219 Td /F1 9.8 Tf  [(< 0.001\), as well as those who were working in )] TJ ET
BT 26.250 250.315 Td /F1 9.8 Tf  [(health or child care \(adjusted OR = 1.54, )] TJ ET
BT 204.275 250.315 Td /F5 9.8 Tf  [(p)] TJ ET
BT 209.696 250.315 Td /F1 9.8 Tf  [( = 0.013\), were also significantly more likely to accept vaccination against the 2009 )] TJ ET
BT 26.250 238.410 Td /F1 9.8 Tf  [(pandemic H1N1 influenza.)] TJ ET
BT 26.250 219.005 Td /F4 9.8 Tf  [(Table 2. Categories of reasons reported by participants for accepting vaccination against the 2009 pandemic H1N1 )] TJ ET
BT 26.250 207.100 Td /F4 9.8 Tf  [(influenza.)] TJ ET
1.000 1.000 1.000 rg
31.650 79.419 549.600 125.300 re f
0.000 0.000 0.000 rg
32.025 203.219 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 186.588 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 32.400 193.364 Td /F4 9.8 Tf  [(Categories of self-reported reasons)] TJ ET
0.000 0.000 0.000 rg
442.840 203.219 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 193.364 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
516.936 203.219 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 186.588 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 516.936 193.364 Td /F4 9.8 Tf  [(%)] TJ ET
0.000 0.000 0.000 rg
32.025 186.588 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 172.207 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 177.483 Td /F1 9.8 Tf  [(Self-protection � including perception of personal risk factors)] TJ ET
0.000 0.000 0.000 rg
442.840 186.588 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 177.483 Td /F1 9.8 Tf  [(126)] TJ ET
0.000 0.000 0.000 rg
516.936 186.588 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 172.207 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 516.936 177.483 Td /F1 9.8 Tf  [(45.8)] TJ ET
0.267 0.267 0.267 rg
32.025 157.076 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 162.352 Td /F1 9.8 Tf  [(Protection of significant others \(parents, children, friends, etc.\))] TJ ET
BT 442.840 162.352 Td /F1 9.8 Tf  [(77)] TJ ET
0.267 0.267 0.267 rg
580.125 157.076 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 162.352 Td /F1 9.8 Tf  [(28.0)] TJ ET
0.267 0.267 0.267 rg
32.025 141.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 147.221 Td /F1 9.8 Tf  [(Protection of patients or colleagues � including work ethic)] TJ ET
BT 442.840 147.221 Td /F1 9.8 Tf  [(35)] TJ ET
0.267 0.267 0.267 rg
580.125 141.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 147.221 Td /F1 9.8 Tf  [(12.7)] TJ ET
0.267 0.267 0.267 rg
32.025 126.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 132.089 Td /F1 9.8 Tf  [(Trust in the vaccine; compliance with recommendation)] TJ ET
BT 442.840 132.089 Td /F1 9.8 Tf  [(25)] TJ ET
0.267 0.267 0.267 rg
580.125 126.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 132.089 Td /F1 9.8 Tf  [(9.1)] TJ ET
0.267 0.267 0.267 rg
32.025 111.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 116.958 Td /F1 9.8 Tf  [(Fear of change in the nature of the disease)] TJ ET
BT 442.840 116.958 Td /F1 9.8 Tf  [(6)] TJ ET
0.267 0.267 0.267 rg
580.125 111.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 116.958 Td /F1 9.8 Tf  [(2.2)] TJ ET
0.267 0.267 0.267 rg
32.025 95.551 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 101.827 Td /F1 9.8 Tf  [(Other reasons)] TJ ET
BT 442.840 101.827 Td /F1 9.8 Tf  [(6)] TJ ET
0.267 0.267 0.267 rg
580.125 95.551 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 516.936 101.827 Td /F1 9.8 Tf  [(2.2)] TJ ET
0.000 0.000 0.000 rg
32.025 95.551 410.815 1.000 re f
32.025 79.419 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 79.419 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 86.196 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
442.840 95.551 74.096 1.000 re f
442.840 79.419 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 86.196 Td /F4 9.8 Tf  [(275)] TJ ET
0.000 0.000 0.000 rg
516.936 95.551 63.939 1.000 re f
516.936 79.419 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 79.419 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 516.936 86.196 Td /F4 9.8 Tf  [(100.0)] TJ ET
BT 26.250 32.396 Td /F4 9.8 Tf  [(Table 3. Categories of reasons reported by participants for refusing vaccination against the 2009 pandemic H1N1 )] TJ ET
BT 26.250 20.491 Td /F4 9.8 Tf  [(influenza.)] TJ ET
1.000 1.000 1.000 rg
31.650 0.860 549.600 17.250 re f
Q
q
15.000 0.860 577.500 776.140 re W n
1.000 1.000 1.000 rg
31.650 411.981 549.600 365.019 re f
0.267 0.267 0.267 rg
32.025 746.869 0.750 30.131 re f
0.271 0.267 0.267 rg
BT 32.400 767.145 Td /F1 9.8 Tf  [(Working)] TJ ET
BT 302.230 767.145 Td /F1 9.8 Tf  [(152)] TJ ET
BT 385.178 767.145 Td /F1 9.8 Tf  [(24.4 \(21.1 to 27.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 746.869 0.750 30.131 re f
0.271 0.267 0.267 rg
BT 533.095 767.145 Td /F1 9.8 Tf  [(623)] TJ ET
0.267 0.267 0.267 rg
32.025 731.737 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 737.014 Td /F1 9.8 Tf  [(Retired)] TJ ET
BT 302.230 737.014 Td /F1 9.8 Tf  [(93)] TJ ET
BT 385.178 737.014 Td /F1 9.8 Tf  [(42.1 \(35.6 to 48.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 731.737 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 737.014 Td /F1 9.8 Tf  [(221)] TJ ET
0.267 0.267 0.267 rg
32.025 716.606 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 721.883 Td /F4 9.8 Tf  [(Education)] TJ ET
0.267 0.267 0.267 rg
580.125 716.606 0.750 15.131 re f
32.025 701.475 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 706.751 Td /F1 9.8 Tf  [(Low)] TJ ET
BT 302.230 706.751 Td /F1 9.8 Tf  [(92)] TJ ET
BT 385.178 706.751 Td /F1 9.8 Tf  [(25.4 \(21.0 to 29.8\))] TJ ET
0.267 0.267 0.267 rg
580.125 701.475 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 706.751 Td /F1 9.8 Tf  [(362)] TJ ET
0.267 0.267 0.267 rg
32.025 686.344 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 691.620 Td /F1 9.8 Tf  [(Intermediate)] TJ ET
BT 302.230 691.620 Td /F1 9.8 Tf  [(46)] TJ ET
BT 385.178 691.620 Td /F1 9.8 Tf  [(23.1 \(17.3 to 28.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 686.344 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 691.620 Td /F1 9.8 Tf  [(199)] TJ ET
0.267 0.267 0.267 rg
32.025 671.212 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 676.489 Td /F1 9.8 Tf  [(High)] TJ ET
BT 302.230 676.489 Td /F1 9.8 Tf  [(137)] TJ ET
BT 385.178 676.489 Td /F1 9.8 Tf  [(31.0 \(26.7 to 35.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 671.212 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 676.489 Td /F1 9.8 Tf  [(442)] TJ ET
0.267 0.267 0.267 rg
32.025 656.081 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 661.358 Td /F4 9.8 Tf  [(Monthly Income)] TJ ET
0.267 0.267 0.267 rg
580.125 656.081 0.750 15.131 re f
32.025 640.950 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 646.226 Td /F1 9.8 Tf  [(< �3,000)] TJ ET
BT 302.230 646.226 Td /F1 9.8 Tf  [(134)] TJ ET
BT 385.178 646.226 Td /F1 9.8 Tf  [(23.7 \(20.2 to 27.2\))] TJ ET
0.267 0.267 0.267 rg
580.125 640.950 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 646.226 Td /F1 9.8 Tf  [(565)] TJ ET
0.267 0.267 0.267 rg
32.025 625.819 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 631.095 Td /F1 9.8 Tf  [(�3,000 � �4,500)] TJ ET
BT 302.230 631.095 Td /F1 9.8 Tf  [(59)] TJ ET
BT 385.178 631.095 Td /F1 9.8 Tf  [(28.6 \(22.5 to 34.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 625.819 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 631.095 Td /F1 9.8 Tf  [(206)] TJ ET
0.267 0.267 0.267 rg
32.025 610.688 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 615.964 Td /F1 9.8 Tf  [(> �4,500)] TJ ET
BT 302.230 615.964 Td /F1 9.8 Tf  [(82)] TJ ET
BT 385.178 615.964 Td /F1 9.8 Tf  [(32.2 \(26.5 to 37.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 610.688 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 615.964 Td /F1 9.8 Tf  [(255)] TJ ET
0.267 0.267 0.267 rg
32.025 595.556 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 600.833 Td /F4 9.8 Tf  [(Risk factors)] TJ ET
0.267 0.267 0.267 rg
580.125 595.556 0.750 15.131 re f
32.025 580.425 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 585.701 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 585.701 Td /F1 9.8 Tf  [(62)] TJ ET
BT 385.178 585.701 Td /F1 9.8 Tf  [(36.8 \(29.5 to 44.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 580.425 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 585.701 Td /F1 9.8 Tf  [(168)] TJ ET
0.267 0.267 0.267 rg
32.025 565.294 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 570.570 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 570.570 Td /F1 9.8 Tf  [(213)] TJ ET
BT 385.178 570.570 Td /F1 9.8 Tf  [(25.7 \(22.8 to 28.6\))] TJ ET
0.267 0.267 0.267 rg
580.125 565.294 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 570.570 Td /F1 9.8 Tf  [(829)] TJ ET
0.267 0.267 0.267 rg
32.025 550.163 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 555.439 Td /F4 9.8 Tf  [(Parental status)] TJ ET
0.267 0.267 0.267 rg
580.125 550.163 0.750 15.131 re f
32.025 535.031 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 540.308 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 540.308 Td /F1 9.8 Tf  [(13)] TJ ET
BT 385.178 540.308 Td /F1 9.8 Tf  [(33.3 \(18.5 to 48.1\))] TJ ET
0.267 0.267 0.267 rg
580.125 535.031 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 540.308 Td /F1 9.8 Tf  [(39)] TJ ET
0.267 0.267 0.267 rg
32.025 519.900 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 525.176 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 525.176 Td /F1 9.8 Tf  [(262)] TJ ET
BT 385.178 525.176 Td /F1 9.8 Tf  [(27.2 \(24.5 to 29.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 519.900 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 525.176 Td /F1 9.8 Tf  [(963)] TJ ET
0.267 0.267 0.267 rg
32.025 504.769 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 510.045 Td /F4 9.8 Tf  [(Working in health or child care)] TJ ET
0.267 0.267 0.267 rg
580.125 504.769 0.750 15.131 re f
32.025 489.637 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 494.914 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 494.914 Td /F1 9.8 Tf  [(81)] TJ ET
BT 385.178 494.914 Td /F1 9.8 Tf  [(30.8 \(25.3 to 36.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 489.637 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 494.914 Td /F1 9.8 Tf  [(263)] TJ ET
0.267 0.267 0.267 rg
32.025 474.506 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 479.782 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 479.782 Td /F1 9.8 Tf  [(194)] TJ ET
BT 385.178 479.782 Td /F1 9.8 Tf  [(26.2 \(23.1 to 29.3\))] TJ ET
0.267 0.267 0.267 rg
580.125 474.506 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 479.782 Td /F1 9.8 Tf  [(740)] TJ ET
0.267 0.267 0.267 rg
32.025 459.375 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 464.651 Td /F4 9.8 Tf  [(Previous influenza vaccine receipt)] TJ ET
0.267 0.267 0.267 rg
580.125 459.375 0.750 15.131 re f
32.025 444.244 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 449.520 Td /F1 9.8 Tf  [(Yes)] TJ ET
BT 302.230 449.520 Td /F1 9.8 Tf  [(156)] TJ ET
BT 385.178 449.520 Td /F1 9.8 Tf  [(41.7 \(36.8 to 46.7\))] TJ ET
0.267 0.267 0.267 rg
580.125 444.244 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 533.095 449.520 Td /F1 9.8 Tf  [(374)] TJ ET
0.267 0.267 0.267 rg
32.025 428.112 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 434.389 Td /F1 9.8 Tf  [(No)] TJ ET
BT 302.230 434.389 Td /F1 9.8 Tf  [(119)] TJ ET
BT 385.178 434.389 Td /F1 9.8 Tf  [(18.9 \(15.9 to 21.9\))] TJ ET
0.267 0.267 0.267 rg
580.125 428.112 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 533.095 434.389 Td /F1 9.8 Tf  [(630)] TJ ET
0.000 0.000 0.000 rg
32.025 428.112 270.205 1.000 re f
32.025 411.981 270.205 1.500 re f
0.267 0.267 0.267 rg
32.025 411.981 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 418.757 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
302.230 428.112 82.948 1.000 re f
302.230 411.981 82.948 1.500 re f
0.271 0.267 0.267 rg
BT 302.230 418.757 Td /F4 9.8 Tf  [(275)] TJ ET
0.000 0.000 0.000 rg
385.178 428.112 147.918 1.000 re f
385.178 411.981 147.918 1.500 re f
0.271 0.267 0.267 rg
BT 385.178 418.757 Td /F4 9.8 Tf  [(27.4 \()] TJ ET
BT 410.109 418.757 Td /F4 9.8 Tf  [(24.7 to 30.1\))] TJ ET
0.000 0.000 0.000 rg
533.095 428.112 47.780 1.000 re f
533.095 411.981 47.780 1.500 re f
0.267 0.267 0.267 rg
580.125 411.981 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 533.095 418.757 Td /F1 9.8 Tf  [(1004)] TJ ET
BT 26.250 364.957 Td /F6 9.8 Tf  [(Predictive factors of vaccine acceptance)] TJ ET
BT 26.250 345.553 Td /F1 9.8 Tf  [(As indicated in table 1, rates of vaccination acceptance did not differ substantially according to the familial \(whether respondent )] TJ ET
BT 26.250 333.648 Td /F1 9.8 Tf  [(had children younger than 6 years of age\) and professional status \(whether respondents worked in health or childcare services\), )] TJ ET
BT 26.250 321.743 Td /F1 9.8 Tf  [(or the level of education of the participants. By contrast, the health status, income, gender, age, and previous influenza vaccine )] TJ ET
BT 26.250 309.838 Td /F1 9.8 Tf  [(receipt of the respondents were significantly associated with the reported vaccination acceptance \()] TJ ET
BT 450.570 309.838 Td /F5 9.8 Tf  [(p)] TJ ET
BT 455.991 309.838 Td /F1 9.8 Tf  [(> 0.05\). However, after )] TJ ET
BT 26.250 297.934 Td /F1 9.8 Tf  [(adjusting for other socioeconomic or health variables, we only found that vaccination acceptance was higher among men than )] TJ ET
BT 26.250 286.029 Td /F1 9.8 Tf  [(women \(adjusted OR = 1.61, )] TJ ET
BT 153.332 286.029 Td /F5 9.8 Tf  [(p)] TJ ET
BT 158.752 286.029 Td /F1 9.8 Tf  [( = 0.003\), higher among more educated people than less educated people \(adjusted OR = 1.20, )] TJ ET
BT 574.454 286.029 Td /F5 9.8 Tf  [(p)] TJ ET
BT 26.250 274.124 Td /F1 9.8 Tf  [(= 0.047\), and higher among wealthier people than poorer people \(adjusted OR = 1.24, )] TJ ET
BT 400.211 274.124 Td /F5 9.8 Tf  [(p)] TJ ET
BT 405.632 274.124 Td /F1 9.8 Tf  [( = 0.024\). The participants who had an )] TJ ET
BT 26.250 262.219 Td /F1 9.8 Tf  [(experience with influenza vaccination in previous years \(adjusted OR = 2.36, )] TJ ET
BT 359.252 262.219 Td /F5 9.8 Tf  [(p)] TJ ET
BT 364.673 262.219 Td /F1 9.8 Tf  [(< 0.001\), as well as those who were working in )] TJ ET
BT 26.250 250.315 Td /F1 9.8 Tf  [(health or child care \(adjusted OR = 1.54, )] TJ ET
BT 204.275 250.315 Td /F5 9.8 Tf  [(p)] TJ ET
BT 209.696 250.315 Td /F1 9.8 Tf  [( = 0.013\), were also significantly more likely to accept vaccination against the 2009 )] TJ ET
BT 26.250 238.410 Td /F1 9.8 Tf  [(pandemic H1N1 influenza.)] TJ ET
BT 26.250 219.005 Td /F4 9.8 Tf  [(Table 2. Categories of reasons reported by participants for accepting vaccination against the 2009 pandemic H1N1 )] TJ ET
BT 26.250 207.100 Td /F4 9.8 Tf  [(influenza.)] TJ ET
1.000 1.000 1.000 rg
31.650 79.419 549.600 125.300 re f
0.000 0.000 0.000 rg
32.025 203.219 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 186.588 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 32.400 193.364 Td /F4 9.8 Tf  [(Categories of self-reported reasons)] TJ ET
0.000 0.000 0.000 rg
442.840 203.219 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 193.364 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
516.936 203.219 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 186.588 0.750 18.131 re f
0.271 0.267 0.267 rg
BT 516.936 193.364 Td /F4 9.8 Tf  [(%)] TJ ET
0.000 0.000 0.000 rg
32.025 186.588 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 172.207 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 177.483 Td /F1 9.8 Tf  [(Self-protection � including perception of personal risk factors)] TJ ET
0.000 0.000 0.000 rg
442.840 186.588 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 177.483 Td /F1 9.8 Tf  [(126)] TJ ET
0.000 0.000 0.000 rg
516.936 186.588 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 172.207 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 516.936 177.483 Td /F1 9.8 Tf  [(45.8)] TJ ET
0.267 0.267 0.267 rg
32.025 157.076 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 162.352 Td /F1 9.8 Tf  [(Protection of significant others \(parents, children, friends, etc.\))] TJ ET
BT 442.840 162.352 Td /F1 9.8 Tf  [(77)] TJ ET
0.267 0.267 0.267 rg
580.125 157.076 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 162.352 Td /F1 9.8 Tf  [(28.0)] TJ ET
0.267 0.267 0.267 rg
32.025 141.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 147.221 Td /F1 9.8 Tf  [(Protection of patients or colleagues � including work ethic)] TJ ET
BT 442.840 147.221 Td /F1 9.8 Tf  [(35)] TJ ET
0.267 0.267 0.267 rg
580.125 141.944 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 147.221 Td /F1 9.8 Tf  [(12.7)] TJ ET
0.267 0.267 0.267 rg
32.025 126.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 132.089 Td /F1 9.8 Tf  [(Trust in the vaccine; compliance with recommendation)] TJ ET
BT 442.840 132.089 Td /F1 9.8 Tf  [(25)] TJ ET
0.267 0.267 0.267 rg
580.125 126.813 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 132.089 Td /F1 9.8 Tf  [(9.1)] TJ ET
0.267 0.267 0.267 rg
32.025 111.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 116.958 Td /F1 9.8 Tf  [(Fear of change in the nature of the disease)] TJ ET
BT 442.840 116.958 Td /F1 9.8 Tf  [(6)] TJ ET
0.267 0.267 0.267 rg
580.125 111.682 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 516.936 116.958 Td /F1 9.8 Tf  [(2.2)] TJ ET
0.267 0.267 0.267 rg
32.025 95.551 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 101.827 Td /F1 9.8 Tf  [(Other reasons)] TJ ET
BT 442.840 101.827 Td /F1 9.8 Tf  [(6)] TJ ET
0.267 0.267 0.267 rg
580.125 95.551 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 516.936 101.827 Td /F1 9.8 Tf  [(2.2)] TJ ET
0.000 0.000 0.000 rg
32.025 95.551 410.815 1.000 re f
32.025 79.419 410.815 1.500 re f
0.267 0.267 0.267 rg
32.025 79.419 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 86.196 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
442.840 95.551 74.096 1.000 re f
442.840 79.419 74.096 1.500 re f
0.271 0.267 0.267 rg
BT 442.840 86.196 Td /F4 9.8 Tf  [(275)] TJ ET
0.000 0.000 0.000 rg
516.936 95.551 63.939 1.000 re f
516.936 79.419 63.939 1.500 re f
0.267 0.267 0.267 rg
580.125 79.419 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 516.936 86.196 Td /F4 9.8 Tf  [(100.0)] TJ ET
BT 26.250 32.396 Td /F4 9.8 Tf  [(Table 3. Categories of reasons reported by participants for refusing vaccination against the 2009 pandemic H1N1 )] TJ ET
BT 26.250 20.491 Td /F4 9.8 Tf  [(influenza.)] TJ ET
1.000 1.000 1.000 rg
31.650 0.860 549.600 17.250 re f
Q
q
0.000 0.000 0.000 rg
BT 291.710 19.825 Td /F1 11.0 Tf  [(3)] TJ ET
BT 25.000 19.825 Td /F1 11.0 Tf  [(PLOS Currents Influenza)] TJ ET

Q
endstream
endobj
73 0 obj
<< /Type /Font
/Subtype /Type1
/Name /F6
/BaseFont /Helvetica-BoldOblique
/Encoding /WinAnsiEncoding
>>
endobj
74 0 obj
<< /Type /Page
/Parent 3 0 R
/Annots [ 76 0 R 78 0 R 80 0 R 82 0 R 84 0 R 86 0 R 88 0 R 90 0 R 92 0 R 94 0 R 96 0 R 98 0 R 100 0 R 102 0 R 104 0 R 106 0 R 108 0 R 110 0 R 112 0 R 114 0 R 116 0 R 118 0 R 120 0 R 122 0 R ]
/Contents 75 0 R
>>
endobj
75 0 obj
<<
/Length 35527 >>
stream

1.000 1.000 1.000 rg
q
15.000 25.464 577.500 751.536 re W n
1.000 1.000 1.000 rg
31.650 598.806 549.600 178.194 re f
0.000 0.000 0.000 rg
32.025 776.250 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 743.869 0.750 33.881 re f
0.271 0.267 0.267 rg
BT 32.400 766.395 Td /F4 9.8 Tf  [(Categories of self-reported reasons)] TJ ET
0.000 0.000 0.000 rg
465.962 776.250 17.814 1.500 re f
483.776 776.250 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 766.395 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
532.138 776.250 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 743.869 0.750 33.881 re f
0.271 0.267 0.267 rg
BT 532.138 766.395 Td /F4 9.8 Tf  [(%)] TJ ET
0.000 0.000 0.000 rg
32.025 743.869 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 729.487 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 734.764 Td /F1 9.8 Tf  [(Belief that the vaccine is dangerous, fear of adverse reactions)] TJ ET
0.000 0.000 0.000 rg
465.962 743.869 17.814 1.500 re f
483.776 743.869 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 734.764 Td /F1 9.8 Tf  [(218)] TJ ET
0.000 0.000 0.000 rg
532.138 743.869 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 729.487 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 532.138 734.764 Td /F1 9.8 Tf  [(35.2)] TJ ET
0.267 0.267 0.267 rg
32.025 714.356 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 719.633 Td /F1 9.8 Tf  [(Belief that pandemic influenza is a minor illness, lack of perception of own risk)] TJ ET
BT 483.776 719.633 Td /F1 9.8 Tf  [(173)] TJ ET
0.267 0.267 0.267 rg
580.125 714.356 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 719.633 Td /F1 9.8 Tf  [(27.9)] TJ ET
0.267 0.267 0.267 rg
32.025 699.225 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 704.501 Td /F1 9.8 Tf  [(Belief that the vaccine is not effective)] TJ ET
BT 483.776 704.501 Td /F1 9.8 Tf  [(73)] TJ ET
0.267 0.267 0.267 rg
580.125 699.225 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 704.501 Td /F1 9.8 Tf  [(11.8)] TJ ET
0.267 0.267 0.267 rg
32.025 684.094 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 689.370 Td /F1 9.8 Tf  [(Belief that he or she has already contracted the disease)] TJ ET
BT 483.776 689.370 Td /F1 9.8 Tf  [(54)] TJ ET
0.267 0.267 0.267 rg
580.125 684.094 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 689.370 Td /F1 9.8 Tf  [(8.7)] TJ ET
0.267 0.267 0.267 rg
32.025 668.962 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 674.239 Td /F1 9.8 Tf  [(Preference for alternative methods of protection)] TJ ET
BT 483.776 674.239 Td /F1 9.8 Tf  [(40)] TJ ET
0.267 0.267 0.267 rg
580.125 668.962 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 674.239 Td /F1 9.8 Tf  [(6.5)] TJ ET
0.267 0.267 0.267 rg
32.025 646.200 0.750 22.762 re f
0.271 0.267 0.267 rg
BT 32.400 659.108 Td /F1 9.8 Tf  [(Distrust of media, pharmaceutical companies or public authorities \(including belief in conspiracy )] TJ ET
BT 32.400 651.476 Td /F1 9.8 Tf  [(theories\))] TJ ET
BT 483.776 659.108 Td /F1 9.8 Tf  [(38)] TJ ET
0.267 0.267 0.267 rg
580.125 646.200 0.750 22.762 re f
0.271 0.267 0.267 rg
BT 532.138 659.108 Td /F1 9.8 Tf  [(6.1)] TJ ET
0.267 0.267 0.267 rg
32.025 631.069 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 636.345 Td /F1 9.8 Tf  [(Medical or lay recommendation against vaccination)] TJ ET
BT 483.776 636.345 Td /F1 9.8 Tf  [(15)] TJ ET
0.267 0.267 0.267 rg
580.125 631.069 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 636.345 Td /F1 9.8 Tf  [(2.4)] TJ ET
0.267 0.267 0.267 rg
32.025 614.938 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 621.214 Td /F1 9.8 Tf  [(Other reasons)] TJ ET
BT 483.776 621.214 Td /F1 9.8 Tf  [(8)] TJ ET
0.267 0.267 0.267 rg
580.125 614.938 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 532.138 621.214 Td /F1 9.8 Tf  [(1.3)] TJ ET
0.000 0.000 0.000 rg
32.025 614.938 433.937 1.000 re f
32.025 598.806 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 598.806 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 605.583 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
465.962 614.938 17.814 1.000 re f
465.962 598.806 17.814 1.500 re f
483.776 614.938 48.362 1.000 re f
483.776 598.806 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 605.583 Td /F4 9.8 Tf  [(619)] TJ ET
0.000 0.000 0.000 rg
532.138 614.938 48.737 1.000 re f
532.138 598.806 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 598.806 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 532.138 605.583 Td /F4 9.8 Tf  [(100.0)] TJ ET
BT 26.250 551.782 Td /F6 9.8 Tf  [(Reported reasons for vaccine acceptance)] TJ ET
BT 26.250 532.378 Td /F1 9.8 Tf  [(The primary motives for acceptance or non-acceptance of the 2009 pandemic H1N1 influenza vaccine reported by the )] TJ ET
BT 26.250 520.473 Td /F1 9.8 Tf  [(respondents in the survey are presented in tables 2 and 3 respectively. As indicated in table 2, the most frequent reasons that )] TJ ET
BT 26.250 508.568 Td /F1 9.8 Tf  [(participants reported for accepting vaccination against the pandemic influenza included mainly protection of self or significant )] TJ ET
BT 26.250 496.663 Td /F1 9.8 Tf  [(others \(members of family, friends, patients or colleagues\) and trust in the vaccine or biomedical community. Unsurprisingly, )] TJ ET
BT 26.250 484.759 Td /F1 9.8 Tf  [(participants that were identified as persons at higher risk by the public health authorities were substantially more likely than the )] TJ ET
BT 26.250 472.854 Td /F1 9.8 Tf  [(other participants to cite self-protection as a primary motive for vaccination acceptance \(62.9% )] TJ ET
BT 435.916 472.854 Td /F5 9.8 Tf  [(vs)] TJ ET
BT 445.666 472.854 Td /F1 9.8 Tf  [(. 40.8%, )] TJ ET
BT 484.149 472.854 Td /F5 9.8 Tf  [(x�)] TJ ET
BT 492.271 472.854 Td /F1 9.8 Tf  [( = 9.4, )] TJ ET
BT 522.359 472.854 Td /F5 9.8 Tf  [(p)] TJ ET
BT 527.780 472.854 Td /F1 9.8 Tf  [(= 0.002\). )] TJ ET
BT 26.250 460.949 Td /F1 9.8 Tf  [(On the other hand, the major reasons reported by the respondents for reluctance to vaccinate \(table 3\) included perceived risk )] TJ ET
BT 26.250 449.044 Td /F1 9.8 Tf  [(of potential adverse effects, belief that the pandemic influenza was a benign illness, and belief that the vaccine was ineffective )] TJ ET
BT 26.250 437.140 Td /F1 9.8 Tf  [(or useless. Interestingly, respondents that belonged to higher risk groups for the pandemic H1N1 influenza were more likely )] TJ ET
BT 26.250 425.235 Td /F1 9.8 Tf  [(than other reluctant respondents to report that they feared side effects from the vaccine \(38.8% )] TJ ET
BT 438.675 425.235 Td /F5 9.8 Tf  [(vs)] TJ ET
BT 448.425 425.235 Td /F1 9.8 Tf  [(. 28.6% respectively, )] TJ ET
BT 541.089 425.235 Td /F5 9.8 Tf  [(x�)] TJ ET
BT 549.211 425.235 Td /F1 9.8 Tf  [( = )] TJ ET
BT 26.250 413.330 Td /F1 9.8 Tf  [(15.8, )] TJ ET
BT 50.645 413.330 Td /F5 9.8 Tf  [(p)] TJ ET
BT 56.066 413.330 Td /F1 9.8 Tf  [(< 0.05\).)] TJ ET
BT 26.250 376.728 Td /F4 12.0 Tf  [(Discussion)] TJ ET
BT 26.250 356.773 Td /F1 9.8 Tf  [(In this study, we investigated the level and distribution of vaccination acceptance against the 2009 H1N1 influenza virus during )] TJ ET
BT 26.250 344.869 Td /F1 9.8 Tf  [(the peak of the epidemic in France. This provided an exceptional opportunity to investigate the impact of social and health )] TJ ET
BT 26.250 332.964 Td /F1 9.8 Tf  [(conditions on vaccination behavior in the context of spreading of an emerging infectious disease. To the best of our knowledge, )] TJ ET
BT 26.250 321.059 Td /F1 9.8 Tf  [(few studies have examined the role of these factors in the epidemiology of pandemic A \(H1N1\) influenza immunization in the )] TJ ET
BT 26.250 309.154 Td /F1 9.8 Tf  [(general population. On the basis of this telephone survey performed in December 2009, the rate of vaccination acceptance, )] TJ ET
BT 26.250 297.250 Td /F1 9.8 Tf  [(which includes self-reported intentions or actions of immunization, could be estimated at about one quarter \(27.4%\) of the )] TJ ET
BT 26.250 285.345 Td /F1 9.8 Tf  [(French population ? 16 years of age. More precisely, actual vaccination against the pandemic H1N1 influenza virus was )] TJ ET
BT 26.250 273.440 Td /F1 9.8 Tf  [(estimated at 7.5%, which is congruent with the more or less 10% estimate of the vaccination rate calculated by the French )] TJ ET
BT 26.250 261.535 Td /F1 9.8 Tf  [(Ministry of Health from the number of persons who received the vaccine in the vaccination centers for the immunization period )] TJ ET
BT 26.250 249.631 Td /F1 9.8 Tf  [(2009-10 )] TJ ET
0.267 0.267 0.267 rg
BT 64.733 249.631 Td /F1 9.8 Tf  [([2])] TJ ET
0.271 0.267 0.267 rg
BT 75.575 249.631 Td /F1 9.8 Tf  [(. Concerning the socio-demographic distribution of vaccination acceptance among French adults, our data have )] TJ ET
BT 26.250 237.726 Td /F1 9.8 Tf  [(shown that the male, older and more advantaged participants � who are characterized by higher educational and material )] TJ ET
BT 26.250 225.821 Td /F1 9.8 Tf  [(resources � were more likely to accept the vaccine. Surprisingly, with the notable exception of sex, these results are quite )] TJ ET
BT 26.250 213.916 Td /F1 9.8 Tf  [(comparable to those of many epidemiological surveys conducted in developed countries about seasonal influenza vaccination )] TJ ET
0.267 0.267 0.267 rg
BT 26.250 202.012 Td /F1 9.8 Tf  [([5])] TJ ET
BT 37.092 202.012 Td /F1 9.8 Tf  [([6])] TJ ET
BT 47.934 202.012 Td /F1 9.8 Tf  [([7])] TJ ET
BT 58.776 202.012 Td /F1 9.8 Tf  [([8])] TJ ET
BT 69.618 202.012 Td /F1 9.8 Tf  [([9])] TJ ET
0.271 0.267 0.267 rg
BT 80.460 202.012 Td /F1 9.8 Tf  [(. Indeed, a large range of socioeconomic variables such as age, education level and income have consistently )] TJ ET
BT 26.250 190.107 Td /F1 9.8 Tf  [(been demonstrated to influence influenza vaccination behaviors. Nevertheless, after controlling for other potential confounding )] TJ ET
BT 26.250 178.202 Td /F1 9.8 Tf  [(variables, we found that vaccination acceptance was much more determined by individuals� experiences of seasonal influenza )] TJ ET
BT 26.250 166.297 Td /F1 9.8 Tf  [(vaccination in previous years than by age, which is consistent with the available data from various surveys related to pandemic )] TJ ET
BT 26.250 154.393 Td /F1 9.8 Tf  [(influenza )] TJ ET
0.267 0.267 0.267 rg
BT 67.980 154.393 Td /F1 9.8 Tf  [([9])] TJ ET
BT 78.822 154.393 Td /F1 9.8 Tf  [([10])] TJ ET
0.271 0.267 0.267 rg
BT 95.085 154.393 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 134.988 Td /F1 9.8 Tf  [(Noticeably, vaccination acceptance was not considerably higher among the participants belonging to the categories that were )] TJ ET
BT 26.250 123.083 Td /F1 9.8 Tf  [(identified as priority groups for pandemic vaccination by the public health authorities. As indicated in table 1, only the )] TJ ET
BT 26.250 111.178 Td /F1 9.8 Tf  [(respondents affected by chronic diseases or pregnancy were found to report a significantly higher rate of vaccination )] TJ ET
BT 26.250 99.274 Td /F1 9.8 Tf  [(acceptance. To further examine the influence on these factors on vaccination acceptance, a simultaneous logistic regression )] TJ ET
BT 26.250 87.369 Td /F1 9.8 Tf  [(was performed to control for other potentially confounding socio-demographic variables. Interestingly, health condition dropped )] TJ ET
BT 26.250 75.464 Td /F1 9.8 Tf  [(out as a predictor, suggesting that risk factors are perhaps only indirectly associated with attitude toward vaccination through )] TJ ET
BT 26.250 63.559 Td /F1 9.8 Tf  [(the influence of a range of socio-demographic variables such as age or occupational status. On the contrary, professional status )] TJ ET
BT 26.250 51.655 Td /F1 9.8 Tf  [(was found to significantly affect vaccination acceptance after adjusting for other socio-demographic variables. This might be )] TJ ET
BT 26.250 39.750 Td /F1 9.8 Tf  [(attributable to the fact that those working in the health or childcare fields were subjected to more immediate and personal )] TJ ET
Q
q
15.000 25.464 577.500 751.536 re W n
1.000 1.000 1.000 rg
31.650 598.806 549.600 178.194 re f
0.000 0.000 0.000 rg
32.025 776.250 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 743.869 0.750 33.881 re f
0.271 0.267 0.267 rg
BT 32.400 766.395 Td /F4 9.8 Tf  [(Categories of self-reported reasons)] TJ ET
0.000 0.000 0.000 rg
465.962 776.250 17.814 1.500 re f
483.776 776.250 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 766.395 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
532.138 776.250 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 743.869 0.750 33.881 re f
0.271 0.267 0.267 rg
BT 532.138 766.395 Td /F4 9.8 Tf  [(%)] TJ ET
0.000 0.000 0.000 rg
32.025 743.869 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 729.487 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 734.764 Td /F1 9.8 Tf  [(Belief that the vaccine is dangerous, fear of adverse reactions)] TJ ET
0.000 0.000 0.000 rg
465.962 743.869 17.814 1.500 re f
483.776 743.869 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 734.764 Td /F1 9.8 Tf  [(218)] TJ ET
0.000 0.000 0.000 rg
532.138 743.869 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 729.487 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 532.138 734.764 Td /F1 9.8 Tf  [(35.2)] TJ ET
0.267 0.267 0.267 rg
32.025 714.356 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 719.633 Td /F1 9.8 Tf  [(Belief that pandemic influenza is a minor illness, lack of perception of own risk)] TJ ET
BT 483.776 719.633 Td /F1 9.8 Tf  [(173)] TJ ET
0.267 0.267 0.267 rg
580.125 714.356 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 719.633 Td /F1 9.8 Tf  [(27.9)] TJ ET
0.267 0.267 0.267 rg
32.025 699.225 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 704.501 Td /F1 9.8 Tf  [(Belief that the vaccine is not effective)] TJ ET
BT 483.776 704.501 Td /F1 9.8 Tf  [(73)] TJ ET
0.267 0.267 0.267 rg
580.125 699.225 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 704.501 Td /F1 9.8 Tf  [(11.8)] TJ ET
0.267 0.267 0.267 rg
32.025 684.094 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 689.370 Td /F1 9.8 Tf  [(Belief that he or she has already contracted the disease)] TJ ET
BT 483.776 689.370 Td /F1 9.8 Tf  [(54)] TJ ET
0.267 0.267 0.267 rg
580.125 684.094 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 689.370 Td /F1 9.8 Tf  [(8.7)] TJ ET
0.267 0.267 0.267 rg
32.025 668.962 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 674.239 Td /F1 9.8 Tf  [(Preference for alternative methods of protection)] TJ ET
BT 483.776 674.239 Td /F1 9.8 Tf  [(40)] TJ ET
0.267 0.267 0.267 rg
580.125 668.962 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 674.239 Td /F1 9.8 Tf  [(6.5)] TJ ET
0.267 0.267 0.267 rg
32.025 646.200 0.750 22.762 re f
0.271 0.267 0.267 rg
BT 32.400 659.108 Td /F1 9.8 Tf  [(Distrust of media, pharmaceutical companies or public authorities \(including belief in conspiracy )] TJ ET
BT 32.400 651.476 Td /F1 9.8 Tf  [(theories\))] TJ ET
BT 483.776 659.108 Td /F1 9.8 Tf  [(38)] TJ ET
0.267 0.267 0.267 rg
580.125 646.200 0.750 22.762 re f
0.271 0.267 0.267 rg
BT 532.138 659.108 Td /F1 9.8 Tf  [(6.1)] TJ ET
0.267 0.267 0.267 rg
32.025 631.069 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 636.345 Td /F1 9.8 Tf  [(Medical or lay recommendation against vaccination)] TJ ET
BT 483.776 636.345 Td /F1 9.8 Tf  [(15)] TJ ET
0.267 0.267 0.267 rg
580.125 631.069 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 636.345 Td /F1 9.8 Tf  [(2.4)] TJ ET
0.267 0.267 0.267 rg
32.025 614.938 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 621.214 Td /F1 9.8 Tf  [(Other reasons)] TJ ET
BT 483.776 621.214 Td /F1 9.8 Tf  [(8)] TJ ET
0.267 0.267 0.267 rg
580.125 614.938 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 532.138 621.214 Td /F1 9.8 Tf  [(1.3)] TJ ET
0.000 0.000 0.000 rg
32.025 614.938 433.937 1.000 re f
32.025 598.806 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 598.806 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 605.583 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
465.962 614.938 17.814 1.000 re f
465.962 598.806 17.814 1.500 re f
483.776 614.938 48.362 1.000 re f
483.776 598.806 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 605.583 Td /F4 9.8 Tf  [(619)] TJ ET
0.000 0.000 0.000 rg
532.138 614.938 48.737 1.000 re f
532.138 598.806 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 598.806 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 532.138 605.583 Td /F4 9.8 Tf  [(100.0)] TJ ET
BT 26.250 551.782 Td /F6 9.8 Tf  [(Reported reasons for vaccine acceptance)] TJ ET
BT 26.250 532.378 Td /F1 9.8 Tf  [(The primary motives for acceptance or non-acceptance of the 2009 pandemic H1N1 influenza vaccine reported by the )] TJ ET
BT 26.250 520.473 Td /F1 9.8 Tf  [(respondents in the survey are presented in tables 2 and 3 respectively. As indicated in table 2, the most frequent reasons that )] TJ ET
BT 26.250 508.568 Td /F1 9.8 Tf  [(participants reported for accepting vaccination against the pandemic influenza included mainly protection of self or significant )] TJ ET
BT 26.250 496.663 Td /F1 9.8 Tf  [(others \(members of family, friends, patients or colleagues\) and trust in the vaccine or biomedical community. Unsurprisingly, )] TJ ET
BT 26.250 484.759 Td /F1 9.8 Tf  [(participants that were identified as persons at higher risk by the public health authorities were substantially more likely than the )] TJ ET
BT 26.250 472.854 Td /F1 9.8 Tf  [(other participants to cite self-protection as a primary motive for vaccination acceptance \(62.9% )] TJ ET
BT 435.916 472.854 Td /F5 9.8 Tf  [(vs)] TJ ET
BT 445.666 472.854 Td /F1 9.8 Tf  [(. 40.8%, )] TJ ET
BT 484.149 472.854 Td /F5 9.8 Tf  [(x�)] TJ ET
BT 492.271 472.854 Td /F1 9.8 Tf  [( = 9.4, )] TJ ET
BT 522.359 472.854 Td /F5 9.8 Tf  [(p)] TJ ET
BT 527.780 472.854 Td /F1 9.8 Tf  [(= 0.002\). )] TJ ET
BT 26.250 460.949 Td /F1 9.8 Tf  [(On the other hand, the major reasons reported by the respondents for reluctance to vaccinate \(table 3\) included perceived risk )] TJ ET
BT 26.250 449.044 Td /F1 9.8 Tf  [(of potential adverse effects, belief that the pandemic influenza was a benign illness, and belief that the vaccine was ineffective )] TJ ET
BT 26.250 437.140 Td /F1 9.8 Tf  [(or useless. Interestingly, respondents that belonged to higher risk groups for the pandemic H1N1 influenza were more likely )] TJ ET
BT 26.250 425.235 Td /F1 9.8 Tf  [(than other reluctant respondents to report that they feared side effects from the vaccine \(38.8% )] TJ ET
BT 438.675 425.235 Td /F5 9.8 Tf  [(vs)] TJ ET
BT 448.425 425.235 Td /F1 9.8 Tf  [(. 28.6% respectively, )] TJ ET
BT 541.089 425.235 Td /F5 9.8 Tf  [(x�)] TJ ET
BT 549.211 425.235 Td /F1 9.8 Tf  [( = )] TJ ET
BT 26.250 413.330 Td /F1 9.8 Tf  [(15.8, )] TJ ET
BT 50.645 413.330 Td /F5 9.8 Tf  [(p)] TJ ET
BT 56.066 413.330 Td /F1 9.8 Tf  [(< 0.05\).)] TJ ET
BT 26.250 376.728 Td /F4 12.0 Tf  [(Discussion)] TJ ET
BT 26.250 356.773 Td /F1 9.8 Tf  [(In this study, we investigated the level and distribution of vaccination acceptance against the 2009 H1N1 influenza virus during )] TJ ET
BT 26.250 344.869 Td /F1 9.8 Tf  [(the peak of the epidemic in France. This provided an exceptional opportunity to investigate the impact of social and health )] TJ ET
BT 26.250 332.964 Td /F1 9.8 Tf  [(conditions on vaccination behavior in the context of spreading of an emerging infectious disease. To the best of our knowledge, )] TJ ET
BT 26.250 321.059 Td /F1 9.8 Tf  [(few studies have examined the role of these factors in the epidemiology of pandemic A \(H1N1\) influenza immunization in the )] TJ ET
BT 26.250 309.154 Td /F1 9.8 Tf  [(general population. On the basis of this telephone survey performed in December 2009, the rate of vaccination acceptance, )] TJ ET
BT 26.250 297.250 Td /F1 9.8 Tf  [(which includes self-reported intentions or actions of immunization, could be estimated at about one quarter \(27.4%\) of the )] TJ ET
BT 26.250 285.345 Td /F1 9.8 Tf  [(French population ? 16 years of age. More precisely, actual vaccination against the pandemic H1N1 influenza virus was )] TJ ET
BT 26.250 273.440 Td /F1 9.8 Tf  [(estimated at 7.5%, which is congruent with the more or less 10% estimate of the vaccination rate calculated by the French )] TJ ET
BT 26.250 261.535 Td /F1 9.8 Tf  [(Ministry of Health from the number of persons who received the vaccine in the vaccination centers for the immunization period )] TJ ET
BT 26.250 249.631 Td /F1 9.8 Tf  [(2009-10 )] TJ ET
0.267 0.267 0.267 rg
BT 64.733 249.631 Td /F1 9.8 Tf  [([2])] TJ ET
0.271 0.267 0.267 rg
BT 75.575 249.631 Td /F1 9.8 Tf  [(. Concerning the socio-demographic distribution of vaccination acceptance among French adults, our data have )] TJ ET
BT 26.250 237.726 Td /F1 9.8 Tf  [(shown that the male, older and more advantaged participants � who are characterized by higher educational and material )] TJ ET
BT 26.250 225.821 Td /F1 9.8 Tf  [(resources � were more likely to accept the vaccine. Surprisingly, with the notable exception of sex, these results are quite )] TJ ET
BT 26.250 213.916 Td /F1 9.8 Tf  [(comparable to those of many epidemiological surveys conducted in developed countries about seasonal influenza vaccination )] TJ ET
0.267 0.267 0.267 rg
BT 26.250 202.012 Td /F1 9.8 Tf  [([5])] TJ ET
BT 37.092 202.012 Td /F1 9.8 Tf  [([6])] TJ ET
BT 47.934 202.012 Td /F1 9.8 Tf  [([7])] TJ ET
BT 58.776 202.012 Td /F1 9.8 Tf  [([8])] TJ ET
BT 69.618 202.012 Td /F1 9.8 Tf  [([9])] TJ ET
0.271 0.267 0.267 rg
BT 80.460 202.012 Td /F1 9.8 Tf  [(. Indeed, a large range of socioeconomic variables such as age, education level and income have consistently )] TJ ET
BT 26.250 190.107 Td /F1 9.8 Tf  [(been demonstrated to influence influenza vaccination behaviors. Nevertheless, after controlling for other potential confounding )] TJ ET
BT 26.250 178.202 Td /F1 9.8 Tf  [(variables, we found that vaccination acceptance was much more determined by individuals� experiences of seasonal influenza )] TJ ET
BT 26.250 166.297 Td /F1 9.8 Tf  [(vaccination in previous years than by age, which is consistent with the available data from various surveys related to pandemic )] TJ ET
BT 26.250 154.393 Td /F1 9.8 Tf  [(influenza )] TJ ET
0.267 0.267 0.267 rg
BT 67.980 154.393 Td /F1 9.8 Tf  [([9])] TJ ET
BT 78.822 154.393 Td /F1 9.8 Tf  [([10])] TJ ET
0.271 0.267 0.267 rg
BT 95.085 154.393 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 134.988 Td /F1 9.8 Tf  [(Noticeably, vaccination acceptance was not considerably higher among the participants belonging to the categories that were )] TJ ET
BT 26.250 123.083 Td /F1 9.8 Tf  [(identified as priority groups for pandemic vaccination by the public health authorities. As indicated in table 1, only the )] TJ ET
BT 26.250 111.178 Td /F1 9.8 Tf  [(respondents affected by chronic diseases or pregnancy were found to report a significantly higher rate of vaccination )] TJ ET
BT 26.250 99.274 Td /F1 9.8 Tf  [(acceptance. To further examine the influence on these factors on vaccination acceptance, a simultaneous logistic regression )] TJ ET
BT 26.250 87.369 Td /F1 9.8 Tf  [(was performed to control for other potentially confounding socio-demographic variables. Interestingly, health condition dropped )] TJ ET
BT 26.250 75.464 Td /F1 9.8 Tf  [(out as a predictor, suggesting that risk factors are perhaps only indirectly associated with attitude toward vaccination through )] TJ ET
BT 26.250 63.559 Td /F1 9.8 Tf  [(the influence of a range of socio-demographic variables such as age or occupational status. On the contrary, professional status )] TJ ET
BT 26.250 51.655 Td /F1 9.8 Tf  [(was found to significantly affect vaccination acceptance after adjusting for other socio-demographic variables. This might be )] TJ ET
BT 26.250 39.750 Td /F1 9.8 Tf  [(attributable to the fact that those working in the health or childcare fields were subjected to more immediate and personal )] TJ ET
Q
q
15.000 25.464 577.500 751.536 re W n
1.000 1.000 1.000 rg
31.650 598.806 549.600 178.194 re f
0.000 0.000 0.000 rg
32.025 776.250 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 743.869 0.750 33.881 re f
0.271 0.267 0.267 rg
BT 32.400 766.395 Td /F4 9.8 Tf  [(Categories of self-reported reasons)] TJ ET
0.000 0.000 0.000 rg
465.962 776.250 17.814 1.500 re f
483.776 776.250 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 766.395 Td /F4 9.8 Tf  [(N)] TJ ET
0.000 0.000 0.000 rg
532.138 776.250 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 743.869 0.750 33.881 re f
0.271 0.267 0.267 rg
BT 532.138 766.395 Td /F4 9.8 Tf  [(%)] TJ ET
0.000 0.000 0.000 rg
32.025 743.869 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 729.487 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 32.400 734.764 Td /F1 9.8 Tf  [(Belief that the vaccine is dangerous, fear of adverse reactions)] TJ ET
0.000 0.000 0.000 rg
465.962 743.869 17.814 1.500 re f
483.776 743.869 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 734.764 Td /F1 9.8 Tf  [(218)] TJ ET
0.000 0.000 0.000 rg
532.138 743.869 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 729.487 0.750 15.881 re f
0.271 0.267 0.267 rg
BT 532.138 734.764 Td /F1 9.8 Tf  [(35.2)] TJ ET
0.267 0.267 0.267 rg
32.025 714.356 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 719.633 Td /F1 9.8 Tf  [(Belief that pandemic influenza is a minor illness, lack of perception of own risk)] TJ ET
BT 483.776 719.633 Td /F1 9.8 Tf  [(173)] TJ ET
0.267 0.267 0.267 rg
580.125 714.356 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 719.633 Td /F1 9.8 Tf  [(27.9)] TJ ET
0.267 0.267 0.267 rg
32.025 699.225 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 704.501 Td /F1 9.8 Tf  [(Belief that the vaccine is not effective)] TJ ET
BT 483.776 704.501 Td /F1 9.8 Tf  [(73)] TJ ET
0.267 0.267 0.267 rg
580.125 699.225 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 704.501 Td /F1 9.8 Tf  [(11.8)] TJ ET
0.267 0.267 0.267 rg
32.025 684.094 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 689.370 Td /F1 9.8 Tf  [(Belief that he or she has already contracted the disease)] TJ ET
BT 483.776 689.370 Td /F1 9.8 Tf  [(54)] TJ ET
0.267 0.267 0.267 rg
580.125 684.094 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 689.370 Td /F1 9.8 Tf  [(8.7)] TJ ET
0.267 0.267 0.267 rg
32.025 668.962 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 674.239 Td /F1 9.8 Tf  [(Preference for alternative methods of protection)] TJ ET
BT 483.776 674.239 Td /F1 9.8 Tf  [(40)] TJ ET
0.267 0.267 0.267 rg
580.125 668.962 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 674.239 Td /F1 9.8 Tf  [(6.5)] TJ ET
0.267 0.267 0.267 rg
32.025 646.200 0.750 22.762 re f
0.271 0.267 0.267 rg
BT 32.400 659.108 Td /F1 9.8 Tf  [(Distrust of media, pharmaceutical companies or public authorities \(including belief in conspiracy )] TJ ET
BT 32.400 651.476 Td /F1 9.8 Tf  [(theories\))] TJ ET
BT 483.776 659.108 Td /F1 9.8 Tf  [(38)] TJ ET
0.267 0.267 0.267 rg
580.125 646.200 0.750 22.762 re f
0.271 0.267 0.267 rg
BT 532.138 659.108 Td /F1 9.8 Tf  [(6.1)] TJ ET
0.267 0.267 0.267 rg
32.025 631.069 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 32.400 636.345 Td /F1 9.8 Tf  [(Medical or lay recommendation against vaccination)] TJ ET
BT 483.776 636.345 Td /F1 9.8 Tf  [(15)] TJ ET
0.267 0.267 0.267 rg
580.125 631.069 0.750 15.131 re f
0.271 0.267 0.267 rg
BT 532.138 636.345 Td /F1 9.8 Tf  [(2.4)] TJ ET
0.267 0.267 0.267 rg
32.025 614.938 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 32.400 621.214 Td /F1 9.8 Tf  [(Other reasons)] TJ ET
BT 483.776 621.214 Td /F1 9.8 Tf  [(8)] TJ ET
0.267 0.267 0.267 rg
580.125 614.938 0.750 16.131 re f
0.271 0.267 0.267 rg
BT 532.138 621.214 Td /F1 9.8 Tf  [(1.3)] TJ ET
0.000 0.000 0.000 rg
32.025 614.938 433.937 1.000 re f
32.025 598.806 433.937 1.500 re f
0.267 0.267 0.267 rg
32.025 598.806 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 32.400 605.583 Td /F4 9.8 Tf  [(Total)] TJ ET
0.000 0.000 0.000 rg
465.962 614.938 17.814 1.000 re f
465.962 598.806 17.814 1.500 re f
483.776 614.938 48.362 1.000 re f
483.776 598.806 48.362 1.500 re f
0.271 0.267 0.267 rg
BT 483.776 605.583 Td /F4 9.8 Tf  [(619)] TJ ET
0.000 0.000 0.000 rg
532.138 614.938 48.737 1.000 re f
532.138 598.806 48.737 1.500 re f
0.267 0.267 0.267 rg
580.125 598.806 0.750 17.131 re f
0.271 0.267 0.267 rg
BT 532.138 605.583 Td /F4 9.8 Tf  [(100.0)] TJ ET
BT 26.250 551.782 Td /F6 9.8 Tf  [(Reported reasons for vaccine acceptance)] TJ ET
BT 26.250 532.378 Td /F1 9.8 Tf  [(The primary motives for acceptance or non-acceptance of the 2009 pandemic H1N1 influenza vaccine reported by the )] TJ ET
BT 26.250 520.473 Td /F1 9.8 Tf  [(respondents in the survey are presented in tables 2 and 3 respectively. As indicated in table 2, the most frequent reasons that )] TJ ET
BT 26.250 508.568 Td /F1 9.8 Tf  [(participants reported for accepting vaccination against the pandemic influenza included mainly protection of self or significant )] TJ ET
BT 26.250 496.663 Td /F1 9.8 Tf  [(others \(members of family, friends, patients or colleagues\) and trust in the vaccine or biomedical community. Unsurprisingly, )] TJ ET
BT 26.250 484.759 Td /F1 9.8 Tf  [(participants that were identified as persons at higher risk by the public health authorities were substantially more likely than the )] TJ ET
BT 26.250 472.854 Td /F1 9.8 Tf  [(other participants to cite self-protection as a primary motive for vaccination acceptance \(62.9% )] TJ ET
BT 435.916 472.854 Td /F5 9.8 Tf  [(vs)] TJ ET
BT 445.666 472.854 Td /F1 9.8 Tf  [(. 40.8%, )] TJ ET
BT 484.149 472.854 Td /F5 9.8 Tf  [(x�)] TJ ET
BT 492.271 472.854 Td /F1 9.8 Tf  [( = 9.4, )] TJ ET
BT 522.359 472.854 Td /F5 9.8 Tf  [(p)] TJ ET
BT 527.780 472.854 Td /F1 9.8 Tf  [(= 0.002\). )] TJ ET
BT 26.250 460.949 Td /F1 9.8 Tf  [(On the other hand, the major reasons reported by the respondents for reluctance to vaccinate \(table 3\) included perceived risk )] TJ ET
BT 26.250 449.044 Td /F1 9.8 Tf  [(of potential adverse effects, belief that the pandemic influenza was a benign illness, and belief that the vaccine was ineffective )] TJ ET
BT 26.250 437.140 Td /F1 9.8 Tf  [(or useless. Interestingly, respondents that belonged to higher risk groups for the pandemic H1N1 influenza were more likely )] TJ ET
BT 26.250 425.235 Td /F1 9.8 Tf  [(than other reluctant respondents to report that they feared side effects from the vaccine \(38.8% )] TJ ET
BT 438.675 425.235 Td /F5 9.8 Tf  [(vs)] TJ ET
BT 448.425 425.235 Td /F1 9.8 Tf  [(. 28.6% respectively, )] TJ ET
BT 541.089 425.235 Td /F5 9.8 Tf  [(x�)] TJ ET
BT 549.211 425.235 Td /F1 9.8 Tf  [( = )] TJ ET
BT 26.250 413.330 Td /F1 9.8 Tf  [(15.8, )] TJ ET
BT 50.645 413.330 Td /F5 9.8 Tf  [(p)] TJ ET
BT 56.066 413.330 Td /F1 9.8 Tf  [(< 0.05\).)] TJ ET
BT 26.250 376.728 Td /F4 12.0 Tf  [(Discussion)] TJ ET
BT 26.250 356.773 Td /F1 9.8 Tf  [(In this study, we investigated the level and distribution of vaccination acceptance against the 2009 H1N1 influenza virus during )] TJ ET
BT 26.250 344.869 Td /F1 9.8 Tf  [(the peak of the epidemic in France. This provided an exceptional opportunity to investigate the impact of social and health )] TJ ET
BT 26.250 332.964 Td /F1 9.8 Tf  [(conditions on vaccination behavior in the context of spreading of an emerging infectious disease. To the best of our knowledge, )] TJ ET
BT 26.250 321.059 Td /F1 9.8 Tf  [(few studies have examined the role of these factors in the epidemiology of pandemic A \(H1N1\) influenza immunization in the )] TJ ET
BT 26.250 309.154 Td /F1 9.8 Tf  [(general population. On the basis of this telephone survey performed in December 2009, the rate of vaccination acceptance, )] TJ ET
BT 26.250 297.250 Td /F1 9.8 Tf  [(which includes self-reported intentions or actions of immunization, could be estimated at about one quarter \(27.4%\) of the )] TJ ET
BT 26.250 285.345 Td /F1 9.8 Tf  [(French population ? 16 years of age. More precisely, actual vaccination against the pandemic H1N1 influenza virus was )] TJ ET
BT 26.250 273.440 Td /F1 9.8 Tf  [(estimated at 7.5%, which is congruent with the more or less 10% estimate of the vaccination rate calculated by the French )] TJ ET
BT 26.250 261.535 Td /F1 9.8 Tf  [(Ministry of Health from the number of persons who received the vaccine in the vaccination centers for the immunization period )] TJ ET
BT 26.250 249.631 Td /F1 9.8 Tf  [(2009-10 )] TJ ET
0.267 0.267 0.267 rg
BT 64.733 249.631 Td /F1 9.8 Tf  [([2])] TJ ET
0.271 0.267 0.267 rg
BT 75.575 249.631 Td /F1 9.8 Tf  [(. Concerning the socio-demographic distribution of vaccination acceptance among French adults, our data have )] TJ ET
BT 26.250 237.726 Td /F1 9.8 Tf  [(shown that the male, older and more advantaged participants � who are characterized by higher educational and material )] TJ ET
BT 26.250 225.821 Td /F1 9.8 Tf  [(resources � were more likely to accept the vaccine. Surprisingly, with the notable exception of sex, these results are quite )] TJ ET
BT 26.250 213.916 Td /F1 9.8 Tf  [(comparable to those of many epidemiological surveys conducted in developed countries about seasonal influenza vaccination )] TJ ET
0.267 0.267 0.267 rg
BT 26.250 202.012 Td /F1 9.8 Tf  [([5])] TJ ET
BT 37.092 202.012 Td /F1 9.8 Tf  [([6])] TJ ET
BT 47.934 202.012 Td /F1 9.8 Tf  [([7])] TJ ET
BT 58.776 202.012 Td /F1 9.8 Tf  [([8])] TJ ET
BT 69.618 202.012 Td /F1 9.8 Tf  [([9])] TJ ET
0.271 0.267 0.267 rg
BT 80.460 202.012 Td /F1 9.8 Tf  [(. Indeed, a large range of socioeconomic variables such as age, education level and income have consistently )] TJ ET
BT 26.250 190.107 Td /F1 9.8 Tf  [(been demonstrated to influence influenza vaccination behaviors. Nevertheless, after controlling for other potential confounding )] TJ ET
BT 26.250 178.202 Td /F1 9.8 Tf  [(variables, we found that vaccination acceptance was much more determined by individuals� experiences of seasonal influenza )] TJ ET
BT 26.250 166.297 Td /F1 9.8 Tf  [(vaccination in previous years than by age, which is consistent with the available data from various surveys related to pandemic )] TJ ET
BT 26.250 154.393 Td /F1 9.8 Tf  [(influenza )] TJ ET
0.267 0.267 0.267 rg
BT 67.980 154.393 Td /F1 9.8 Tf  [([9])] TJ ET
BT 78.822 154.393 Td /F1 9.8 Tf  [([10])] TJ ET
0.271 0.267 0.267 rg
BT 95.085 154.393 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 134.988 Td /F1 9.8 Tf  [(Noticeably, vaccination acceptance was not considerably higher among the participants belonging to the categories that were )] TJ ET
BT 26.250 123.083 Td /F1 9.8 Tf  [(identified as priority groups for pandemic vaccination by the public health authorities. As indicated in table 1, only the )] TJ ET
BT 26.250 111.178 Td /F1 9.8 Tf  [(respondents affected by chronic diseases or pregnancy were found to report a significantly higher rate of vaccination )] TJ ET
BT 26.250 99.274 Td /F1 9.8 Tf  [(acceptance. To further examine the influence on these factors on vaccination acceptance, a simultaneous logistic regression )] TJ ET
BT 26.250 87.369 Td /F1 9.8 Tf  [(was performed to control for other potentially confounding socio-demographic variables. Interestingly, health condition dropped )] TJ ET
BT 26.250 75.464 Td /F1 9.8 Tf  [(out as a predictor, suggesting that risk factors are perhaps only indirectly associated with attitude toward vaccination through )] TJ ET
BT 26.250 63.559 Td /F1 9.8 Tf  [(the influence of a range of socio-demographic variables such as age or occupational status. On the contrary, professional status )] TJ ET
BT 26.250 51.655 Td /F1 9.8 Tf  [(was found to significantly affect vaccination acceptance after adjusting for other socio-demographic variables. This might be )] TJ ET
BT 26.250 39.750 Td /F1 9.8 Tf  [(attributable to the fact that those working in the health or childcare fields were subjected to more immediate and personal )] TJ ET
Q
q
0.000 0.000 0.000 rg
BT 291.710 19.825 Td /F1 11.0 Tf  [(4)] TJ ET
BT 25.000 19.825 Td /F1 11.0 Tf  [(PLOS Currents Influenza)] TJ ET

Q
endstream
endobj
76 0 obj
<< /Type /Annot
/Subtype /Link
/A 77 0 R
/Border [0 0 0]
/H /I
/Rect [ 64.7332 248.7288 75.5752 258.6495 ]
>>
endobj
77 0 obj
<< /Type /Action
>>
endobj
78 0 obj
<< /Type /Annot
/Subtype /Link
/A 79 0 R
/Border [0 0 0]
/H /I
/Rect [ 26.2500 201.1098 37.0920 211.0305 ]
>>
endobj
79 0 obj
<< /Type /Action
>>
endobj
80 0 obj
<< /Type /Annot
/Subtype /Link
/A 81 0 R
/Border [0 0 0]
/H /I
/Rect [ 37.0920 201.1098 47.9340 211.0305 ]
>>
endobj
81 0 obj
<< /Type /Action
>>
endobj
82 0 obj
<< /Type /Annot
/Subtype /Link
/A 83 0 R
/Border [0 0 0]
/H /I
/Rect [ 47.9340 201.1098 58.7760 211.0305 ]
>>
endobj
83 0 obj
<< /Type /Action
>>
endobj
84 0 obj
<< /Type /Annot
/Subtype /Link
/A 85 0 R
/Border [0 0 0]
/H /I
/Rect [ 58.7760 201.1098 69.6180 211.0305 ]
>>
endobj
85 0 obj
<< /Type /Action
>>
endobj
86 0 obj
<< /Type /Annot
/Subtype /Link
/A 87 0 R
/Border [0 0 0]
/H /I
/Rect [ 69.6180 201.1098 80.4600 211.0305 ]
>>
endobj
87 0 obj
<< /Type /Action
>>
endobj
88 0 obj
<< /Type /Annot
/Subtype /Link
/A 89 0 R
/Border [0 0 0]
/H /I
/Rect [ 67.9800 153.4908 78.8220 163.4115 ]
>>
endobj
89 0 obj
<< /Type /Action
>>
endobj
90 0 obj
<< /Type /Annot
/Subtype /Link
/A 91 0 R
/Border [0 0 0]
/H /I
/Rect [ 78.8220 153.4908 95.0850 163.4115 ]
>>
endobj
91 0 obj
<< /Type /Action
>>
endobj
92 0 obj
<< /Type /Annot
/Subtype /Link
/A 93 0 R
/Border [0 0 0]
/H /I
/Rect [ 64.7332 248.7288 75.5752 258.6495 ]
>>
endobj
93 0 obj
<< /Type /Action
>>
endobj
94 0 obj
<< /Type /Annot
/Subtype /Link
/A 95 0 R
/Border [0 0 0]
/H /I
/Rect [ 26.2500 201.1098 37.0920 211.0305 ]
>>
endobj
95 0 obj
<< /Type /Action
>>
endobj
96 0 obj
<< /Type /Annot
/Subtype /Link
/A 97 0 R
/Border [0 0 0]
/H /I
/Rect [ 37.0920 201.1098 47.9340 211.0305 ]
>>
endobj
97 0 obj
<< /Type /Action
>>
endobj
98 0 obj
<< /Type /Annot
/Subtype /Link
/A 99 0 R
/Border [0 0 0]
/H /I
/Rect [ 47.9340 201.1098 58.7760 211.0305 ]
>>
endobj
99 0 obj
<< /Type /Action
>>
endobj
100 0 obj
<< /Type /Annot
/Subtype /Link
/A 101 0 R
/Border [0 0 0]
/H /I
/Rect [ 58.7760 201.1098 69.6180 211.0305 ]
>>
endobj
101 0 obj
<< /Type /Action
>>
endobj
102 0 obj
<< /Type /Annot
/Subtype /Link
/A 103 0 R
/Border [0 0 0]
/H /I
/Rect [ 69.6180 201.1098 80.4600 211.0305 ]
>>
endobj
103 0 obj
<< /Type /Action
>>
endobj
104 0 obj
<< /Type /Annot
/Subtype /Link
/A 105 0 R
/Border [0 0 0]
/H /I
/Rect [ 67.9800 153.4908 78.8220 163.4115 ]
>>
endobj
105 0 obj
<< /Type /Action
>>
endobj
106 0 obj
<< /Type /Annot
/Subtype /Link
/A 107 0 R
/Border [0 0 0]
/H /I
/Rect [ 78.8220 153.4908 95.0850 163.4115 ]
>>
endobj
107 0 obj
<< /Type /Action
>>
endobj
108 0 obj
<< /Type /Annot
/Subtype /Link
/A 109 0 R
/Border [0 0 0]
/H /I
/Rect [ 64.7332 248.7288 75.5752 258.6495 ]
>>
endobj
109 0 obj
<< /Type /Action
>>
endobj
110 0 obj
<< /Type /Annot
/Subtype /Link
/A 111 0 R
/Border [0 0 0]
/H /I
/Rect [ 26.2500 201.1098 37.0920 211.0305 ]
>>
endobj
111 0 obj
<< /Type /Action
>>
endobj
112 0 obj
<< /Type /Annot
/Subtype /Link
/A 113 0 R
/Border [0 0 0]
/H /I
/Rect [ 37.0920 201.1098 47.9340 211.0305 ]
>>
endobj
113 0 obj
<< /Type /Action
>>
endobj
114 0 obj
<< /Type /Annot
/Subtype /Link
/A 115 0 R
/Border [0 0 0]
/H /I
/Rect [ 47.9340 201.1098 58.7760 211.0305 ]
>>
endobj
115 0 obj
<< /Type /Action
>>
endobj
116 0 obj
<< /Type /Annot
/Subtype /Link
/A 117 0 R
/Border [0 0 0]
/H /I
/Rect [ 58.7760 201.1098 69.6180 211.0305 ]
>>
endobj
117 0 obj
<< /Type /Action
>>
endobj
118 0 obj
<< /Type /Annot
/Subtype /Link
/A 119 0 R
/Border [0 0 0]
/H /I
/Rect [ 69.6180 201.1098 80.4600 211.0305 ]
>>
endobj
119 0 obj
<< /Type /Action
>>
endobj
120 0 obj
<< /Type /Annot
/Subtype /Link
/A 121 0 R
/Border [0 0 0]
/H /I
/Rect [ 67.9800 153.4908 78.8220 163.4115 ]
>>
endobj
121 0 obj
<< /Type /Action
>>
endobj
122 0 obj
<< /Type /Annot
/Subtype /Link
/A 123 0 R
/Border [0 0 0]
/H /I
/Rect [ 78.8220 153.4908 95.0850 163.4115 ]
>>
endobj
123 0 obj
<< /Type /Action
>>
endobj
124 0 obj
<< /Type /Page
/Parent 3 0 R
/Annots [ 126 0 R 128 0 R 130 0 R 132 0 R 134 0 R 136 0 R 138 0 R 140 0 R 142 0 R 144 0 R 146 0 R 148 0 R 150 0 R 152 0 R 154 0 R 156 0 R 158 0 R 160 0 R 162 0 R 164 0 R 166 0 R 168 0 R 170 0 R 172 0 R 174 0 R 176 0 R 178 0 R 180 0 R 182 0 R 184 0 R 186 0 R 188 0 R 190 0 R ]
/Contents 125 0 R
>>
endobj
125 0 obj
<<
/Length 31672 >>
stream

0.271 0.267 0.267 rg
q
15.000 37.120 577.500 739.880 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(pressures from their social and institutional environment. Nevertheless, the effects of social conformity remained relatively weak )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(since less than one third of members of this key target group were likely to accept vaccination. Overall, the rate of acceptance of )] TJ ET
BT 26.250 743.667 Td /F1 9.8 Tf  [(pandemic influenza vaccination among health and childcare workers was not substantially different from those observed for )] TJ ET
BT 26.250 731.762 Td /F1 9.8 Tf  [(seasonal influenza in previous years in European countries )] TJ ET
0.267 0.267 0.267 rg
BT 283.660 731.762 Td /F1 9.8 Tf  [([11])] TJ ET
BT 299.923 731.762 Td /F1 9.8 Tf  [([12])] TJ ET
BT 316.186 731.762 Td /F1 9.8 Tf  [([13])] TJ ET
0.271 0.267 0.267 rg
BT 332.449 731.762 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 712.357 Td /F1 9.8 Tf  [(At this stage, it remains necessary to uncover the reasons why certain persons or groups were more likely to accept )] TJ ET
BT 26.250 700.452 Td /F1 9.8 Tf  [(immunization against the 2009 pandemic H1N1 influenza virus than others, even when socio-demographic variables, as well as )] TJ ET
BT 26.250 688.548 Td /F1 9.8 Tf  [(risk factors, were controlled for. In the recent literature, one of the dominant strategies has been to use open-ended questions )] TJ ET
BT 26.250 676.643 Td /F1 9.8 Tf  [(within large-scale surveys. This type of questioning is known to encourage more complete and meaningful answers in surveys )] TJ ET
BT 26.250 664.738 Td /F1 9.8 Tf  [(by permitting subjects to express their motivations and/or sentiments in their own phrasing )] TJ ET
0.267 0.267 0.267 rg
BT 417.488 664.738 Td /F1 9.8 Tf  [([4])] TJ ET
0.271 0.267 0.267 rg
BT 428.330 664.738 Td /F1 9.8 Tf  [(. In the present study, the primary )] TJ ET
BT 26.250 652.833 Td /F1 9.8 Tf  [(reasons associated with acceptance and rejection of vaccination can be broadly divided into 3 groups. The first group )] TJ ET
BT 26.250 640.929 Td /F1 9.8 Tf  [(addresses the mental representation of the threat � in particular the beliefs and judgments related to the severity of the illness )] TJ ET
BT 26.250 629.024 Td /F1 9.8 Tf  [(and risk factors \(i.e., which groups are more vulnerable to the infection\), as well as the emotional response to the risk of )] TJ ET
BT 26.250 617.119 Td /F1 9.8 Tf  [(contracting the disease. The second relates to the perception of the vaccine, including concerns about its safety or )] TJ ET
BT 26.250 605.214 Td /F1 9.8 Tf  [(effectiveness. The third group of motives can be associated with issues of trust toward those advocating the vaccine \(the )] TJ ET
BT 26.250 593.310 Td /F1 9.8 Tf  [(government, the pharmaceutical industry, or biomedical experts\) � including beliefs in conspiracy theories.)] TJ ET
BT 26.250 573.905 Td /F1 9.8 Tf  [(Eventually, the motivations that underlie the acceptability of vaccination could be approached to a large extent from a traditional )] TJ ET
BT 26.250 562.000 Td /F1 9.8 Tf  [(risk/benefit analysis. According to this basic model of decision-making under uncertainty, the acceptance or rejection of any )] TJ ET
BT 26.250 550.095 Td /F1 9.8 Tf  [(protective action should be interpreted as the outcome of a trade-off between the risks and personal or societal benefits )] TJ ET
BT 26.250 538.191 Td /F1 9.8 Tf  [(associated with products or activities that are recognized for their preventive value. From this theoretical perspective, the public )] TJ ET
BT 26.250 526.286 Td /F1 9.8 Tf  [(acceptability of vaccination is expected to vary roughly as a direct function of both perceived risk and perceived benefit. )] TJ ET
BT 26.250 514.381 Td /F1 9.8 Tf  [(Moreover, the perceived benefit associated with immunization depends in turn, for a large part, on the perceived risk of )] TJ ET
BT 26.250 502.476 Td /F1 9.8 Tf  [(contracting the disease � which is generally known to result from two main cognitive components: the personal likelihood of )] TJ ET
BT 26.250 490.572 Td /F1 9.8 Tf  [(becoming infected \(vulnerability\) and the seriousness of the consequences of that infection \(severity\). Although the relevance of )] TJ ET
BT 26.250 478.667 Td /F1 9.8 Tf  [(the risk/benefit approach would deserve a more complex discussion that is beyond the scope of this article, most of the primary )] TJ ET
BT 26.250 466.762 Td /F1 9.8 Tf  [(reasons that were spontaneously invoked by the respondents might indicate that people actually perform a sort of trade-off )] TJ ET
BT 26.250 454.857 Td /F1 9.8 Tf  [(between the perceived risk and the perceived benefit associated with the vaccine uptake.)] TJ ET
BT 26.250 435.453 Td /F1 9.8 Tf  [(For example, among the principal reasons for the non-acceptance of vaccination were \(1\) belief that the vaccine against the )] TJ ET
BT 26.250 423.548 Td /F1 9.8 Tf  [(2009 pandemic H1N1 influenza virus is dangerous or ineffective and \(2\) belief that the pandemic influenza is not a serious )] TJ ET
BT 26.250 411.643 Td /F1 9.8 Tf  [(illness, suggesting that the perceived risk exceeds the perceived benefit associated with pandemic influenza vaccination. Thus, )] TJ ET
BT 26.250 399.738 Td /F1 9.8 Tf  [(almost half of the reluctant respondents \(47.0%\) indicated that they had doubts about either safety or efficacy of the pandemic )] TJ ET
BT 26.250 387.834 Td /F1 9.8 Tf  [(vaccine, and more than one quarter \(27.9%\) felt that the pandemic H1N1 influenza could be considered to be a minor illness. )] TJ ET
BT 26.250 375.929 Td /F1 9.8 Tf  [(Finally the motives captured by open-ended questions provided results that are largely consistent with those of previous )] TJ ET
BT 26.250 364.024 Td /F1 9.8 Tf  [(quantitative and qualitative studies on the determinants of seasonal influenza vaccine acceptance. According to certain reviews )] TJ ET
BT 26.250 352.119 Td /F1 9.8 Tf  [(of literature, the fear of side effects can be easily identified as one of the most commonly reported barriers to vaccination across )] TJ ET
BT 26.250 340.215 Td /F1 9.8 Tf  [(all communicable diseases )] TJ ET
0.267 0.267 0.267 rg
BT 145.454 340.215 Td /F1 9.8 Tf  [([14])] TJ ET
BT 161.716 340.215 Td /F1 9.8 Tf  [([15])] TJ ET
BT 177.980 340.215 Td /F1 9.8 Tf  [([16])] TJ ET
0.271 0.267 0.267 rg
BT 194.243 340.215 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 320.810 Td /F1 9.8 Tf  [(Several limitations can be pointed out in this study. First, even if the sampled population did not significantly differ from the )] TJ ET
BT 26.250 308.905 Td /F1 9.8 Tf  [(general population in terms of age, gender, occupation and place of residence, it cannot be ruled out that the subjects who )] TJ ET
BT 26.250 297.000 Td /F1 9.8 Tf  [(refused to participate in our study were characterized by a range of psychological and/or sociological attributes that made them )] TJ ET
BT 26.250 285.096 Td /F1 9.8 Tf  [(different from the cooperating subjects with regards to vaccination acceptance or non-acceptance. Second, the timing of the )] TJ ET
BT 26.250 273.191 Td /F1 9.8 Tf  [(survey \(early December\) might have led to both an underestimate of the vaccination coverage rate, and an overestimate of )] TJ ET
BT 26.250 261.286 Td /F1 9.8 Tf  [(vaccination intention among the French adult population since the controversy about the safety and/or necessity of the )] TJ ET
BT 26.250 249.381 Td /F1 9.8 Tf  [(pandemic H1N1 influenza vaccination was growing over time. As noted above, the actual vaccination coverage rate was )] TJ ET
BT 26.250 237.477 Td /F1 9.8 Tf  [(assessed at the end of the domestic outbreak by the Ministry of health and found to include approximately 10% of the French. )] TJ ET
BT 26.250 225.572 Td /F1 9.8 Tf  [(Third, the nature of reasons offered by the participants to justify their acceptance or refusal to get vaccinated against the )] TJ ET
BT 26.250 213.667 Td /F1 9.8 Tf  [(pandemic influenza might have been subject to possible biases of social desirability \(or conformity\). This typical bias � which )] TJ ET
BT 26.250 201.762 Td /F1 9.8 Tf  [(describes the subjects� propensity to report a range of reasons for a particular behaviour that are different from their �real� )] TJ ET
BT 26.250 189.858 Td /F1 9.8 Tf  [(motivation because they are viewed as more socially acceptable � has been extensively well-documented in the methodological )] TJ ET
BT 26.250 177.953 Td /F1 9.8 Tf  [(literature )] TJ ET
0.267 0.267 0.267 rg
BT 66.888 177.953 Td /F1 9.8 Tf  [([4])] TJ ET
BT 77.730 177.953 Td /F1 9.8 Tf  [([17])] TJ ET
0.271 0.267 0.267 rg
BT 93.993 177.953 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 158.548 Td /F1 9.8 Tf  [(To conclude, the results of this study tend to show that the 2009 pandemic H1N1 influenza was not perceived by the French )] TJ ET
BT 26.250 146.643 Td /F1 9.8 Tf  [(population to be significantly different from the seasonal influenza. Notably, the distribution and justification of vaccination )] TJ ET
BT 26.250 134.739 Td /F1 9.8 Tf  [(acceptance among the participants were strongly similar to those of seasonal influenza vaccination acceptance )] TJ ET
0.267 0.267 0.267 rg
BT 507.471 134.739 Td /F1 9.8 Tf  [([18])] TJ ET
BT 523.734 134.739 Td /F1 9.8 Tf  [([19])] TJ ET
0.271 0.267 0.267 rg
BT 539.997 134.739 Td /F1 9.8 Tf  [(, and )] TJ ET
BT 26.250 122.834 Td /F1 9.8 Tf  [(consequently contributed to the maintenance of health inequalities in France. In this regard, it should be noted that the )] TJ ET
BT 26.250 110.929 Td /F1 9.8 Tf  [(pandemic H1N1 influenza has been commonly and ironically named �grippette� \(little flu\) in France. Thus, as long as the )] TJ ET
BT 26.250 99.024 Td /F1 9.8 Tf  [(patterns of mortality and/or morbidity associated with the pandemic influenza did not differ crucially from those related to the )] TJ ET
BT 26.250 87.120 Td /F1 9.8 Tf  [(recent seasonal influenza, it would probably have been difficult to observe substantially higher vaccination coverage rates for )] TJ ET
BT 26.250 75.215 Td /F1 9.8 Tf  [(this emerging infectious disease among the various key subgroups within the French population. In terms of risk )] TJ ET
BT 26.250 63.310 Td /F1 9.8 Tf  [(communication, these results have one major implication: the failure of the immunization campaign cannot be solely attributed )] TJ ET
BT 26.250 51.405 Td /F1 9.8 Tf  [(to the controversy about the potential side effects of the vaccine, but also to the nature and level of the perceived risk )] TJ ET
Q
q
15.000 37.120 577.500 739.880 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(pressures from their social and institutional environment. Nevertheless, the effects of social conformity remained relatively weak )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(since less than one third of members of this key target group were likely to accept vaccination. Overall, the rate of acceptance of )] TJ ET
BT 26.250 743.667 Td /F1 9.8 Tf  [(pandemic influenza vaccination among health and childcare workers was not substantially different from those observed for )] TJ ET
BT 26.250 731.762 Td /F1 9.8 Tf  [(seasonal influenza in previous years in European countries )] TJ ET
0.267 0.267 0.267 rg
BT 283.660 731.762 Td /F1 9.8 Tf  [([11])] TJ ET
BT 299.923 731.762 Td /F1 9.8 Tf  [([12])] TJ ET
BT 316.186 731.762 Td /F1 9.8 Tf  [([13])] TJ ET
0.271 0.267 0.267 rg
BT 332.449 731.762 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 712.357 Td /F1 9.8 Tf  [(At this stage, it remains necessary to uncover the reasons why certain persons or groups were more likely to accept )] TJ ET
BT 26.250 700.452 Td /F1 9.8 Tf  [(immunization against the 2009 pandemic H1N1 influenza virus than others, even when socio-demographic variables, as well as )] TJ ET
BT 26.250 688.548 Td /F1 9.8 Tf  [(risk factors, were controlled for. In the recent literature, one of the dominant strategies has been to use open-ended questions )] TJ ET
BT 26.250 676.643 Td /F1 9.8 Tf  [(within large-scale surveys. This type of questioning is known to encourage more complete and meaningful answers in surveys )] TJ ET
BT 26.250 664.738 Td /F1 9.8 Tf  [(by permitting subjects to express their motivations and/or sentiments in their own phrasing )] TJ ET
0.267 0.267 0.267 rg
BT 417.488 664.738 Td /F1 9.8 Tf  [([4])] TJ ET
0.271 0.267 0.267 rg
BT 428.330 664.738 Td /F1 9.8 Tf  [(. In the present study, the primary )] TJ ET
BT 26.250 652.833 Td /F1 9.8 Tf  [(reasons associated with acceptance and rejection of vaccination can be broadly divided into 3 groups. The first group )] TJ ET
BT 26.250 640.929 Td /F1 9.8 Tf  [(addresses the mental representation of the threat � in particular the beliefs and judgments related to the severity of the illness )] TJ ET
BT 26.250 629.024 Td /F1 9.8 Tf  [(and risk factors \(i.e., which groups are more vulnerable to the infection\), as well as the emotional response to the risk of )] TJ ET
BT 26.250 617.119 Td /F1 9.8 Tf  [(contracting the disease. The second relates to the perception of the vaccine, including concerns about its safety or )] TJ ET
BT 26.250 605.214 Td /F1 9.8 Tf  [(effectiveness. The third group of motives can be associated with issues of trust toward those advocating the vaccine \(the )] TJ ET
BT 26.250 593.310 Td /F1 9.8 Tf  [(government, the pharmaceutical industry, or biomedical experts\) � including beliefs in conspiracy theories.)] TJ ET
BT 26.250 573.905 Td /F1 9.8 Tf  [(Eventually, the motivations that underlie the acceptability of vaccination could be approached to a large extent from a traditional )] TJ ET
BT 26.250 562.000 Td /F1 9.8 Tf  [(risk/benefit analysis. According to this basic model of decision-making under uncertainty, the acceptance or rejection of any )] TJ ET
BT 26.250 550.095 Td /F1 9.8 Tf  [(protective action should be interpreted as the outcome of a trade-off between the risks and personal or societal benefits )] TJ ET
BT 26.250 538.191 Td /F1 9.8 Tf  [(associated with products or activities that are recognized for their preventive value. From this theoretical perspective, the public )] TJ ET
BT 26.250 526.286 Td /F1 9.8 Tf  [(acceptability of vaccination is expected to vary roughly as a direct function of both perceived risk and perceived benefit. )] TJ ET
BT 26.250 514.381 Td /F1 9.8 Tf  [(Moreover, the perceived benefit associated with immunization depends in turn, for a large part, on the perceived risk of )] TJ ET
BT 26.250 502.476 Td /F1 9.8 Tf  [(contracting the disease � which is generally known to result from two main cognitive components: the personal likelihood of )] TJ ET
BT 26.250 490.572 Td /F1 9.8 Tf  [(becoming infected \(vulnerability\) and the seriousness of the consequences of that infection \(severity\). Although the relevance of )] TJ ET
BT 26.250 478.667 Td /F1 9.8 Tf  [(the risk/benefit approach would deserve a more complex discussion that is beyond the scope of this article, most of the primary )] TJ ET
BT 26.250 466.762 Td /F1 9.8 Tf  [(reasons that were spontaneously invoked by the respondents might indicate that people actually perform a sort of trade-off )] TJ ET
BT 26.250 454.857 Td /F1 9.8 Tf  [(between the perceived risk and the perceived benefit associated with the vaccine uptake.)] TJ ET
BT 26.250 435.453 Td /F1 9.8 Tf  [(For example, among the principal reasons for the non-acceptance of vaccination were \(1\) belief that the vaccine against the )] TJ ET
BT 26.250 423.548 Td /F1 9.8 Tf  [(2009 pandemic H1N1 influenza virus is dangerous or ineffective and \(2\) belief that the pandemic influenza is not a serious )] TJ ET
BT 26.250 411.643 Td /F1 9.8 Tf  [(illness, suggesting that the perceived risk exceeds the perceived benefit associated with pandemic influenza vaccination. Thus, )] TJ ET
BT 26.250 399.738 Td /F1 9.8 Tf  [(almost half of the reluctant respondents \(47.0%\) indicated that they had doubts about either safety or efficacy of the pandemic )] TJ ET
BT 26.250 387.834 Td /F1 9.8 Tf  [(vaccine, and more than one quarter \(27.9%\) felt that the pandemic H1N1 influenza could be considered to be a minor illness. )] TJ ET
BT 26.250 375.929 Td /F1 9.8 Tf  [(Finally the motives captured by open-ended questions provided results that are largely consistent with those of previous )] TJ ET
BT 26.250 364.024 Td /F1 9.8 Tf  [(quantitative and qualitative studies on the determinants of seasonal influenza vaccine acceptance. According to certain reviews )] TJ ET
BT 26.250 352.119 Td /F1 9.8 Tf  [(of literature, the fear of side effects can be easily identified as one of the most commonly reported barriers to vaccination across )] TJ ET
BT 26.250 340.215 Td /F1 9.8 Tf  [(all communicable diseases )] TJ ET
0.267 0.267 0.267 rg
BT 145.454 340.215 Td /F1 9.8 Tf  [([14])] TJ ET
BT 161.716 340.215 Td /F1 9.8 Tf  [([15])] TJ ET
BT 177.980 340.215 Td /F1 9.8 Tf  [([16])] TJ ET
0.271 0.267 0.267 rg
BT 194.243 340.215 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 320.810 Td /F1 9.8 Tf  [(Several limitations can be pointed out in this study. First, even if the sampled population did not significantly differ from the )] TJ ET
BT 26.250 308.905 Td /F1 9.8 Tf  [(general population in terms of age, gender, occupation and place of residence, it cannot be ruled out that the subjects who )] TJ ET
BT 26.250 297.000 Td /F1 9.8 Tf  [(refused to participate in our study were characterized by a range of psychological and/or sociological attributes that made them )] TJ ET
BT 26.250 285.096 Td /F1 9.8 Tf  [(different from the cooperating subjects with regards to vaccination acceptance or non-acceptance. Second, the timing of the )] TJ ET
BT 26.250 273.191 Td /F1 9.8 Tf  [(survey \(early December\) might have led to both an underestimate of the vaccination coverage rate, and an overestimate of )] TJ ET
BT 26.250 261.286 Td /F1 9.8 Tf  [(vaccination intention among the French adult population since the controversy about the safety and/or necessity of the )] TJ ET
BT 26.250 249.381 Td /F1 9.8 Tf  [(pandemic H1N1 influenza vaccination was growing over time. As noted above, the actual vaccination coverage rate was )] TJ ET
BT 26.250 237.477 Td /F1 9.8 Tf  [(assessed at the end of the domestic outbreak by the Ministry of health and found to include approximately 10% of the French. )] TJ ET
BT 26.250 225.572 Td /F1 9.8 Tf  [(Third, the nature of reasons offered by the participants to justify their acceptance or refusal to get vaccinated against the )] TJ ET
BT 26.250 213.667 Td /F1 9.8 Tf  [(pandemic influenza might have been subject to possible biases of social desirability \(or conformity\). This typical bias � which )] TJ ET
BT 26.250 201.762 Td /F1 9.8 Tf  [(describes the subjects� propensity to report a range of reasons for a particular behaviour that are different from their �real� )] TJ ET
BT 26.250 189.858 Td /F1 9.8 Tf  [(motivation because they are viewed as more socially acceptable � has been extensively well-documented in the methodological )] TJ ET
BT 26.250 177.953 Td /F1 9.8 Tf  [(literature )] TJ ET
0.267 0.267 0.267 rg
BT 66.888 177.953 Td /F1 9.8 Tf  [([4])] TJ ET
BT 77.730 177.953 Td /F1 9.8 Tf  [([17])] TJ ET
0.271 0.267 0.267 rg
BT 93.993 177.953 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 158.548 Td /F1 9.8 Tf  [(To conclude, the results of this study tend to show that the 2009 pandemic H1N1 influenza was not perceived by the French )] TJ ET
BT 26.250 146.643 Td /F1 9.8 Tf  [(population to be significantly different from the seasonal influenza. Notably, the distribution and justification of vaccination )] TJ ET
BT 26.250 134.739 Td /F1 9.8 Tf  [(acceptance among the participants were strongly similar to those of seasonal influenza vaccination acceptance )] TJ ET
0.267 0.267 0.267 rg
BT 507.471 134.739 Td /F1 9.8 Tf  [([18])] TJ ET
BT 523.734 134.739 Td /F1 9.8 Tf  [([19])] TJ ET
0.271 0.267 0.267 rg
BT 539.997 134.739 Td /F1 9.8 Tf  [(, and )] TJ ET
BT 26.250 122.834 Td /F1 9.8 Tf  [(consequently contributed to the maintenance of health inequalities in France. In this regard, it should be noted that the )] TJ ET
BT 26.250 110.929 Td /F1 9.8 Tf  [(pandemic H1N1 influenza has been commonly and ironically named �grippette� \(little flu\) in France. Thus, as long as the )] TJ ET
BT 26.250 99.024 Td /F1 9.8 Tf  [(patterns of mortality and/or morbidity associated with the pandemic influenza did not differ crucially from those related to the )] TJ ET
BT 26.250 87.120 Td /F1 9.8 Tf  [(recent seasonal influenza, it would probably have been difficult to observe substantially higher vaccination coverage rates for )] TJ ET
BT 26.250 75.215 Td /F1 9.8 Tf  [(this emerging infectious disease among the various key subgroups within the French population. In terms of risk )] TJ ET
BT 26.250 63.310 Td /F1 9.8 Tf  [(communication, these results have one major implication: the failure of the immunization campaign cannot be solely attributed )] TJ ET
BT 26.250 51.405 Td /F1 9.8 Tf  [(to the controversy about the potential side effects of the vaccine, but also to the nature and level of the perceived risk )] TJ ET
Q
q
15.000 37.120 577.500 739.880 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(pressures from their social and institutional environment. Nevertheless, the effects of social conformity remained relatively weak )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(since less than one third of members of this key target group were likely to accept vaccination. Overall, the rate of acceptance of )] TJ ET
BT 26.250 743.667 Td /F1 9.8 Tf  [(pandemic influenza vaccination among health and childcare workers was not substantially different from those observed for )] TJ ET
BT 26.250 731.762 Td /F1 9.8 Tf  [(seasonal influenza in previous years in European countries )] TJ ET
0.267 0.267 0.267 rg
BT 283.660 731.762 Td /F1 9.8 Tf  [([11])] TJ ET
BT 299.923 731.762 Td /F1 9.8 Tf  [([12])] TJ ET
BT 316.186 731.762 Td /F1 9.8 Tf  [([13])] TJ ET
0.271 0.267 0.267 rg
BT 332.449 731.762 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 712.357 Td /F1 9.8 Tf  [(At this stage, it remains necessary to uncover the reasons why certain persons or groups were more likely to accept )] TJ ET
BT 26.250 700.452 Td /F1 9.8 Tf  [(immunization against the 2009 pandemic H1N1 influenza virus than others, even when socio-demographic variables, as well as )] TJ ET
BT 26.250 688.548 Td /F1 9.8 Tf  [(risk factors, were controlled for. In the recent literature, one of the dominant strategies has been to use open-ended questions )] TJ ET
BT 26.250 676.643 Td /F1 9.8 Tf  [(within large-scale surveys. This type of questioning is known to encourage more complete and meaningful answers in surveys )] TJ ET
BT 26.250 664.738 Td /F1 9.8 Tf  [(by permitting subjects to express their motivations and/or sentiments in their own phrasing )] TJ ET
0.267 0.267 0.267 rg
BT 417.488 664.738 Td /F1 9.8 Tf  [([4])] TJ ET
0.271 0.267 0.267 rg
BT 428.330 664.738 Td /F1 9.8 Tf  [(. In the present study, the primary )] TJ ET
BT 26.250 652.833 Td /F1 9.8 Tf  [(reasons associated with acceptance and rejection of vaccination can be broadly divided into 3 groups. The first group )] TJ ET
BT 26.250 640.929 Td /F1 9.8 Tf  [(addresses the mental representation of the threat � in particular the beliefs and judgments related to the severity of the illness )] TJ ET
BT 26.250 629.024 Td /F1 9.8 Tf  [(and risk factors \(i.e., which groups are more vulnerable to the infection\), as well as the emotional response to the risk of )] TJ ET
BT 26.250 617.119 Td /F1 9.8 Tf  [(contracting the disease. The second relates to the perception of the vaccine, including concerns about its safety or )] TJ ET
BT 26.250 605.214 Td /F1 9.8 Tf  [(effectiveness. The third group of motives can be associated with issues of trust toward those advocating the vaccine \(the )] TJ ET
BT 26.250 593.310 Td /F1 9.8 Tf  [(government, the pharmaceutical industry, or biomedical experts\) � including beliefs in conspiracy theories.)] TJ ET
BT 26.250 573.905 Td /F1 9.8 Tf  [(Eventually, the motivations that underlie the acceptability of vaccination could be approached to a large extent from a traditional )] TJ ET
BT 26.250 562.000 Td /F1 9.8 Tf  [(risk/benefit analysis. According to this basic model of decision-making under uncertainty, the acceptance or rejection of any )] TJ ET
BT 26.250 550.095 Td /F1 9.8 Tf  [(protective action should be interpreted as the outcome of a trade-off between the risks and personal or societal benefits )] TJ ET
BT 26.250 538.191 Td /F1 9.8 Tf  [(associated with products or activities that are recognized for their preventive value. From this theoretical perspective, the public )] TJ ET
BT 26.250 526.286 Td /F1 9.8 Tf  [(acceptability of vaccination is expected to vary roughly as a direct function of both perceived risk and perceived benefit. )] TJ ET
BT 26.250 514.381 Td /F1 9.8 Tf  [(Moreover, the perceived benefit associated with immunization depends in turn, for a large part, on the perceived risk of )] TJ ET
BT 26.250 502.476 Td /F1 9.8 Tf  [(contracting the disease � which is generally known to result from two main cognitive components: the personal likelihood of )] TJ ET
BT 26.250 490.572 Td /F1 9.8 Tf  [(becoming infected \(vulnerability\) and the seriousness of the consequences of that infection \(severity\). Although the relevance of )] TJ ET
BT 26.250 478.667 Td /F1 9.8 Tf  [(the risk/benefit approach would deserve a more complex discussion that is beyond the scope of this article, most of the primary )] TJ ET
BT 26.250 466.762 Td /F1 9.8 Tf  [(reasons that were spontaneously invoked by the respondents might indicate that people actually perform a sort of trade-off )] TJ ET
BT 26.250 454.857 Td /F1 9.8 Tf  [(between the perceived risk and the perceived benefit associated with the vaccine uptake.)] TJ ET
BT 26.250 435.453 Td /F1 9.8 Tf  [(For example, among the principal reasons for the non-acceptance of vaccination were \(1\) belief that the vaccine against the )] TJ ET
BT 26.250 423.548 Td /F1 9.8 Tf  [(2009 pandemic H1N1 influenza virus is dangerous or ineffective and \(2\) belief that the pandemic influenza is not a serious )] TJ ET
BT 26.250 411.643 Td /F1 9.8 Tf  [(illness, suggesting that the perceived risk exceeds the perceived benefit associated with pandemic influenza vaccination. Thus, )] TJ ET
BT 26.250 399.738 Td /F1 9.8 Tf  [(almost half of the reluctant respondents \(47.0%\) indicated that they had doubts about either safety or efficacy of the pandemic )] TJ ET
BT 26.250 387.834 Td /F1 9.8 Tf  [(vaccine, and more than one quarter \(27.9%\) felt that the pandemic H1N1 influenza could be considered to be a minor illness. )] TJ ET
BT 26.250 375.929 Td /F1 9.8 Tf  [(Finally the motives captured by open-ended questions provided results that are largely consistent with those of previous )] TJ ET
BT 26.250 364.024 Td /F1 9.8 Tf  [(quantitative and qualitative studies on the determinants of seasonal influenza vaccine acceptance. According to certain reviews )] TJ ET
BT 26.250 352.119 Td /F1 9.8 Tf  [(of literature, the fear of side effects can be easily identified as one of the most commonly reported barriers to vaccination across )] TJ ET
BT 26.250 340.215 Td /F1 9.8 Tf  [(all communicable diseases )] TJ ET
0.267 0.267 0.267 rg
BT 145.454 340.215 Td /F1 9.8 Tf  [([14])] TJ ET
BT 161.716 340.215 Td /F1 9.8 Tf  [([15])] TJ ET
BT 177.980 340.215 Td /F1 9.8 Tf  [([16])] TJ ET
0.271 0.267 0.267 rg
BT 194.243 340.215 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 320.810 Td /F1 9.8 Tf  [(Several limitations can be pointed out in this study. First, even if the sampled population did not significantly differ from the )] TJ ET
BT 26.250 308.905 Td /F1 9.8 Tf  [(general population in terms of age, gender, occupation and place of residence, it cannot be ruled out that the subjects who )] TJ ET
BT 26.250 297.000 Td /F1 9.8 Tf  [(refused to participate in our study were characterized by a range of psychological and/or sociological attributes that made them )] TJ ET
BT 26.250 285.096 Td /F1 9.8 Tf  [(different from the cooperating subjects with regards to vaccination acceptance or non-acceptance. Second, the timing of the )] TJ ET
BT 26.250 273.191 Td /F1 9.8 Tf  [(survey \(early December\) might have led to both an underestimate of the vaccination coverage rate, and an overestimate of )] TJ ET
BT 26.250 261.286 Td /F1 9.8 Tf  [(vaccination intention among the French adult population since the controversy about the safety and/or necessity of the )] TJ ET
BT 26.250 249.381 Td /F1 9.8 Tf  [(pandemic H1N1 influenza vaccination was growing over time. As noted above, the actual vaccination coverage rate was )] TJ ET
BT 26.250 237.477 Td /F1 9.8 Tf  [(assessed at the end of the domestic outbreak by the Ministry of health and found to include approximately 10% of the French. )] TJ ET
BT 26.250 225.572 Td /F1 9.8 Tf  [(Third, the nature of reasons offered by the participants to justify their acceptance or refusal to get vaccinated against the )] TJ ET
BT 26.250 213.667 Td /F1 9.8 Tf  [(pandemic influenza might have been subject to possible biases of social desirability \(or conformity\). This typical bias � which )] TJ ET
BT 26.250 201.762 Td /F1 9.8 Tf  [(describes the subjects� propensity to report a range of reasons for a particular behaviour that are different from their �real� )] TJ ET
BT 26.250 189.858 Td /F1 9.8 Tf  [(motivation because they are viewed as more socially acceptable � has been extensively well-documented in the methodological )] TJ ET
BT 26.250 177.953 Td /F1 9.8 Tf  [(literature )] TJ ET
0.267 0.267 0.267 rg
BT 66.888 177.953 Td /F1 9.8 Tf  [([4])] TJ ET
BT 77.730 177.953 Td /F1 9.8 Tf  [([17])] TJ ET
0.271 0.267 0.267 rg
BT 93.993 177.953 Td /F1 9.8 Tf  [(.)] TJ ET
BT 26.250 158.548 Td /F1 9.8 Tf  [(To conclude, the results of this study tend to show that the 2009 pandemic H1N1 influenza was not perceived by the French )] TJ ET
BT 26.250 146.643 Td /F1 9.8 Tf  [(population to be significantly different from the seasonal influenza. Notably, the distribution and justification of vaccination )] TJ ET
BT 26.250 134.739 Td /F1 9.8 Tf  [(acceptance among the participants were strongly similar to those of seasonal influenza vaccination acceptance )] TJ ET
0.267 0.267 0.267 rg
BT 507.471 134.739 Td /F1 9.8 Tf  [([18])] TJ ET
BT 523.734 134.739 Td /F1 9.8 Tf  [([19])] TJ ET
0.271 0.267 0.267 rg
BT 539.997 134.739 Td /F1 9.8 Tf  [(, and )] TJ ET
BT 26.250 122.834 Td /F1 9.8 Tf  [(consequently contributed to the maintenance of health inequalities in France. In this regard, it should be noted that the )] TJ ET
BT 26.250 110.929 Td /F1 9.8 Tf  [(pandemic H1N1 influenza has been commonly and ironically named �grippette� \(little flu\) in France. Thus, as long as the )] TJ ET
BT 26.250 99.024 Td /F1 9.8 Tf  [(patterns of mortality and/or morbidity associated with the pandemic influenza did not differ crucially from those related to the )] TJ ET
BT 26.250 87.120 Td /F1 9.8 Tf  [(recent seasonal influenza, it would probably have been difficult to observe substantially higher vaccination coverage rates for )] TJ ET
BT 26.250 75.215 Td /F1 9.8 Tf  [(this emerging infectious disease among the various key subgroups within the French population. In terms of risk )] TJ ET
BT 26.250 63.310 Td /F1 9.8 Tf  [(communication, these results have one major implication: the failure of the immunization campaign cannot be solely attributed )] TJ ET
BT 26.250 51.405 Td /F1 9.8 Tf  [(to the controversy about the potential side effects of the vaccine, but also to the nature and level of the perceived risk )] TJ ET
Q
q
0.000 0.000 0.000 rg
BT 291.710 19.825 Td /F1 11.0 Tf  [(5)] TJ ET
BT 25.000 19.825 Td /F1 11.0 Tf  [(PLOS Currents Influenza)] TJ ET

Q
endstream
endobj
126 0 obj
<< /Type /Annot
/Subtype /Link
/A 127 0 R
/Border [0 0 0]
/H /I
/Rect [ 283.6597 730.8601 299.9227 740.7807 ]
>>
endobj
127 0 obj
<< /Type /Action
>>
endobj
128 0 obj
<< /Type /Annot
/Subtype /Link
/A 129 0 R
/Border [0 0 0]
/H /I
/Rect [ 299.9227 730.8601 316.1857 740.7807 ]
>>
endobj
129 0 obj
<< /Type /Action
>>
endobj
130 0 obj
<< /Type /Annot
/Subtype /Link
/A 131 0 R
/Border [0 0 0]
/H /I
/Rect [ 316.1857 730.8601 332.4487 740.7807 ]
>>
endobj
131 0 obj
<< /Type /Action
>>
endobj
132 0 obj
<< /Type /Annot
/Subtype /Link
/A 133 0 R
/Border [0 0 0]
/H /I
/Rect [ 417.4882 663.8363 428.3302 673.7569 ]
>>
endobj
133 0 obj
<< /Type /Action
>>
endobj
134 0 obj
<< /Type /Annot
/Subtype /Link
/A 135 0 R
/Border [0 0 0]
/H /I
/Rect [ 145.4535 339.3128 161.7165 349.2335 ]
>>
endobj
135 0 obj
<< /Type /Action
>>
endobj
136 0 obj
<< /Type /Annot
/Subtype /Link
/A 137 0 R
/Border [0 0 0]
/H /I
/Rect [ 161.7165 339.3128 177.9795 349.2335 ]
>>
endobj
137 0 obj
<< /Type /Action
>>
endobj
138 0 obj
<< /Type /Annot
/Subtype /Link
/A 139 0 R
/Border [0 0 0]
/H /I
/Rect [ 177.9795 339.3128 194.2425 349.2335 ]
>>
endobj
139 0 obj
<< /Type /Action
>>
endobj
140 0 obj
<< /Type /Annot
/Subtype /Link
/A 141 0 R
/Border [0 0 0]
/H /I
/Rect [ 66.8880 177.0511 77.7300 186.9717 ]
>>
endobj
141 0 obj
<< /Type /Action
>>
endobj
142 0 obj
<< /Type /Annot
/Subtype /Link
/A 143 0 R
/Border [0 0 0]
/H /I
/Rect [ 77.7300 177.0511 93.9930 186.9717 ]
>>
endobj
143 0 obj
<< /Type /Action
>>
endobj
144 0 obj
<< /Type /Annot
/Subtype /Link
/A 145 0 R
/Border [0 0 0]
/H /I
/Rect [ 507.4710 133.8368 523.7340 143.7575 ]
>>
endobj
145 0 obj
<< /Type /Action
>>
endobj
146 0 obj
<< /Type /Annot
/Subtype /Link
/A 147 0 R
/Border [0 0 0]
/H /I
/Rect [ 523.7340 133.8368 539.9970 143.7575 ]
>>
endobj
147 0 obj
<< /Type /Action
>>
endobj
148 0 obj
<< /Type /Annot
/Subtype /Link
/A 149 0 R
/Border [0 0 0]
/H /I
/Rect [ 283.6597 730.8601 299.9227 740.7807 ]
>>
endobj
149 0 obj
<< /Type /Action
>>
endobj
150 0 obj
<< /Type /Annot
/Subtype /Link
/A 151 0 R
/Border [0 0 0]
/H /I
/Rect [ 299.9227 730.8601 316.1857 740.7807 ]
>>
endobj
151 0 obj
<< /Type /Action
>>
endobj
152 0 obj
<< /Type /Annot
/Subtype /Link
/A 153 0 R
/Border [0 0 0]
/H /I
/Rect [ 316.1857 730.8601 332.4487 740.7807 ]
>>
endobj
153 0 obj
<< /Type /Action
>>
endobj
154 0 obj
<< /Type /Annot
/Subtype /Link
/A 155 0 R
/Border [0 0 0]
/H /I
/Rect [ 417.4882 663.8363 428.3302 673.7569 ]
>>
endobj
155 0 obj
<< /Type /Action
>>
endobj
156 0 obj
<< /Type /Annot
/Subtype /Link
/A 157 0 R
/Border [0 0 0]
/H /I
/Rect [ 145.4535 339.3128 161.7165 349.2335 ]
>>
endobj
157 0 obj
<< /Type /Action
>>
endobj
158 0 obj
<< /Type /Annot
/Subtype /Link
/A 159 0 R
/Border [0 0 0]
/H /I
/Rect [ 161.7165 339.3128 177.9795 349.2335 ]
>>
endobj
159 0 obj
<< /Type /Action
>>
endobj
160 0 obj
<< /Type /Annot
/Subtype /Link
/A 161 0 R
/Border [0 0 0]
/H /I
/Rect [ 177.9795 339.3128 194.2425 349.2335 ]
>>
endobj
161 0 obj
<< /Type /Action
>>
endobj
162 0 obj
<< /Type /Annot
/Subtype /Link
/A 163 0 R
/Border [0 0 0]
/H /I
/Rect [ 66.8880 177.0511 77.7300 186.9717 ]
>>
endobj
163 0 obj
<< /Type /Action
>>
endobj
164 0 obj
<< /Type /Annot
/Subtype /Link
/A 165 0 R
/Border [0 0 0]
/H /I
/Rect [ 77.7300 177.0511 93.9930 186.9717 ]
>>
endobj
165 0 obj
<< /Type /Action
>>
endobj
166 0 obj
<< /Type /Annot
/Subtype /Link
/A 167 0 R
/Border [0 0 0]
/H /I
/Rect [ 507.4710 133.8368 523.7340 143.7575 ]
>>
endobj
167 0 obj
<< /Type /Action
>>
endobj
168 0 obj
<< /Type /Annot
/Subtype /Link
/A 169 0 R
/Border [0 0 0]
/H /I
/Rect [ 523.7340 133.8368 539.9970 143.7575 ]
>>
endobj
169 0 obj
<< /Type /Action
>>
endobj
170 0 obj
<< /Type /Annot
/Subtype /Link
/A 171 0 R
/Border [0 0 0]
/H /I
/Rect [ 283.6597 730.8601 299.9227 740.7807 ]
>>
endobj
171 0 obj
<< /Type /Action
>>
endobj
172 0 obj
<< /Type /Annot
/Subtype /Link
/A 173 0 R
/Border [0 0 0]
/H /I
/Rect [ 299.9227 730.8601 316.1857 740.7807 ]
>>
endobj
173 0 obj
<< /Type /Action
>>
endobj
174 0 obj
<< /Type /Annot
/Subtype /Link
/A 175 0 R
/Border [0 0 0]
/H /I
/Rect [ 316.1857 730.8601 332.4487 740.7807 ]
>>
endobj
175 0 obj
<< /Type /Action
>>
endobj
176 0 obj
<< /Type /Annot
/Subtype /Link
/A 177 0 R
/Border [0 0 0]
/H /I
/Rect [ 417.4882 663.8363 428.3302 673.7569 ]
>>
endobj
177 0 obj
<< /Type /Action
>>
endobj
178 0 obj
<< /Type /Annot
/Subtype /Link
/A 179 0 R
/Border [0 0 0]
/H /I
/Rect [ 145.4535 339.3128 161.7165 349.2335 ]
>>
endobj
179 0 obj
<< /Type /Action
>>
endobj
180 0 obj
<< /Type /Annot
/Subtype /Link
/A 181 0 R
/Border [0 0 0]
/H /I
/Rect [ 161.7165 339.3128 177.9795 349.2335 ]
>>
endobj
181 0 obj
<< /Type /Action
>>
endobj
182 0 obj
<< /Type /Annot
/Subtype /Link
/A 183 0 R
/Border [0 0 0]
/H /I
/Rect [ 177.9795 339.3128 194.2425 349.2335 ]
>>
endobj
183 0 obj
<< /Type /Action
>>
endobj
184 0 obj
<< /Type /Annot
/Subtype /Link
/A 185 0 R
/Border [0 0 0]
/H /I
/Rect [ 66.8880 177.0511 77.7300 186.9717 ]
>>
endobj
185 0 obj
<< /Type /Action
>>
endobj
186 0 obj
<< /Type /Annot
/Subtype /Link
/A 187 0 R
/Border [0 0 0]
/H /I
/Rect [ 77.7300 177.0511 93.9930 186.9717 ]
>>
endobj
187 0 obj
<< /Type /Action
>>
endobj
188 0 obj
<< /Type /Annot
/Subtype /Link
/A 189 0 R
/Border [0 0 0]
/H /I
/Rect [ 507.4710 133.8368 523.7340 143.7575 ]
>>
endobj
189 0 obj
<< /Type /Action
>>
endobj
190 0 obj
<< /Type /Annot
/Subtype /Link
/A 191 0 R
/Border [0 0 0]
/H /I
/Rect [ 523.7340 133.8368 539.9970 143.7575 ]
>>
endobj
191 0 obj
<< /Type /Action
>>
endobj
192 0 obj
<< /Type /Page
/Parent 3 0 R
/Contents 193 0 R
>>
endobj
193 0 obj
<<
/Length 19636 >>
stream

0.271 0.267 0.267 rg
q
15.000 73.411 577.500 703.589 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(associated with the pandemic H1N1 influenza. From this point of view, a public health information campaign that primarily )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(focuses on convincing people of the safety of the vaccine would likely be less fruitful than expected.)] TJ ET
BT 26.250 726.469 Td /F4 12.0 Tf  [(Competing interests)] TJ ET
BT 26.250 706.515 Td /F1 9.8 Tf  [(The authors have declared that no competing interests exist.)] TJ ET
BT 26.250 669.912 Td /F4 12.0 Tf  [(References)] TJ ET
BT 26.250 642.458 Td /F1 9.8 Tf  [(1.)] TJ ET
BT 38.132 642.458 Td /F1 9.8 Tf  [(Center for Disease Control. Preliminary results surveillance for Guillain-Barr� syndrome after receipt of influenza A \(H1N1\) )] TJ ET
BT 26.250 630.553 Td /F1 9.8 Tf  [(2009 monovalent vaccine - United States, 2009-2010. Morbidity and Mortality Weekly Report. 2010; 59\(21\):657-61.)] TJ ET
BT 26.250 611.148 Td /F1 9.8 Tf  [(2.)] TJ ET
BT 38.132 611.148 Td /F1 9.8 Tf  [(R�publique Fran�aise. Grippe A\(H1N1\) : l'�pid�mie recule mais un second pic pand�mique reste possible. January 15, 2010. )] TJ ET
BT 26.250 599.244 Td /F1 9.8 Tf  [(\(Accessed June 10, 2010, at http://www.gouvernement.fr/gouvernement/grippe-ah1n1-l-epidemie-recule-mais-un-second-pic-)] TJ ET
BT 26.250 587.339 Td /F1 9.8 Tf  [(pandemique-reste-possible\).)] TJ ET
BT 26.250 567.934 Td /F1 9.8 Tf  [(3.)] TJ ET
BT 38.132 567.934 Td /F1 9.8 Tf  [(PoteVellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in )] TJ ET
BT 26.250 556.029 Td /F1 9.8 Tf  [(adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27:2114-20.)] TJ ET
BT 26.250 536.625 Td /F1 9.8 Tf  [(4.)] TJ ET
BT 38.132 536.625 Td /F1 9.8 Tf  [(Aday, L.A. Designing And Conducting Health Surveys: A Comprehensive Guide. San Fransisco: Jossey-Bass, 2006.)] TJ ET
BT 26.250 517.220 Td /F1 9.8 Tf  [(5.)] TJ ET
BT 38.132 517.220 Td /F1 9.8 Tf  [(Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999-2000. )] TJ ET
BT 26.250 505.315 Td /F1 9.8 Tf  [(Emerg Infect Dis. 2002;8\(12\):1442-47.)] TJ ET
BT 26.250 485.910 Td /F1 9.8 Tf  [(6.)] TJ ET
BT 38.132 485.910 Td /F1 9.8 Tf  [(Chapman GB, Coups EJ. Predictors of influenza vaccine acceptance among healthy adults. Prev Med \(1999\) 29:249-62.)] TJ ET
BT 26.250 466.506 Td /F1 9.8 Tf  [(7.)] TJ ET
BT 38.132 466.506 Td /F1 9.8 Tf  [(Jones TF, Ingram LA, Craig AS, Schaffner W. Determinants of influenza vaccination, 2003-2004: shortages, fallacies and )] TJ ET
BT 26.250 454.601 Td /F1 9.8 Tf  [(disparities. Clin Infect Dis. 2004;39\(12\):1824-28.)] TJ ET
BT 26.250 435.196 Td /F1 9.8 Tf  [(8.)] TJ ET
BT 38.132 435.196 Td /F1 9.8 Tf  [(Endrich MM, Blank PR, Szucs TD. Influenza vaccination uptake and socioeconomic determinants in 11 European countries. )] TJ ET
BT 26.250 423.291 Td /F1 9.8 Tf  [(Vaccine 2009;27\(30\):4018-24.)] TJ ET
BT 26.250 403.887 Td /F1 9.8 Tf  [(9.)] TJ ET
BT 38.132 403.887 Td /F1 9.8 Tf  [(Setbon, M, Raude, J. Factors in vaccination intention against the pandemic influenza A/H1N1. European Journal of Public )] TJ ET
BT 26.250 391.982 Td /F1 9.8 Tf  [(Health \(Access published online on May 5, 2010\).)] TJ ET
BT 26.250 372.577 Td /F1 9.8 Tf  [(10.)] TJ ET
BT 43.553 372.577 Td /F1 9.8 Tf  [(Maurer J, Harris KM, Parker A, Lurie N. Does receipt of seasonal influenza vaccine predict intention to receive novel H1N1 )] TJ ET
BT 26.250 360.672 Td /F1 9.8 Tf  [(vaccine: evidence from a nationally representative survey of U.S. adults. Vaccine \(2009\) 27:5732-4.)] TJ ET
BT 26.250 341.268 Td /F1 9.8 Tf  [(11.)] TJ ET
BT 43.553 341.268 Td /F1 9.8 Tf  [(Maltezou HC, Maragos A, Katerelos P, Paisi A, Karageorgou K,Papadimitriou T, et al. Influenza vaccination acceptance )] TJ ET
BT 26.250 329.363 Td /F1 9.8 Tf  [(among health-care workers: a nationwide survey. Vaccine. 2008;26\(11\):1408-10.)] TJ ET
BT 26.250 309.958 Td /F1 9.8 Tf  [(12.)] TJ ET
BT 43.553 309.958 Td /F1 9.8 Tf  [(Leitmeyer K, Buchholz U, Kramer M. Influenza vaccination in German health care workers: effects and findings after two )] TJ ET
BT 26.250 298.053 Td /F1 9.8 Tf  [(rounds of a nationwide awareness campaign. Vaccine 2006;24\(47-48\):7003-8.)] TJ ET
BT 26.250 278.649 Td /F1 9.8 Tf  [(13.)] TJ ET
BT 43.553 278.649 Td /F1 9.8 Tf  [(Rothan-Tondeur M, deWazieres B, Lejeune B, Gavazzi G. Influenza vaccine coverage for healthcare workers in geriatric )] TJ ET
BT 26.250 266.744 Td /F1 9.8 Tf  [(settings in France. Aging Clin Exp Res, 2006;18\(6\):512-6.)] TJ ET
BT 26.250 247.339 Td /F1 9.8 Tf  [(14.)] TJ ET
BT 43.553 247.339 Td /F1 9.8 Tf  [(Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care workers in hospitals: a review of )] TJ ET
BT 26.250 235.434 Td /F1 9.8 Tf  [(studies on attitudes and predictors. Vaccine 2009;27\(30\): 3935-44.)] TJ ET
BT 26.250 216.030 Td /F1 9.8 Tf  [(15.)] TJ ET
BT 43.553 216.030 Td /F1 9.8 Tf  [(Mills E, Jadad AR, Ross C, Wilson K. Systematic review of qualitative studies exploring parental beliefs and attitudes toward )] TJ ET
BT 26.250 204.125 Td /F1 9.8 Tf  [(childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol. 2005;58\(11\):1081-88.)] TJ ET
BT 26.250 184.720 Td /F1 9.8 Tf  [(16.)] TJ ET
BT 43.553 184.720 Td /F1 9.8 Tf  [(Streefland P, Chowdhuryb AMR, Ramos-Jimenezc P. Patterns of vaccination acceptance. Social Science & Medicine. )] TJ ET
BT 26.250 172.815 Td /F1 9.8 Tf  [(1999;49\(12\):1705-1716.)] TJ ET
BT 26.250 153.411 Td /F1 9.8 Tf  [(17.)] TJ ET
BT 43.553 153.411 Td /F1 9.8 Tf  [(Tourangeau R, Yan T. Sensitive questions in surveys. Psychological Bulletin. 2007; 133\(5\): 859-883.)] TJ ET
BT 26.250 134.006 Td /F1 9.8 Tf  [(18.)] TJ ET
BT 43.553 134.006 Td /F1 9.8 Tf  [(M�ller D, Szucs TD. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional )] TJ ET
BT 26.250 122.101 Td /F1 9.8 Tf  [(analysis of the seasons 02/03, 03/04 and 04/05. Infection. 2007;35\(5\):308-19.)] TJ ET
BT 26.250 102.696 Td /F1 9.8 Tf  [(19.)] TJ ET
BT 43.553 102.696 Td /F1 9.8 Tf  [(Groupe d�Expertise et d�Information sur la Grippe \(GEIG\). Le taux de couverture vaccinale en France. \(Accessed June 10, )] TJ ET
BT 26.250 90.792 Td /F1 9.8 Tf  [(2010, at http://grippe-geig.com/fr/vaccination/couverture_vaccin.php.\).)] TJ ET
Q
q
15.000 73.411 577.500 703.589 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(associated with the pandemic H1N1 influenza. From this point of view, a public health information campaign that primarily )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(focuses on convincing people of the safety of the vaccine would likely be less fruitful than expected.)] TJ ET
BT 26.250 726.469 Td /F4 12.0 Tf  [(Competing interests)] TJ ET
BT 26.250 706.515 Td /F1 9.8 Tf  [(The authors have declared that no competing interests exist.)] TJ ET
BT 26.250 669.912 Td /F4 12.0 Tf  [(References)] TJ ET
BT 26.250 642.458 Td /F1 9.8 Tf  [(1.)] TJ ET
BT 38.132 642.458 Td /F1 9.8 Tf  [(Center for Disease Control. Preliminary results surveillance for Guillain-Barr� syndrome after receipt of influenza A \(H1N1\) )] TJ ET
BT 26.250 630.553 Td /F1 9.8 Tf  [(2009 monovalent vaccine - United States, 2009-2010. Morbidity and Mortality Weekly Report. 2010; 59\(21\):657-61.)] TJ ET
BT 26.250 611.148 Td /F1 9.8 Tf  [(2.)] TJ ET
BT 38.132 611.148 Td /F1 9.8 Tf  [(R�publique Fran�aise. Grippe A\(H1N1\) : l'�pid�mie recule mais un second pic pand�mique reste possible. January 15, 2010. )] TJ ET
BT 26.250 599.244 Td /F1 9.8 Tf  [(\(Accessed June 10, 2010, at http://www.gouvernement.fr/gouvernement/grippe-ah1n1-l-epidemie-recule-mais-un-second-pic-)] TJ ET
BT 26.250 587.339 Td /F1 9.8 Tf  [(pandemique-reste-possible\).)] TJ ET
BT 26.250 567.934 Td /F1 9.8 Tf  [(3.)] TJ ET
BT 38.132 567.934 Td /F1 9.8 Tf  [(PoteVellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in )] TJ ET
BT 26.250 556.029 Td /F1 9.8 Tf  [(adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27:2114-20.)] TJ ET
BT 26.250 536.625 Td /F1 9.8 Tf  [(4.)] TJ ET
BT 38.132 536.625 Td /F1 9.8 Tf  [(Aday, L.A. Designing And Conducting Health Surveys: A Comprehensive Guide. San Fransisco: Jossey-Bass, 2006.)] TJ ET
BT 26.250 517.220 Td /F1 9.8 Tf  [(5.)] TJ ET
BT 38.132 517.220 Td /F1 9.8 Tf  [(Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999-2000. )] TJ ET
BT 26.250 505.315 Td /F1 9.8 Tf  [(Emerg Infect Dis. 2002;8\(12\):1442-47.)] TJ ET
BT 26.250 485.910 Td /F1 9.8 Tf  [(6.)] TJ ET
BT 38.132 485.910 Td /F1 9.8 Tf  [(Chapman GB, Coups EJ. Predictors of influenza vaccine acceptance among healthy adults. Prev Med \(1999\) 29:249-62.)] TJ ET
BT 26.250 466.506 Td /F1 9.8 Tf  [(7.)] TJ ET
BT 38.132 466.506 Td /F1 9.8 Tf  [(Jones TF, Ingram LA, Craig AS, Schaffner W. Determinants of influenza vaccination, 2003-2004: shortages, fallacies and )] TJ ET
BT 26.250 454.601 Td /F1 9.8 Tf  [(disparities. Clin Infect Dis. 2004;39\(12\):1824-28.)] TJ ET
BT 26.250 435.196 Td /F1 9.8 Tf  [(8.)] TJ ET
BT 38.132 435.196 Td /F1 9.8 Tf  [(Endrich MM, Blank PR, Szucs TD. Influenza vaccination uptake and socioeconomic determinants in 11 European countries. )] TJ ET
BT 26.250 423.291 Td /F1 9.8 Tf  [(Vaccine 2009;27\(30\):4018-24.)] TJ ET
BT 26.250 403.887 Td /F1 9.8 Tf  [(9.)] TJ ET
BT 38.132 403.887 Td /F1 9.8 Tf  [(Setbon, M, Raude, J. Factors in vaccination intention against the pandemic influenza A/H1N1. European Journal of Public )] TJ ET
BT 26.250 391.982 Td /F1 9.8 Tf  [(Health \(Access published online on May 5, 2010\).)] TJ ET
BT 26.250 372.577 Td /F1 9.8 Tf  [(10.)] TJ ET
BT 43.553 372.577 Td /F1 9.8 Tf  [(Maurer J, Harris KM, Parker A, Lurie N. Does receipt of seasonal influenza vaccine predict intention to receive novel H1N1 )] TJ ET
BT 26.250 360.672 Td /F1 9.8 Tf  [(vaccine: evidence from a nationally representative survey of U.S. adults. Vaccine \(2009\) 27:5732-4.)] TJ ET
BT 26.250 341.268 Td /F1 9.8 Tf  [(11.)] TJ ET
BT 43.553 341.268 Td /F1 9.8 Tf  [(Maltezou HC, Maragos A, Katerelos P, Paisi A, Karageorgou K,Papadimitriou T, et al. Influenza vaccination acceptance )] TJ ET
BT 26.250 329.363 Td /F1 9.8 Tf  [(among health-care workers: a nationwide survey. Vaccine. 2008;26\(11\):1408-10.)] TJ ET
BT 26.250 309.958 Td /F1 9.8 Tf  [(12.)] TJ ET
BT 43.553 309.958 Td /F1 9.8 Tf  [(Leitmeyer K, Buchholz U, Kramer M. Influenza vaccination in German health care workers: effects and findings after two )] TJ ET
BT 26.250 298.053 Td /F1 9.8 Tf  [(rounds of a nationwide awareness campaign. Vaccine 2006;24\(47-48\):7003-8.)] TJ ET
BT 26.250 278.649 Td /F1 9.8 Tf  [(13.)] TJ ET
BT 43.553 278.649 Td /F1 9.8 Tf  [(Rothan-Tondeur M, deWazieres B, Lejeune B, Gavazzi G. Influenza vaccine coverage for healthcare workers in geriatric )] TJ ET
BT 26.250 266.744 Td /F1 9.8 Tf  [(settings in France. Aging Clin Exp Res, 2006;18\(6\):512-6.)] TJ ET
BT 26.250 247.339 Td /F1 9.8 Tf  [(14.)] TJ ET
BT 43.553 247.339 Td /F1 9.8 Tf  [(Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care workers in hospitals: a review of )] TJ ET
BT 26.250 235.434 Td /F1 9.8 Tf  [(studies on attitudes and predictors. Vaccine 2009;27\(30\): 3935-44.)] TJ ET
BT 26.250 216.030 Td /F1 9.8 Tf  [(15.)] TJ ET
BT 43.553 216.030 Td /F1 9.8 Tf  [(Mills E, Jadad AR, Ross C, Wilson K. Systematic review of qualitative studies exploring parental beliefs and attitudes toward )] TJ ET
BT 26.250 204.125 Td /F1 9.8 Tf  [(childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol. 2005;58\(11\):1081-88.)] TJ ET
BT 26.250 184.720 Td /F1 9.8 Tf  [(16.)] TJ ET
BT 43.553 184.720 Td /F1 9.8 Tf  [(Streefland P, Chowdhuryb AMR, Ramos-Jimenezc P. Patterns of vaccination acceptance. Social Science & Medicine. )] TJ ET
BT 26.250 172.815 Td /F1 9.8 Tf  [(1999;49\(12\):1705-1716.)] TJ ET
BT 26.250 153.411 Td /F1 9.8 Tf  [(17.)] TJ ET
BT 43.553 153.411 Td /F1 9.8 Tf  [(Tourangeau R, Yan T. Sensitive questions in surveys. Psychological Bulletin. 2007; 133\(5\): 859-883.)] TJ ET
BT 26.250 134.006 Td /F1 9.8 Tf  [(18.)] TJ ET
BT 43.553 134.006 Td /F1 9.8 Tf  [(M�ller D, Szucs TD. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional )] TJ ET
BT 26.250 122.101 Td /F1 9.8 Tf  [(analysis of the seasons 02/03, 03/04 and 04/05. Infection. 2007;35\(5\):308-19.)] TJ ET
BT 26.250 102.696 Td /F1 9.8 Tf  [(19.)] TJ ET
BT 43.553 102.696 Td /F1 9.8 Tf  [(Groupe d�Expertise et d�Information sur la Grippe \(GEIG\). Le taux de couverture vaccinale en France. \(Accessed June 10, )] TJ ET
BT 26.250 90.792 Td /F1 9.8 Tf  [(2010, at http://grippe-geig.com/fr/vaccination/couverture_vaccin.php.\).)] TJ ET
Q
q
15.000 73.411 577.500 703.589 re W n
0.271 0.267 0.267 rg
BT 26.250 767.476 Td /F1 9.8 Tf  [(associated with the pandemic H1N1 influenza. From this point of view, a public health information campaign that primarily )] TJ ET
BT 26.250 755.571 Td /F1 9.8 Tf  [(focuses on convincing people of the safety of the vaccine would likely be less fruitful than expected.)] TJ ET
BT 26.250 726.469 Td /F4 12.0 Tf  [(Competing interests)] TJ ET
BT 26.250 706.515 Td /F1 9.8 Tf  [(The authors have declared that no competing interests exist.)] TJ ET
BT 26.250 669.912 Td /F4 12.0 Tf  [(References)] TJ ET
BT 26.250 642.458 Td /F1 9.8 Tf  [(1.)] TJ ET
BT 38.132 642.458 Td /F1 9.8 Tf  [(Center for Disease Control. Preliminary results surveillance for Guillain-Barr� syndrome after receipt of influenza A \(H1N1\) )] TJ ET
BT 26.250 630.553 Td /F1 9.8 Tf  [(2009 monovalent vaccine - United States, 2009-2010. Morbidity and Mortality Weekly Report. 2010; 59\(21\):657-61.)] TJ ET
BT 26.250 611.148 Td /F1 9.8 Tf  [(2.)] TJ ET
BT 38.132 611.148 Td /F1 9.8 Tf  [(R�publique Fran�aise. Grippe A\(H1N1\) : l'�pid�mie recule mais un second pic pand�mique reste possible. January 15, 2010. )] TJ ET
BT 26.250 599.244 Td /F1 9.8 Tf  [(\(Accessed June 10, 2010, at http://www.gouvernement.fr/gouvernement/grippe-ah1n1-l-epidemie-recule-mais-un-second-pic-)] TJ ET
BT 26.250 587.339 Td /F1 9.8 Tf  [(pandemique-reste-possible\).)] TJ ET
BT 26.250 567.934 Td /F1 9.8 Tf  [(3.)] TJ ET
BT 38.132 567.934 Td /F1 9.8 Tf  [(PoteVellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in )] TJ ET
BT 26.250 556.029 Td /F1 9.8 Tf  [(adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27:2114-20.)] TJ ET
BT 26.250 536.625 Td /F1 9.8 Tf  [(4.)] TJ ET
BT 38.132 536.625 Td /F1 9.8 Tf  [(Aday, L.A. Designing And Conducting Health Surveys: A Comprehensive Guide. San Fransisco: Jossey-Bass, 2006.)] TJ ET
BT 26.250 517.220 Td /F1 9.8 Tf  [(5.)] TJ ET
BT 38.132 517.220 Td /F1 9.8 Tf  [(Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999-2000. )] TJ ET
BT 26.250 505.315 Td /F1 9.8 Tf  [(Emerg Infect Dis. 2002;8\(12\):1442-47.)] TJ ET
BT 26.250 485.910 Td /F1 9.8 Tf  [(6.)] TJ ET
BT 38.132 485.910 Td /F1 9.8 Tf  [(Chapman GB, Coups EJ. Predictors of influenza vaccine acceptance among healthy adults. Prev Med \(1999\) 29:249-62.)] TJ ET
BT 26.250 466.506 Td /F1 9.8 Tf  [(7.)] TJ ET
BT 38.132 466.506 Td /F1 9.8 Tf  [(Jones TF, Ingram LA, Craig AS, Schaffner W. Determinants of influenza vaccination, 2003-2004: shortages, fallacies and )] TJ ET
BT 26.250 454.601 Td /F1 9.8 Tf  [(disparities. Clin Infect Dis. 2004;39\(12\):1824-28.)] TJ ET
BT 26.250 435.196 Td /F1 9.8 Tf  [(8.)] TJ ET
BT 38.132 435.196 Td /F1 9.8 Tf  [(Endrich MM, Blank PR, Szucs TD. Influenza vaccination uptake and socioeconomic determinants in 11 European countries. )] TJ ET
BT 26.250 423.291 Td /F1 9.8 Tf  [(Vaccine 2009;27\(30\):4018-24.)] TJ ET
BT 26.250 403.887 Td /F1 9.8 Tf  [(9.)] TJ ET
BT 38.132 403.887 Td /F1 9.8 Tf  [(Setbon, M, Raude, J. Factors in vaccination intention against the pandemic influenza A/H1N1. European Journal of Public )] TJ ET
BT 26.250 391.982 Td /F1 9.8 Tf  [(Health \(Access published online on May 5, 2010\).)] TJ ET
BT 26.250 372.577 Td /F1 9.8 Tf  [(10.)] TJ ET
BT 43.553 372.577 Td /F1 9.8 Tf  [(Maurer J, Harris KM, Parker A, Lurie N. Does receipt of seasonal influenza vaccine predict intention to receive novel H1N1 )] TJ ET
BT 26.250 360.672 Td /F1 9.8 Tf  [(vaccine: evidence from a nationally representative survey of U.S. adults. Vaccine \(2009\) 27:5732-4.)] TJ ET
BT 26.250 341.268 Td /F1 9.8 Tf  [(11.)] TJ ET
BT 43.553 341.268 Td /F1 9.8 Tf  [(Maltezou HC, Maragos A, Katerelos P, Paisi A, Karageorgou K,Papadimitriou T, et al. Influenza vaccination acceptance )] TJ ET
BT 26.250 329.363 Td /F1 9.8 Tf  [(among health-care workers: a nationwide survey. Vaccine. 2008;26\(11\):1408-10.)] TJ ET
BT 26.250 309.958 Td /F1 9.8 Tf  [(12.)] TJ ET
BT 43.553 309.958 Td /F1 9.8 Tf  [(Leitmeyer K, Buchholz U, Kramer M. Influenza vaccination in German health care workers: effects and findings after two )] TJ ET
BT 26.250 298.053 Td /F1 9.8 Tf  [(rounds of a nationwide awareness campaign. Vaccine 2006;24\(47-48\):7003-8.)] TJ ET
BT 26.250 278.649 Td /F1 9.8 Tf  [(13.)] TJ ET
BT 43.553 278.649 Td /F1 9.8 Tf  [(Rothan-Tondeur M, deWazieres B, Lejeune B, Gavazzi G. Influenza vaccine coverage for healthcare workers in geriatric )] TJ ET
BT 26.250 266.744 Td /F1 9.8 Tf  [(settings in France. Aging Clin Exp Res, 2006;18\(6\):512-6.)] TJ ET
BT 26.250 247.339 Td /F1 9.8 Tf  [(14.)] TJ ET
BT 43.553 247.339 Td /F1 9.8 Tf  [(Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care workers in hospitals: a review of )] TJ ET
BT 26.250 235.434 Td /F1 9.8 Tf  [(studies on attitudes and predictors. Vaccine 2009;27\(30\): 3935-44.)] TJ ET
BT 26.250 216.030 Td /F1 9.8 Tf  [(15.)] TJ ET
BT 43.553 216.030 Td /F1 9.8 Tf  [(Mills E, Jadad AR, Ross C, Wilson K. Systematic review of qualitative studies exploring parental beliefs and attitudes toward )] TJ ET
BT 26.250 204.125 Td /F1 9.8 Tf  [(childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol. 2005;58\(11\):1081-88.)] TJ ET
BT 26.250 184.720 Td /F1 9.8 Tf  [(16.)] TJ ET
BT 43.553 184.720 Td /F1 9.8 Tf  [(Streefland P, Chowdhuryb AMR, Ramos-Jimenezc P. Patterns of vaccination acceptance. Social Science & Medicine. )] TJ ET
BT 26.250 172.815 Td /F1 9.8 Tf  [(1999;49\(12\):1705-1716.)] TJ ET
BT 26.250 153.411 Td /F1 9.8 Tf  [(17.)] TJ ET
BT 43.553 153.411 Td /F1 9.8 Tf  [(Tourangeau R, Yan T. Sensitive questions in surveys. Psychological Bulletin. 2007; 133\(5\): 859-883.)] TJ ET
BT 26.250 134.006 Td /F1 9.8 Tf  [(18.)] TJ ET
BT 43.553 134.006 Td /F1 9.8 Tf  [(M�ller D, Szucs TD. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional )] TJ ET
BT 26.250 122.101 Td /F1 9.8 Tf  [(analysis of the seasons 02/03, 03/04 and 04/05. Infection. 2007;35\(5\):308-19.)] TJ ET
BT 26.250 102.696 Td /F1 9.8 Tf  [(19.)] TJ ET
BT 43.553 102.696 Td /F1 9.8 Tf  [(Groupe d�Expertise et d�Information sur la Grippe \(GEIG\). Le taux de couverture vaccinale en France. \(Accessed June 10, )] TJ ET
BT 26.250 90.792 Td /F1 9.8 Tf  [(2010, at http://grippe-geig.com/fr/vaccination/couverture_vaccin.php.\).)] TJ ET
Q
q
0.000 0.000 0.000 rg
BT 291.710 19.825 Td /F1 11.0 Tf  [(6)] TJ ET
BT 25.000 19.825 Td /F1 11.0 Tf  [(PLOS Currents Influenza)] TJ ET

Q
endstream
endobj
xref
0 194
0000000000 65535 f 
0000000008 00000 n 
0000000073 00000 n 
0000000119 00000 n 
0000000402 00000 n 
0000000439 00000 n 
0000000689 00000 n 
0000000932 00000 n 
0000024804 00000 n 
0000024911 00000 n 
0000025019 00000 n 
0000025130 00000 n 
0000025243 00000 n 
0000025359 00000 n 
0000025747 00000 n 
0000029579 00000 n 
0000029706 00000 n 
0000029850 00000 n 
0000029977 00000 n 
0000030121 00000 n 
0000030248 00000 n 
0000030355 00000 n 
0000030483 00000 n 
0000030600 00000 n 
0000030728 00000 n 
0000030835 00000 n 
0000030963 00000 n 
0000030999 00000 n 
0000031127 00000 n 
0000031163 00000 n 
0000031291 00000 n 
0000031327 00000 n 
0000031454 00000 n 
0000031598 00000 n 
0000031725 00000 n 
0000031869 00000 n 
0000031996 00000 n 
0000032103 00000 n 
0000032231 00000 n 
0000032348 00000 n 
0000032476 00000 n 
0000032583 00000 n 
0000032711 00000 n 
0000032747 00000 n 
0000032875 00000 n 
0000032911 00000 n 
0000033039 00000 n 
0000033075 00000 n 
0000033202 00000 n 
0000033346 00000 n 
0000033473 00000 n 
0000033617 00000 n 
0000033744 00000 n 
0000033851 00000 n 
0000033979 00000 n 
0000034096 00000 n 
0000034224 00000 n 
0000034331 00000 n 
0000034459 00000 n 
0000034495 00000 n 
0000034623 00000 n 
0000034659 00000 n 
0000034787 00000 n 
0000034823 00000 n 
0000034921 00000 n 
0000066470 00000 n 
0000066598 00000 n 
0000066634 00000 n 
0000066762 00000 n 
0000066798 00000 n 
0000066926 00000 n 
0000066962 00000 n 
0000067027 00000 n 
0000108515 00000 n 
0000108635 00000 n 
0000108892 00000 n 
0000144473 00000 n 
0000144599 00000 n 
0000144635 00000 n 
0000144761 00000 n 
0000144797 00000 n 
0000144923 00000 n 
0000144959 00000 n 
0000145085 00000 n 
0000145121 00000 n 
0000145247 00000 n 
0000145283 00000 n 
0000145409 00000 n 
0000145445 00000 n 
0000145571 00000 n 
0000145607 00000 n 
0000145733 00000 n 
0000145769 00000 n 
0000145895 00000 n 
0000145931 00000 n 
0000146057 00000 n 
0000146093 00000 n 
0000146219 00000 n 
0000146255 00000 n 
0000146381 00000 n 
0000146417 00000 n 
0000146545 00000 n 
0000146582 00000 n 
0000146710 00000 n 
0000146747 00000 n 
0000146875 00000 n 
0000146912 00000 n 
0000147040 00000 n 
0000147077 00000 n 
0000147205 00000 n 
0000147242 00000 n 
0000147370 00000 n 
0000147407 00000 n 
0000147535 00000 n 
0000147572 00000 n 
0000147700 00000 n 
0000147737 00000 n 
0000147865 00000 n 
0000147902 00000 n 
0000148030 00000 n 
0000148067 00000 n 
0000148195 00000 n 
0000148232 00000 n 
0000148360 00000 n 
0000148397 00000 n 
0000148740 00000 n 
0000180467 00000 n 
0000180597 00000 n 
0000180634 00000 n 
0000180764 00000 n 
0000180801 00000 n 
0000180931 00000 n 
0000180968 00000 n 
0000181098 00000 n 
0000181135 00000 n 
0000181265 00000 n 
0000181302 00000 n 
0000181432 00000 n 
0000181469 00000 n 
0000181599 00000 n 
0000181636 00000 n 
0000181764 00000 n 
0000181801 00000 n 
0000181929 00000 n 
0000181966 00000 n 
0000182096 00000 n 
0000182133 00000 n 
0000182263 00000 n 
0000182300 00000 n 
0000182430 00000 n 
0000182467 00000 n 
0000182597 00000 n 
0000182634 00000 n 
0000182764 00000 n 
0000182801 00000 n 
0000182931 00000 n 
0000182968 00000 n 
0000183098 00000 n 
0000183135 00000 n 
0000183265 00000 n 
0000183302 00000 n 
0000183432 00000 n 
0000183469 00000 n 
0000183597 00000 n 
0000183634 00000 n 
0000183762 00000 n 
0000183799 00000 n 
0000183929 00000 n 
0000183966 00000 n 
0000184096 00000 n 
0000184133 00000 n 
0000184263 00000 n 
0000184300 00000 n 
0000184430 00000 n 
0000184467 00000 n 
0000184597 00000 n 
0000184634 00000 n 
0000184764 00000 n 
0000184801 00000 n 
0000184931 00000 n 
0000184968 00000 n 
0000185098 00000 n 
0000185135 00000 n 
0000185265 00000 n 
0000185302 00000 n 
0000185430 00000 n 
0000185467 00000 n 
0000185595 00000 n 
0000185632 00000 n 
0000185762 00000 n 
0000185799 00000 n 
0000185929 00000 n 
0000185966 00000 n 
0000186033 00000 n 
trailer
<<
/Size 194
/Root 1 0 R
/Info 5 0 R
>>
startxref
205724
%%EOF